Diabetes & Metabolism Journal

Original Article

Others
Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial: Han Na Jang, Eun Shil Hong, Ye Seul Yang, Seong Ok Lee, Myoung-jin Jang, Andrea Mari, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Hye Seung Jung; Received November 21, 2024 Accepted April 28, 2025 Published online August 14, 2025; DOI: https://doi.org/10.4093/dmj.2024.0741 [Epub ahead of print]

1,750 View
66 Download

Abstract PDF Supplementary Material PubReader ePub: Background
We aimed to confirm that once-daily insulin degludec/insulin aspart (IDegAsp) is superior to basal insulin therapy in participants with type 2 diabetes mellitus (T2DM) exhibiting signs of overbasalization. Additionally, we analyzed incretin profiles in relation to the benefits of IDegAsp, providing insights into the underlying mechanisms.
Methods
A prospective study was conducted in participants receiving basal insulin therapy, with a fasting plasma glucose (FPG) level lower than predicted from their glycosylated hemoglobin (HbA1c). Participants were randomly assigned to either IDegAsp or insulin glargine (IGlar) in a 1:1 ratio. After 20 weeks of treatment, the insulins were switched in a crossover design. The primary endpoint was the change in HbA1c from baseline. Incretin profiles, hypoglycemic events, and continuous glucose monitoring (CGM) were also analyzed (Trial registration: www.cris.nih.go.kr; KCT0004597).
Results
The study included 55 participants (male 40%, mean age 65 years, FPG 103 mg/dL, and HbA1c 8.3%). HbA1c significantly decreased to 7.8%±0.8% with IDegAsp, compared to 8.0%±0.7% with IGlar. The mean estimated treatment difference of changes was –0.21% points (95% confidence interval, –0.39 to –0.02; P=0.031), favoring IDegAsp. Hypoglycemic events were comparable. CGM demonstrated significantly lower glucose measures during the daytime with IDegAsp compared to IGlar, and vice versa at dawn. The HbA1c benefit of IDegAsp over IGlar was associated with a low glucagon-like peptide-1 (GLP-1) ratio at 30 minutes relative to baseline (r=0.301, P=0.040), while not with glucose-dependent insulinotropic polypeptide.
Conclusion
The greater reduction in HbA1c achieved with IDegAsp compared to IGlar in individuals with T2DM was associated with an impaired GLP-1 response, facilitating personalized insulin therapy.

Reviews

Pharmacotherapy
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning: Jung A Kim, Hye Jin Yoo; Diabetes Metab J. 2025;49(4):525-541. Published online July 1, 2025; DOI: https://doi.org/10.4093/dmj.2025.0242

30,314 View
1,267 Download
12 Web of Science
17 Crossref

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.

Citations

Citations to this article as recorded by

Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
Journal of Drug Delivery Science and Technology.2026; 118: 108078. CrossRef
Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
Nimet Yılmaz, Mehmet Bastemir
Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
Kwang Hyun Chung, Jaihwan Kim
The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1. CrossRef
Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
Nutrients.2026; 18(4): 553. CrossRef
Oral Administration of Crocus sativus Tepals Extract Restores High‐Fat Diet‐Induced Gut Dysbiosis and Modulates Intestinal Inflammation and Hepatic Lipid Metabolism
Biljana Bursać, Miloš Vratarić, Ljupka Gligorovska, Luisa Bellachioma, Ana Teofilović, Danijela Vojnović Milutinović, Camilla Morresi, Elisabetta Damiani, Tiziana Bacchetti, Ana Djordjevic
BioFactors.2026;[Epub] CrossRef
A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis
Suhasini Rallabandi, Mansi Sharma, Krishnamraju Kosuru, Rahul Kashyap
Cureus.2026;[Epub] CrossRef
The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
Andro Koren, Luciana Koren
British Journal of Clinical Pharmacology.2026;[Epub] CrossRef
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan
Chronic Diseases and Translational Medicine.2026;[Epub] CrossRef
Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
Sleep Medicine.2025; 134: 106709. CrossRef
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Shikha Patel, Sarfaraz K. Niazi
Pharmaceutics.2025; 17(8): 1036. CrossRef
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
Life.2025; 15(9): 1422. CrossRef
Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
Frontiers in Endocrinology.2025;[Epub] CrossRef
Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
Diabetes & Metabolism Journal.2025; 49(6): 1331. CrossRef
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
Ralf Weiskirchen, Amedeo Lonardo
Medical Sciences.2025; 13(4): 265. CrossRef
Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
Epilepsia.2025;[Epub] CrossRef
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Ki Hoon Kwak, Chang Hee Jung
Endocrinology and Metabolism.2025; 40(6): 879. CrossRef
Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
琳娜勾
Advances in Clinical Medicine.2025; 15(12): 2047. CrossRef

Pharmacotherapy
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application: Jae Hyun Bae; Diabetes Metab J. 2025;49(3):386-402. Published online May 1, 2025; DOI: https://doi.org/10.4093/dmj.2025.0220

24,285 View
1,541 Download
24 Web of Science
27 Crossref

Abstract PDF PubReader ePub

Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual risk remains. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management. Beyond glycemic control, these agents provide distinct and complementary cardiorenal benefits through mechanisms such as hemodynamic modulation, anti-inflammatory effects, and metabolic adaptations. Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes. SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. Although indirect comparisons suggest that SGLT2 inhibitors may offer greater protection against kidney function decline, direct head-to-head trials are lacking. Combination therapy holds promise, however further studies are needed to define optimal treatment strategies. This review synthesizes current evidence, evaluates comparative effectiveness, and outlines future directions in DKD management, emphasizing precision medicine approaches to enhance clinical outcomes. The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure.

Citations

Citations to this article as recorded by

Trends in nephrology: kidney metabolism as a therapeutic target
Jessica S Kleer, Markus M Rinschen
Nephrology Dialysis Transplantation.2026; 41(2): 193. CrossRef
Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF
Nermeen Bastawy, Aliaa E. M. K. El-Mosallamy, Rabab Ahmed Rasheed, A. S. Sadek, R. T. Khattab, Esraa Ali, Randa A. Zaghloul, Wael B. A. Ghaly, Amy F. Boushra
Hypertension Research.2026; 49(3): 816. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
Diabetes, Obesity and Metabolism.2026; 28(3): 2265. CrossRef
Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine
Tao Li, Kaili Chen, Yiting Sun, Linqi Zhang
Frontiers in Genetics.2026;[Epub] CrossRef
Nobiletin Ameliorated the Development of Diabetic Kidney Disease via Modulating Ferroptosis and Epithelial–Mesenchymal Transition Involving Gut–Kidney Axis
Tingting Zhao, Chuyun Zhao, Qian Xiang, Xi Zhang, Kin-Fong Hong, Peiyu Liu, Zhongyan Sun, Yadi Liu, Ruiting Huang, Yiran Li, Hio-Fai Cheong, Yuwei Wu, Yingqiu Mo, Yiduo Xu, Yingxi Zhao, Qiruo Huang, Ying Xie, Youhua Xu
The American Journal of Chinese Medicine.2026; 54(01): 303. CrossRef
Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists
Marios Spanakis, Agapi Fournaraki, Frantzeska Nimee, Christos Kontogiorgis, Emmanouil K. Symvoulakis
Pharmaceuticals.2026; 19(2): 271. CrossRef
Diabetic kidney disease in northwest Ethiopia: Prevalence and determinants among adults with type 2 diabetes
Workagegnehu Hailu, Tadesse Asmamaw Dejene, Markeshaw Tiruneh, Meseret Derbew Molla, Eshetie Melese Birru, Shitaye Alemu, Tadesse Awoke, Francesca D'Addio
PLOS One.2026; 21(2): e0343210. CrossRef
The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease
Yinfeng Guo, Yonghao Feng, Henglan Wu, Huanqing Gao
International Journal of Molecular Sciences.2026; 27(5): 2352. CrossRef
Association between cardiovascular-kidney-metabolic syndrome stages and risk of all-cause mortality in U.S. adults: a cross-sectional survey based on NHANES
Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGE–RAGE–NF-κB-mediated cytotoxicity and inflammation in diabetic kidney disease
Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A. Dera, Sivakumar Vijayaraghavalu, Prasanna Rajagopalan
Biochemical and Biophysical Research Communications.2026; 811: 153540. CrossRef
Glucagon-Like Peptide-1 Receptor Agonist and Lupus Nephritis in Systemic Lupus Erythematosus with Type 2 Diabetes
Muhammad Hanif, Jai S. Nagarajan, Ryan Murphy, Shiva P. Sah, Shuang Ye, Andras Perl, Cynthia C. Taub
The American Journal of Medicine.2026;[Epub] CrossRef
Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
Kota V. Ramana
International Journal of Molecular Sciences.2025; 26(12): 5585. CrossRef
Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
Wenfeng Wang, Bi Ke, Chen Wang, Xiaojing Xiong, Xiuyuan Feng, Hua Yan
Frontiers in Medicine.2025;[Epub] CrossRef
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg
Biomedicines.2025; 13(8): 1924. CrossRef
Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
Peter Bramlage, Anjaly Vijayan, Treesa P. Varghese, Deepthy Melepurakkal Sadanandan, Stefanie Lanzinger, Carmen Ferrero Rodriguez
Diabetes, Obesity and Metabolism.2025; 27(11): 6254. CrossRef
Type 2 Diabetes and the Multifaceted Gut-X Axes
Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
Nutrients.2025; 17(16): 2708. CrossRef
Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research
Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park
Clinical Hypertension.2025;[Epub] CrossRef
Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence
Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan
Cureus.2025;[Epub] CrossRef
Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease
Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li
Pharmaceuticals.2025; 18(10): 1449. CrossRef
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Mark E. Cooper, Daniël H. van Raalte
Journal of Clinical Investigation.2025;[Epub] CrossRef
Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis
Hamood AlSudais, Turky AlSulaiman, Badi A. Alotaibi, Abdulrahman Alshalani, Abdulaziz M. Almuqrin, Rehab B. Albakr, Jehad A. Aldali
Journal of Clinical Medicine.2025; 14(22): 7985. CrossRef
Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang
Renal Failure.2025;[Epub] CrossRef
FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice
Jie Zhou, Shuxin Wang, Jiaxin Lou, Beibin Pan, Min Zhao, Qian Li, Jing Zhou, Yali Du, Shuodan Ding, Meiling Yu, Jingjing Zhou, Xinwei Chen, Lingwei Jin, Xinyi Wang, Yepeng Hu, Zhe Wang, Xiaokun Li, Chao Zheng, Jian Sun, Zhifeng Huang
Nature Communications.2025;[Epub] CrossRef
Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration
Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang
Food Science & Nutrition.2025;[Epub] CrossRef
Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 1: основи патофізіології та ключові клінічні дослідження
Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
Ukrainian Journal of Nephrology and Dialysis.2025; (4(88)): 88. CrossRef
GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
American Journal of Hypertension.2025;[Epub] CrossRef

Basic and Translational Research
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies: Joon Seok Park, Kyu Sik Kim, Hyung Jin Choi; Diabetes Metab J. 2025;49(3):333-347. Published online May 1, 2025; DOI: https://doi.org/10.4093/dmj.2025.0106

8,745 View
415 Download
11 Web of Science
16 Crossref

Abstract PDF PubReader ePub

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on the central nervous system to regulate satiation and satiety. This review summarizes the discovery of GLP-1 and the development of GLP-1RAs, with a particular focus on their central mechanisms of action. Human neuroimaging studies demonstrate that GLP-1RAs influence brain activity during food cognition, supporting a role in pre-ingestive satiation. Animal studies on hypothalamic feed-forward regulation of hunger suggest that cognitive hypothalamic mechanisms may also contribute to satiation control. We highlight the brain mechanisms of GLP-1RA-induced satiation and satiety, including cognitive impacts, with an emphasis on animal studies of hypothalamic glucagon-like peptide-1 receptor (GLP-1R) and GLP-1R-expressing neurons. Actions in non-hypothalamic regions are also discussed. Additionally, we review emerging combination drugs and oral GLP-1RA formulations aimed at improving efficacy and patient adherence. In conclusion, the dorsomedial hypothalamus (DMH)—a key GLP-1RA target—mediates pre-ingestive cognitive satiation, while other hypothalamic GLP-1R neurons regulate diverse aspects of feeding behavior, offering potential therapeutic targets for obesity treatment.

Citations

Citations to this article as recorded by

Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
Shambo S. Samajdar, Shashank Joshi
Diabetes, Obesity and Metabolism.2026; 28(1): 779. CrossRef
An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights
Zongrui Zhang, Rangzi Yi, Shihong Xiong, Yushu Zhang, Xuebin Cao, Wenqi Zhen, Yang Yang, Na Gong
Diabetes Research and Clinical Practice.2026; 233: 113055. CrossRef
Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting
Suzanne M. de la Monte, Ming Tong, Rolf I. Carlson, Greg Sutherland
Biomolecules.2026; 16(1): 99. CrossRef
Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
Zoubiri Houda, Saiah Wassila, Otmane Amel, Saidi Hamza, Makrelouf Mohamed, Aitabderrhmane Samir, Haddam Ali El Mahdi, Koceir Elhadj-Ahmed
International Journal of Molecular Sciences.2026; 27(3): 1218. CrossRef
The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior
Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella
American Journal of Gastroenterology.2026;[Epub] CrossRef
Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
Andrijana Koceva, Andrej Janež, Tajda Pečko, Mojca Jensterle
Nutrients.2026; 18(4): 677. CrossRef
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
HK Chopra, Ashwani Mehta, CK Ponde, Navin C Nanda, GS Wander, Abraham Oomman, Prafulla Kerkar, SN Routray, GP Ratnaparkhi, Prashant Advani, Rituparna Shinde, Rajeev Agarwal, Ajay Mahajan, Jay Shah, Gaurav Verma, Sanjay Mittal, Dorairaj Prabhakar, D Ramesh
Journal of The Association of Physicians of India.2026; 74(2): e8. CrossRef
Polysaccharides from Acanthopanax senticosus (Rupr. et Maxim.) Harms: Molecular Messengers Linking the Traditional Efficacy of Fortifying the Spleen, Replenishing Qi, and Calming the Spirit to Gut-Immune Axis Regulation
Bichun Hu, Deyong Zeng, Junli Liu, Weiping Wang, Shuaimin Hu, Weihong Lu
Journal of Future Foods.2026;[Epub] CrossRef
Obestatin: canonical and unexpected functions
Icia Santos-Zas, Uxia Gurriaran-Rodriguez, Tania Cid-Diaz, Saul Leal-Lopez, Felipe F. Casanueva, Yolanda Pazos-Randulfe, Jesus P. Camiña
Reviews in Endocrine and Metabolic Disorders.2026;[Epub] CrossRef
Hijacked Brain in Modern Obesity: Cue, Habit, Addiction, Emotion, and Restraint as Targets for Personalized Digital Therapy and Electroceuticals
Taesung Lee, Seeun Park, Seokhyun Lee, Areum Hwangbo, HanGyeol Bae, Yumin Lee, Hyung Jin Choi
Journal of Obesity & Metabolic Syndrome.2025; 34(3): 196. CrossRef
Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis
Zixuan Li, Zhoubo Han, Rong Sun, Xiuping Xuan, Chenghu Huang
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3611. CrossRef
The LEPR gene: A multifaceted regulator of energy homeostasis, obesity pathogenesis, and metabolic health
Isar Sharma, Nishutosh, Kritika Bakshi, Ritu Mahajan, Nisha Kapoor
Human Gene.2025; 46: 201486. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology
N. V. Gulyaeva
Journal of Evolutionary Biochemistry and Physiology.2025; 61(5): 1326. CrossRef
Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won
Nutrients.2025; 17(23): 3735. CrossRef
A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
E. A. Troshina, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova
Problems of Endocrinology.2025; 71(5): 19. CrossRef
Tirzepatide and Obesity: A Narrative Review
Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
Advances in Human Biology.2025;[Epub] CrossRef

Original Article

Pharmacotherapy
Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus: Mijin Kim, Seung Chan Kim, Jinmi Kim, Bo Hyun Kim; Diabetes Metab J. 2025;49(1):49-59. Published online October 24, 2024; DOI: https://doi.org/10.4093/dmj.2024.0105

8,589 View
392 Download
12 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes mellitus (T2DM) given their extra-pancreatic effects. However, there are concerns about carcinogenesis in the pancreas and thyroid gland. We aimed to evaluate the site-specific incidence of cancer in patients with T2DM-treated GLP-1 RAs using a nationwide cohort.
Methods
This study included data obtained from the Korean National Health Insurance Service (between 2004 and 2021). The primary outcome was newly diagnosed cancer, and the median follow-up duration for all participants was 8 years.
Results
After propensity score matching, 7,827 participants were analyzed; 2,609 individuals each were included in the GLP-1 RA, diabetes mellitus (DM) control, and non-DM control groups. The incidence rate ratio (IRR) of subsequent cancer in patients with T2DM was 1.73, which was higher than that of individuals without DM, and it increased in both men and women. Analysis of patients with T2DM showed no increased cancer risk associated with the use of GLP-1 RA, and similar results were observed in both men and women. The IRRs of pancreatic cancer (0.74), thyroid cancer (1.32), and medullary thyroid cancer (0.34) did not significantly increase in the GLP-1 RA group compared with those in the DM control group.
Conclusion
There was a 73% higher risk of cancer in patients with T2DM compared with the general population. However, among patients with T2DM, there was no association between the use of GLP-1 RAs and new-onset cancers, including pancreatic and medullary thyroid cancers.

Citations

Citations to this article as recorded by

Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
Zhijun Zhang, Jingyun Yang, Ling Gao
Endocrine Practice.2026; 32(1): 60. CrossRef
Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
Current Opinion in Oncology.2026; 38(1): 1. CrossRef
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs
Diabetes, Obesity and Metabolism.2026; 28(2): 1499. CrossRef
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
Setor K. Kunutsor, Samuel Seidu
Drugs.2026; 86(1): 11. CrossRef
Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis
Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal
Cancers.2026; 18(2): 179. CrossRef
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
Journal of Diabetes and its Complications.2026; 40(4): 109289. CrossRef
Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
Yousef A. Ateiwi, Rahil Mahmood, Hon Jen Wong, Chen Ee Low, Chun En Yau, Ainsley Ryan Yan Bin Lee, Pei Chia Eng, Matilda Lee, Mark Y. Chan, Ching-Hui Sia
Diabetes Research and Clinical Practice.2026; 234: 113158. CrossRef
GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
Diabetes, Obesity and Metabolism.2025; 27(8): 4454. CrossRef
Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
Sanjana Balachandra, Rohma Syed, Zhixing Song, Julia Kasmirski, Andrea Gillis, Jessica Fazendin, Brenessa Lindeman, Herbert Chen
Journal of Surgical Research.2025; 312: 104. CrossRef
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Jung A Kim, Hye Jin Yoo
Diabetes & Metabolism Journal.2025; 49(4): 525. CrossRef
Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies
Hyun Jin Park, Si Yoon Lee
Research in Clinical Pharmacy.2025; 3(1): 28. CrossRef
GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A Mansi
American Journal of Medicine Open.2025; 14: 100114. CrossRef
Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Sabina Semiz
Health Sciences Review.2025; 17: 100244. CrossRef
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
Journal of Clinical Investigation.2025;[Epub] CrossRef
GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
Daniela Lucente, Stefania Bellino, Anna La Salvia
Genes.2025; 16(11): 1352. CrossRef
Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
Diabetes & Metabolism Journal.2025; 49(6): 1331. CrossRef
Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert
Clinical Endocrinology.2025;[Epub] CrossRef

Review

Metabolic Risk/Epidemiology
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism: Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan; Diabetes Metab J. 2024;48(3):354-372. Published online April 1, 2024; DOI: https://doi.org/10.4093/dmj.2023.0277

65,535 View
2,172 Download
71 Web of Science
79 Crossref

Abstract PDF PubReader ePub

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.

Citations

Citations to this article as recorded by

Histological efficacy of anti‐diabetic agents in MASH and the mediating role of weight loss: A network meta‐analysis
Mainak Banerjee, Rimesh Pal, Sandip Pal
Diabetes, Obesity and Metabolism.2026; 28(1): 287. CrossRef
Glucagon‐like peptide‐1 receptor agonists in pediatric metabolic dysfunction‐associated steatotic liver disease
Andrea M. Tou, Jennifer Panganiban
Journal of Pediatric Gastroenterology and Nutrition.2026; 82(1): 146. CrossRef
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu
Clinical Pharmacology & Therapeutics.2026; 119(2): 336. CrossRef
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
Setor K. Kunutsor, Samuel Seidu
Drugs.2026; 86(1): 11. CrossRef
Anti-adipogenic effect of cryptotanshinone in 3T3-L1 preadipocytes via binding to glucagon-like peptide 1 receptor and its signaling
Md․Abdur Rakib, Yong-Sik Kim
Phytomedicine.2026; 150: 157666. CrossRef
Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis
Yu‐Ting Lu, Po‐Han Chang, Hsuan‐Ju Chen, Ya‐Wen Hsueh, Chia‐Wei Chang, Hsi‐Chen Hsu, Tung‐Chuan Yang, Wu‐Chou Lin, Hsun‐Ming Chang
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study
Yu-Ning Liao, Tsung-Hsien Yang, Yi-Chin Lu, Liang-Wei Tseng, Ching-Wei Yang, Yu-Tung Huang, Hsing-Yu Chen
Integrative Medicine Research.2026; 15(3): 101291. CrossRef
High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli
Sushmita R. Kumar, Esha Shukla, Gaurav Pandey
Fermentation.2026; 12(1): 53. CrossRef
Improving Lipid Profiles Through Lactobacillus rhamnosus Supplementation in Dyslipidemic Animal Models: A Systematic Review and Meta-Analysis
Sungmin Chung, Jiill Jeong, Yeonwoo Park, Bogyeong Lee, Sumin Kang, Gwang-woong Go
Foods.2026; 15(3): 465. CrossRef
Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control
Tatjana Ábel, Éva Csobod Csajbókné
International Journal of Molecular Sciences.2026; 27(3): 1186. CrossRef
PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS: A LITERATURE REVIEW
Wiktoria Marzec, Hanna Maruchniak, Paulina Biedroń, Anna Skrzypek, Maciej Hutkowski, Mikołaj Zbrożek, Zuzanna Chwostek, Bartłomiej Kosiarski, Patrycja Markowicz, Krzysztof Biłyk
International Journal of Innovative Technologies in Social Science.2026;[Epub] CrossRef
Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
Jianhong Li, Kun Fu, Jiaqian Zhao, Ying Zou, Li Li, Qiuyuan Huang, Limei Long, Xianhong Ou, Ming Lei, Chunxiang Zhang, Xiaoqiu Tan, Tangting Chen
Drug Design, Development and Therapy.2026; Volume 20: 1. CrossRef
Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
Nutrients.2026; 18(4): 553. CrossRef
Lifestyle management approaches for obesity
Matthew J. Landry, Zohaib Bagha
Journal of Clinical Lipidology.2026; 20(1): 38. CrossRef
Oncometabolites and Hypoxia-Regulated Exosomes Shape HIF-Driven Macrophage Programs Across Type 2 Diabetes, Atherosclerosis, and Cancer
Antonina Nowinka, Gabriela Krystek, Zuzanna Gontarek, Martyna Góralczyk, Antonina Waligórska, Marta Walenciak, Dorota Formanowicz
International Journal of Molecular Sciences.2026; 27(5): 2291. CrossRef
The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis
Weena Joongpan, Nittaya Boonmuen, Pimthong Sinchai, Sarawut Lapmanee, Natawat Klamsakul, Nutthapoom Pathomthongtaweechai
Pharmacology Research & Perspectives.2026;[Epub] CrossRef
Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
Jae Hyun Bae, Young Min Cho
Journal of Diabetes Investigation.2025; 16(2): 183. CrossRef
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Kathryn L. Williams, Maya Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka
Progress in Pediatric Cardiology.2025; 76: 101775. CrossRef
The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy
Chien-Yin Kuo, Sing-Hua Tsou, Edy Kornelius, Kuei-Chuan Chan, Kai-Wei Chang, Jung-Chi Li, Chien-Ning Huang, Chih-Li Lin
Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits
Laxman Subedi, Arjun Dhwoj Bamjan, Susmita Phuyal, Jung-Hyun Shim, Seung-Sik Cho, Jong Bae Seo, Kwan-Young Chang, Youngro Byun, Seho Kweon, Jin Woo Park
Journal of Controlled Release.2025; 378: 637. CrossRef
Engineering a high‐throughput clone for industrial‐scale production of long‐acting GLP‐1 analogue with retained bio‐efficacy
Praveen Kumar Reddy J, Murali Tummuru, Kunka Mohanram Ramkumar
Biotechnology Progress.2025;[Epub] CrossRef
Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1α for improved metabolism
Nikola Todorović, Jovan Kuzmanovic, Dejan Javorac, Sergej M. Ostojic
Medical Gas Research.2025; 15(3): 442. CrossRef
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
Long He, Jinwei Li, Xiong Cheng, Li Luo, Yilan Huang
Frontiers in Pharmacology.2025;[Epub] CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot
Eda Kaya, Wing-Kin Syn, Paul Manka
Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide
Mun-Teng Wong, Pei-Hsuan Lin, Wei-Chen Lin, Chi-Jiun Peng, Jon D. Wright, Hui-Ju Lee, Hsing-Mao Chu, Carmay Lim, Tse Wen Chang
Journal of Medicinal Chemistry.2025; 68(6): 6178. CrossRef
Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
Ashley Wang, Savannah Bitzas, Dilsa Perez, Jonathon Schwartz, Saleem Zaidi, Jonathan Oster, Sergio D. Bergese
Life.2025; 15(3): 427. CrossRef
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Blair Suter, Allison Rhodes, Allison Bigeh, Timothy Frommeyer, Laxmi S. Mehta
Current Cardiovascular Risk Reports.2025;[Epub] CrossRef
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases
Eliane Münte, Phillipp Hartmann
Biomolecules.2025; 15(4): 469. CrossRef
Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice
Caroline de Carvalho Picoli, Sergey Tsibulnikov, Mavy Ho, Victoria DeMambro, Tiange Feng, May Eltahir, Phuong T. Le, Carolyn Chlebek, Clifford J. Rosen, Sergey Ryzhov, Ziru Li
American Journal of Physiology-Endocrinology and Metabolism.2025; 328(4): E555. CrossRef
Pre-fertilization-origin preservation of brown fat-mediated energy expenditure in humans
Takeshi Yoneshiro, Mami Matsushita, Sayuri Fuse-Hamaoka, Miyuki Kuroiwa, Yuko Kurosawa, Yosuke Yamada, Makoto Arai, Yuchen Wei, Makoto Iida, Kenichi Kuma, Toshimitsu Kameya, Tomoya Harada, Yoshihiro Matsumura, Tsuyoshi Osawa, Yoshiko Aoki, Hisashi Nakamur
Nature Metabolism.2025; 7(4): 778. CrossRef
Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study
Wenxuan Li, Yangang Wang, Chuanfeng Liu, Yongzhuo Yu, Lili Xu, Bingzi Dong
Diabetes Therapy.2025; 16(5): 993. CrossRef
Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells
Sing-Hua Tsou, Kai-Shin Luo, Chien-Ning Huang, Edy Kornelius, I-Ting Cheng, Hui-Chih Hung, Yu-Chien Hung, Chih-Li Lin, Min-Yen Hsu
International Journal of Molecular Sciences.2025; 26(8): 3704. CrossRef
The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis
Hasan Fareed Siddiqui, Saad Ahmed Waqas, Ruqiat Masooma Batool, Hussain Salim, Abdul Mannan Khan Minhas, Syed Farhan Hasni, Amro Alsaid, Anna Sannino, Aasim M. Afzal, Muhammad Shahzeb Khan
Heart Failure Reviews.2025; 30(5): 991. CrossRef
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice
Luyan Sun, Bingqing Shang, Suyuan Lv, Guolong Liu, Qiu Wu, Yue Geng
Frontiers in Pharmacology.2025;[Epub] CrossRef
Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Luyang Gao, Ke Yang, Yawen Zhao, Jinshan Zhang, Shaohua Jiang, Rujiao Zhang, Wenxin He, Yuhang Zhao, Qianqian Ye, Geyang Xu
Science Advances.2025;[Epub] CrossRef
The potential biomarker value of soluble CD36 in the treatment of diabetic kidney disease: evidence from GLP-1 and insulin interventions
Wenxuan Li, Yangang Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update
Jiamian Geng, Sijia Ma, Hui Tang, Chun Zhang
Biomedicines.2025; 13(6): 1424. CrossRef
The Role of Peptides in Nutrition: Insights into Metabolic, Musculoskeletal, and Behavioral Health: A Systematic Review
Syed Khuram Zakir, Bilal Jawed, Jessica Elisabetta Esposito, Rimsha Kanwal, Riccardo Pulcini, Riccardo Martinotti, Edmondo Ceci, Matteo Botteghi, Francesco Gaudio, Elena Toniato, Stefano Martinotti
International Journal of Molecular Sciences.2025; 26(13): 6043. CrossRef
Effect of Semaglutide Add-on to Metformin on Visceral Adiposity Index and Markers of Visceral Adipose Tissue Activity in Type 2 Diabetic Patients
Abid Shaheer, Mahir Jallo, Shahid Akhtar
Biomedical and Pharmacology Journal.2025; 18(2): 1565. CrossRef
Harnessing adiponectin for sepsis: current knowledge, clinical insights and future therapies
Stefano Gianoli, Justin Tang, Kirsten C. Odegard, Koichi Yuki, Sophia Koutsogiannaki
Critical Care.2025;[Epub] CrossRef
Effects of antidiabetic medications on the relationship between type 2 diabetes mellitus and cognitive impairment
Annalisa Cozza, Chiara Chinigò, Elvira Filicetti, Giada Ida Greco, Rosamaria Lappano, Cinzia Marinaro, Lucia Muglia, Luca Soraci, Andrea Corsonello, Fabrizia Lattanzio, Mara Volpentesta
Ageing Research Reviews.2025; 112: 102834. CrossRef
Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials
Sarah Miranda, Jashkumar Choudhari, Nehabahen Chauhan, Mayur S. Parmar
European Journal of Pharmacology.2025; 1003: 177953. CrossRef
Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
Zhixuan Xie, Zuyi Yang, Dianzhe Tian, Youxin Chen
Frontiers in Pharmacology.2025;[Epub] CrossRef
Glucagon-like peptide-1 receptor agonists improve cholesterol metabolism by inhibiting SREBP-2 via SIRT6-AMPK pathway in HepG2 cells treated with palmitic acid
Jinmi Lee, Eun-Jung Rhee, Yu-Mi Lim, Seok-Woo Hong, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 61. CrossRef
Targeting visceral and ectopic adiposity: Pharmacological and surgical interventions beyond global weight loss
Mustafa Guldan, Lasin Ozbek, Sama M. Abdel‐Rahman, Arif E. Narin, Helin I. Orak, Hayri Kaan Goren, Baris Afsar, Peter Rossing, Mehmet Kanbay
Diabetes, Obesity and Metabolism.2025; 27(11): 6116. CrossRef
Engineered Lactococcus lactis secreting a glucagon-like peptide-1-inducing protein P9 for amelioration of obesity in mice
Wenxuan Di, Xiaoyue Bai, Shuangrui Tian, Liang Zhao, Xi Cao, Yanling Hao, Zhengyuan Zhai
3 Biotech.2025;[Epub] CrossRef
Novel therapies – IMID Co-morbidities
Tsz On Lam, Ho So, Lai-Shan Tam
Best Practice & Research Clinical Rheumatology.2025; 39(4): 102089. CrossRef
Type 2 Diabetes and the Multifaceted Gut-X Axes
Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
Nutrients.2025; 17(16): 2708. CrossRef
Sex- and depot-specific adiposity as a driver of cardiovascular ageing
Pier-Giorgio Masci, Steffen E Petersen
European Heart Journal.2025; 46(46): 5089. CrossRef
A Neural Network Method for Assessing the Nutritional Requirements of a Patient With Type 2 Diabetes
Sidi M. Mwakalu, Vincent O. Omwenga, Patrick J. Ogao, Pramita Mishra
Applied Computational Intelligence and Soft Computing.2025;[Epub] CrossRef
Global status and trends of proteomics in obesity: a bibliometric analysis and knowledge graph study
Xiaoying Wu, Yongming Chen, Tong Wu, Qi Pan, Lixin Guo
Tropical Medicine and Health.2025;[Epub] CrossRef
Estimated glucose disposal rate and its dual role in hyperlipidemia risk and mortality: a secondary analysis of retrospective cohort data from U.S. and Chinese
Shouxin Wei, Sijia Yu, Chuan Qian, Zhengwen Xu, Yindong Jia, Bo Chen
Lipids in Health and Disease.2025;[Epub] CrossRef
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Qihang Fang, Gan Li, Pei Liu, Peng Ding, Youshui Gao
Journal of Advanced Research.2025;[Epub] CrossRef
Comparison of Anti-Obesity Effects of Ginger Extract Alone and Mixed with Long Pepper Extract
Gunju Song, Hyein Han, Heegu Jin, Jongwon Kim, Hyeongmin Kim, Yi-Seul Seo, Heewon Song, Boo-Yong Lee
Biomedicines.2025; 13(9): 2077. CrossRef
Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity
Jingyi Li, Hailian Wu, Wenhui Ma, Tao Yuan, Xiaopan Chen, Yong Pan
European Journal of Pharmacology.2025; 1006: 178133. CrossRef
GLP-1RA Reduces Supraspinatus Fatty Infiltration and Promotes Functional Recovery in a Rat Model of Rotator Cuff Repair
Jong Pil Yoon, Sung-Jin Park, Dong-Hyun Kim, Yoon Seong Choi, Hyun Joo Lee, Jun-Young Kim, Chul-Hyun Cho, Seok Won Chung
The American Journal of Sports Medicine.2025; 53(12): 2973. CrossRef
A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models
Marialuisa de Ceglia, Rubén Tovar, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Elena Baixeras, Fernando Rodríguez de Fonseca, Juan Decara
Biochemical Pharmacology.2025; 242: 117364. CrossRef
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Pasqual Llongueras-Espí, Elena García-Romero, Josep Comín-Colet, José González-Costello
Biomolecules.2025; 15(9): 1342. CrossRef
A Combination of Citrus Aurantifolia Fruit Rind and Theobroma cacao Seed Extracts Ameliorates Obesity in High-Fat Diet-Fed Rats via the AMPK Pathway
SukJin Kim, Sreenath Kundimi, Thirupathi Rao, Sudipta Veeramachaneni, Guru Ramanathan, Yean Kyoung Koo
Journal of Medicinal Food.2025; 28(11): 1091. CrossRef
Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis
Pranjal Rai, Girish Bathla, Niharika Praveen, Shreya Sri Gopikonda, Huanwen Alvin Chen, Hamza A. Salim, Ahmed Azzam, Muhammed Amir Essibayi, David J. Altschul, Adam A. Dmytriw, Vivek S. Yedavalli, Shahrzad Latifi, Ajay Malhotra, Marco Colasurdo, Dheeraj G
Journal of Neurology.2025;[Epub] CrossRef
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Felix Kerlikowsky, Klaus Krämer, Manfred Eggersdorfer, Andreas Hahn
Current Developments in Nutrition.2025; 9(11): 107587. CrossRef
Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates
Magdy Abdelhamid, Mostafa M Abdrabou, Emanuel Faris, Sameh El Kafas, Mohamed Hosny, Ahmed Hassan
Cardiac Failure Review.2025;[Epub] CrossRef
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Marina V. Shestakova, Roza O. Bashlykova
Terapevticheskii arkhiv.2025; 97(10): 823. CrossRef
Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review
Sujitra Tongta, Titiwat Sungkaworn, Nutthapoom Pathomthongtaweechai
International Journal of Molecular Sciences.2025; 26(22): 10974. CrossRef
Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice
Ananyaa Sridhar, Dawood Khan, Rithiga Muthukumar, Swetha Sampathkumar, Nigel Irwin, Peter R. Flatt, R. Charlotte Moffett
Biomolecules.2025; 15(11): 1591. CrossRef
The dual burden of obesity: decoding metabolism and female reproductive endocrinology
Yan Chen, Rongyu Wang, Nannan Zhang, Liangzhi Xu
Frontiers in Physiology.2025;[Epub] CrossRef
High-Density Lipoprotein Dysfunction and Atherosclerotic Cardiovascular Disease: From Quantity to Quality
Amogh Jyothi Arun, Shigeru Kaneki, Madiha Baig, William H. Frishman, Wilbert S. Aronow
Cardiology in Review.2025;[Epub] CrossRef
Assessing the Midface: Nose and Cheeks
Kavita Mariwalla, Sabrina Fabi, Daniel Belkin, José R. Montes, Rebecca Fitzgerald, Amelia Hausauer, Wendy Lee, Charles Boyd, Shilpi Khetarpal, Breanna Pasko Jernigan
Dermatologic Surgery.2025; 51(12S): S15. CrossRef
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Denise Deo Dias, Andrea Rodrigues Vasconcelos, Ana Carolina Remondi Souza, Caroline de Menezes, Isabella Sobral Teixeira e Silva, José João Name
Obesities.2025; 5(4): 88. CrossRef
Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung
Felix Kerlikowsky, Klaus Krämer, Manfred Eggersdorfer, Andreas Hahn
Ernährung & Medizin.2025; 40(04): 167. CrossRef
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Suraj Bala, Kevin C. Allan, Nicole L. Decker, Nadia J. Abbass, Julia H. Joo, Alison Zhao, Katherine E. Talcott, Aleksandra V. Rachitskaya
Survey of Ophthalmology.2025;[Epub] CrossRef
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi
Biomedicines.2024; 12(8): 1630. CrossRef
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Vincenzo Rochira, Carla Greco, Stefano Boni, Francesco Costantino, Leonardo Dalla Valentina, Eleonora Zanni, Leila Itani, Marwan El Ghoch
Diseases.2024; 12(9): 204. CrossRef
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders
John O Olukorode, Dolapo A Orimoloye, Nwachukwu O Nwachukwu, Chidera N Onwuzo, Praise O Oloyede, Temiloluwa Fayemi, Oluwatobi S Odunaike, Petra S Ayobami-Ojo, Nwachi Divine, Demilade J Alo, Chukwurah U Alex
Cureus.2024;[Epub] CrossRef
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Jorge F.A. Model, Rafaella S. Normann, Éverton L. Vogt, Maiza Von Dentz, Marjoriane de Amaral, Rui Xu, Tsvetan Bachvaroff, Poli Mara Spritzer, J. Sook Chung, Anapaula S. Vinagre
Biochemical Pharmacology.2024; 230: 116623. CrossRef
Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies
Karen Feghali, Xilong Li, Naim M. Maalouf
Kidney360.2024; 5(11): 1706. CrossRef
Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway
Mingyun Tang, Long Zhao, Fuchun Huang, Tiangang Wang, Xu Wu, Shanshan Chen, Juan Fu, Chaoli Jiang, Shulin Wei, Xuseng Zeng, Xiaoling Zhang, Xin Zhou, Mei Wei, Zhi Li, Guohui Xiao
Frontiers in Nutrition.2024;[Epub] CrossRef
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
Current Issues in Molecular Biology.2024; 46(12): 14514. CrossRef

Original Articles

Basic Research
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification: Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee; Diabetes Metab J. 2024;48(1):83-96. Published online January 3, 2024; DOI: https://doi.org/10.4093/dmj.2022.0363

9,053 View
322 Download
13 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Glucagon-like peptide-1 receptor agonist (GLP-1RA), which is a therapeutic agent for the treatment of type 2 diabetes mellitus, has a beneficial effect on the cardiovascular system.
Methods
To examine the protective effects of GLP-1RAs on proliferation and migration of vascular smooth muscle cells (VSMCs), A-10 cells exposed to angiotensin II (Ang II) were treated with either exendin-4, liraglutide, or dulaglutide. To examine the effects of GLP-1RAs on vascular calcification, cells exposed to high concentration of inorganic phosphate (Pi) were treated with exendin-4, liraglutide, or dulaglutide.
Results
Ang II increased proliferation and migration of VSMCs, gene expression levels of Ang II receptors AT1 and AT2, proliferation marker of proliferation Ki-67 (Mki-67), proliferating cell nuclear antigen (Pcna), and cyclin D1 (Ccnd1), and the protein expression levels of phospho-extracellular signal-regulated kinase (p-Erk), phospho-c-JUN N-terminal kinase (p-JNK), and phospho-phosphatidylinositol 3-kinase (p-Pi3k). Exendin-4, liraglutide, and dulaglutide significantly decreased the proliferation and migration of VSMCs, the gene expression levels of Pcna, and the protein expression levels of p-Erk and p-JNK in the Ang II-treated VSMCs. Erk inhibitor PD98059 and JNK inhibitor SP600125 decreased the protein expression levels of Pcna and Ccnd1 and proliferation of VSMCs. Inhibition of GLP-1R by siRNA reversed the reduction of the protein expression levels of p-Erk and p-JNK by exendin-4, liraglutide, and dulaglutide in the Ang II-treated VSMCs. Moreover, GLP-1 (9-36) amide also decreased the proliferation and migration of the Ang II-treated VSMCs. In addition, these GLP-1RAs decreased calcium deposition by inhibiting activating transcription factor 4 (Atf4) in Pi-treated VSMCs.
Conclusion
These data show that GLP-1RAs ameliorate aberrant proliferation and migration in VSMCs through both GLP-1Rdependent and independent pathways and inhibit Pi-induced vascular calcification.

Citations

Citations to this article as recorded by

ATF4 in cardiovascular diseases: an emerging therapeutic target
Luning Qin, Ruolan Chen, Chao Huang, Xuezhe Wang, Qinghang Song, Zhaoqing Li, Xiaojian Xu, Zhijun Liu, Banghui Wang, Bing Li, Xian-Ming Chu
Biochemical Pharmacology.2026; 246: 117703. CrossRef
The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion
Nicholas C. Bank, Daniel Whittingslow, Sam Duggan, Joshua L. Morningstar, Douglas S. Weinberg
World Neurosurgery.2026; 206: 124751. CrossRef
Liraglutide Ameliorates Injury‐Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K–mTOR Signaling Pathway
Zongyi Zhang, Guixian Wu, Chaozhi Xu, Shanqian Li, Yulin Zhang, Yue Hu, Wanhua Wu, Hongyu Ding, Yuling Liu, Yue Huang, Wenjun Lu, Meimei Zheng, Yue Zhang, Hongxian Wu, Lina Hu
The FASEB Journal.2026;[Epub] CrossRef
Association between glucagon-like peptide-1 receptor agonists and femur fracture risk in type 2 diabetes: A large-scale target trial emulation
Yao-Jen Chang, Chiou-Shann Fuh, Jie-Fan Chang, Meng-Ting Chen, Ming-Hsien Tsai
Bone.2026; 207: 117851. CrossRef
Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, Angelo Sasso, Luca Gaetano Tarquinio, Federico Cacciapuoti
Heart and Mind.2025; 9(2): 147. CrossRef
Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study
Vedant Agrawal, Saketh Amasa, Mert Karabacak, Konstantinos Margetis
Neurosurgery.2025; 97(1): 91. CrossRef
ALOX15 Aggravates Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice with Type 2 Diabetes via Activating the PPARγ/CD36 Axis
Wenhui Yan, Xin Cui, Tingli Guo, Na Liu, Zhuanzhuan Wang, Yuzhuo Sun, Yuanrui Shang, Jieyun Liu, Yuanyuan Zhu, Yangyang Zhang, Lina Chen
Antioxidants & Redox Signaling.2025; 43(1-3): 37. CrossRef
Targeting the S100A9/P38 MAPK/HSPB1 axis as a novel approach for aortic dissection therapy
Likang Ma, Linfeng Xie, Qingsong Wu, Lei Jin, Jiakang Li, Lele Tang, Li Zhang, Liangwan Chen, Zhihuang Qiu
International Immunopharmacology.2025; 149: 114225. CrossRef
Involvement of miRNA-204 carried by the exosomes of macrophages in the AT2 receptor-mediated improvement of vascular calcification
Hui-Yu Bai, Xiao-Rui Lv, Hai-Bo Gu, Hui Li, Bao-Shuai Shan
Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease
Luxcia Kugathasan, Yarden Aronson, Vikas S. Sridhar, Huajing Ni, Jean-Philippe Ouimet, Christine P. Limonte, Shohinee Sarma, David Z. I. Cherney
Expert Review of Clinical Immunology.2025; 21(8): 1113. CrossRef
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation
Husam Abu-Nejim, Richard C. Becker
Current Atherosclerosis Reports.2025;[Epub] CrossRef
Intracellular angiotensin-II measurement in streptozotocin-induced rat vascular smooth muscle cells and its relationship with angiotensin-II receptors
Zehra Çiçek, Kübra Akıllıoğlu, Zehra Gül Yaşar, Ayşe Doğan
The European Research Journal.2025; : 1. CrossRef
Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies
Youngwoo Jang, Eun-Jung Rhee, Sung Hee Choi
Endocrinology and Metabolism.2025; 40(5): 668. CrossRef
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović, Antonio Simone Laganà
Biomedicines.2024; 12(3): 653. CrossRef
BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease
Yalan Li, Xiaoyue Chen, Yiqing Xiong, Xueqiang Xu, Caidie Xie, Min Min, Dongmei Liang, Cheng Chen, Huijuan Mao
Journal of Translational Medicine.2024;[Epub] CrossRef

Drug/Regimen
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang; Diabetes Metab J. 2023;47(3):394-404. Published online March 6, 2023; DOI: https://doi.org/10.4093/dmj.2022.0221

14,069 View
446 Download
33 Web of Science
37 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care.
Methods
This retrospective cohort study emulating a target trial included patient data from the multi-institutional Chang Gung Research Database in Taiwan. Totally, 33,021 patients with type 2 diabetes mellitus using SGLT2is and GLP1-RAs between 2016 and 2019 were identified. 3,249 patients were excluded due to missing demographics, age <40 years, prior use of any study drug, a diagnosis of retinal disorders, a history of receiving vitreoretinal procedure, no baseline glycosylated hemoglobin, or no follow-up data. Baseline characteristics were balanced using inverse probability of treatment weighting with propensity scores. DR diagnoses and vitreoretinal interventions served as the primary outcomes. Occurrence of proliferative DR and DR receiving vitreoretinal interventions were regarded as vision-threatening DR.
Results
There were 21,491 SGLT2i and 1,887 GLP1-RA users included for the analysis. Patients receiving SGLT2is and GLP-1 RAs exhibited comparable rate of any DR (subdistribution hazard ratio [SHR], 0.90; 95% confidence interval [CI], 0.79 to 1.03), whereas the rate of proliferative DR (SHR, 0.53; 95% CI, 0.42 to 0.68) was significantly lower in the SGLT2i group. Also, SGLT2i users showed significantly reduced risk of composite surgical outcome (SHR, 0.58; 95% CI, 0.48 to 0.70).
Conclusion
Compared to those taking GLP1-RAs, patients receiving SGLT2is had a lower risk of proliferative DR and vitreoretinal interventions, although the rate of any DR was comparable between the SGLT2i and GLP1-RA groups. Thus, SGLT2is may be associated with a lower risk of vision-threatening DR but not DR development.

Citations

Citations to this article as recorded by

The influence of dapagliflozin on diabetic ocular complications: An observational cohort study
Jo-Hsin Chen, Fei-Hung Hung, Yu-Ting Wang, Jin-Hua Chen, Shu-Fen Liao, Chun-Mei Hsueh, Jong-Shiuan Yeh, Gregory Y.H. Lip
European Journal of Pharmaceutical Sciences.2026; 216: 107382. CrossRef
Diabetic retinopathy: why some eyes suffer more – a focus on retina-specific risk factors and metabolic memory
Shanshan Tang, Linlin Jiang, Wenjie Sun, Xuedong An, Xiaomin Kang, Xuefei Zhao, Qing Gao, Zehua Li, Chenran Liu, Hangyu Ji, Fengmei Lian
Journal of Translational Medicine.2026;[Epub] CrossRef
Design and Implementation of Observational Studies Emulating a Target Trial
Yan Ren, Yulong Jia, Lingyan Liu, Houchen Lyv, Liyuan Tao, Yuezhen Li, Peng Zhao, Yiquan Xiong, Guowei Li, Jiayue Xu, Chunrong Liu, Yongmei Lu, Kang Zou, Jing Tan, Xin Sun
JAMA Network Open.2026; 9(2): e2558262. CrossRef
Association between pentoxifylline use and diabetic retinopathy in patients with type 2 diabetes mellitus and chronic kidney disease: A multi-institutional cohort study
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Nan-Kai Wang, Je-Ho Kang, Kuan-Jen Chen, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Biomedical Journal.2025; 48(3): 100771. CrossRef
Impact of glucagon‐like peptide‐1 receptor agonists on diabetic retinopathy: A meta‐analysis of clinical studies emphasising retinal changes as a primary outcome
Ishani Kapoor, Swara M. Sarvepalli, David A. D'Alessio, Majda Hadziahmetovic
Clinical & Experimental Ophthalmology.2025; 53(1): 67. CrossRef
SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy
Maria S. Varughese, Lakshminarayanan Varadhan
Eye.2025; 39(2): 213. CrossRef
Impact of Obstructive Sleep Apnea on Diabetic Retinopathy Progression and Systemic Complications
Ehsan Rahimy, Euna B. Koo, Karen M. Wai, Cassie A. Ludwig, Andrea L. Kossler, Prithvi Mruthyunjaya
American Journal of Ophthalmology.2025; 270: 93. CrossRef
An update on ocular effects of antidiabetic medications
Elham Sadeghi, Elham Rahmanipour, Nicola Valsecchi, Saloni Kapoor, Maria Vittoria Cicinelli, Jay Chhablani
Survey of Ophthalmology.2025; 70(4): 704. CrossRef
Glucagon-like peptide-1 receptor agonists and the eye
David L. Zhang, Avni P. Finn
Current Opinion in Ophthalmology.2025; 36(5): 407. CrossRef
Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies
Nathaniel Eraikhuemen, Bria George, Simon Leung, Shalonda Barnes Warren, Valerie Marcellus, Delany Santos Ferrer, Quovadis Epps
Journal of Clinical Ophthalmology and Research.2025; 13(2): 220. CrossRef
Linear and non-linear association of chronic kidney disease with retina and choroid vessel density in diabetes: a prospective study
Lijian Fang, Ruiheng Zhang, Suoqing Zhuang, Lei Wang, Qiuping Wang, Yong Huang, Mingli Wang, Yu Feng, Min Xiao, Chunyuan Zhou, Lili Wu, Sihan Zhang, Lili Xue, Tong Tian, Yuanyuan Li, Bing Cao, Huaiyu Hao
Photodiagnosis and Photodynamic Therapy.2025; 53: 104625. CrossRef
Comparison of Sodium‐Glucose Cotransporter 2 Inhibitors Versus Glucagon‐Like Peptide‐1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score‐Matched Cohorts Retrospective Study
Yu‐Chi Su, Pei‐Chun Hsieh, Edward Chia‐Cheng Lai, Yu‐Ching Lin
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?
Stela Vujosevic, Caterina Toma, Anna Ferrulli, Stefano De Cillà, Paolo Nucci, Livio Luzi
Acta Diabetologica.2025; 62(10): 1573. CrossRef
Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
Tomoaki Tatsumi, Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomomi Kaiho, Toshiyuki Oshitari, Yuki Shiko, Noriko Asaumi, Shuichi Yamamoto, Koutaro Yokote, Takayuki Baba
Diabetes, Obesity and Metabolism.2025; 27(10): 5812. CrossRef
Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
Kai Liu, Shu Liu, Dong Wang, Hong Qiao
Diabetes & Metabolism.2025; 51(6): 101696. CrossRef
Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study
Yueh‐Tsung Lee, Jheng‐Yan Wu, Tsung W. Chang, Cheng‐Hsien Hung
Diabetes, Obesity and Metabolism.2025; 27(12): 7299. CrossRef
Sodium-glucose cotransporter 2 inhibitors and risk of diabetic retinopathy: systematic review and meta-analysis
Le Liang, Liping Yu, Yani He, Li Liu, Haohuan Yuan, Yating Hu, Jin Sun
Canadian Journal of Ophthalmology.2025;[Epub] CrossRef
SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis
Saba Goodarzi, Faezah Soltani Abhari, Gelareh Azarinoush, Mohammd Ali Rafiei, Hessam Yousefian, Ehsan Heidari, Edris Ekramipour, Afshin Mirzaei, Kosar Namakin, Arman Shafiee
International Ophthalmology.2025;[Epub] CrossRef
Semaglutide and diabetic retinopathy: an OHDSI network study
Cindy Xinji Cai, Akihiko Nishimura, Sally Baxter, Kerry Goetz, Michelle Hribar, Brian Toy, Andrew Barkmeier, Sophia Wang, Swarup Swaminathan, Alexis Flowers, Eric Brown, Benjamin Xu, John Chen, Aiyin Chen, Theodore Leng, Michael Boland, Thamir Alshammari,
BMJ Open Diabetes Research & Care.2025; 13(6): e005424. CrossRef
Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis
Hassan Alwafi, Sarah Saleh Al-Harbi, Ghada Ahmad Aladwani, Safaa M. Alsanosi, Tope Oyelade, Fahd Almalki, Husna Irfan Thalib, Abdallah Y. Naser, Manal Z. Alfahmi, Basil AlOtaibi, Samra Fuad, Mohammed Talha Mohammed Zubair, Abdulelah M. Aldhahir, Widya N.
Frontiers in Medicine.2025;[Epub] CrossRef
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Suraj Bala, Kevin C. Allan, Nicole L. Decker, Nadia J. Abbass, Julia H. Joo, Alison Zhao, Katherine E. Talcott, Aleksandra V. Rachitskaya
Survey of Ophthalmology.2025;[Epub] CrossRef
Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
Diabetes, Obesity and Metabolism.2024; 26(2): 721. CrossRef
Association of sodium–glucose cotransporter‐2 inhibitors and the risk of retinal vascular occlusion: A real‐world retrospective cohort study in Taiwan
Tzu‐Yi Lin, Eugene Yu‐Chuan Kang, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, Nan‐Kai Wang, Sunir J. Garg, Kuan‐Jen Chen, Je‐Ho Kang, Wei‐Chi Wu, Chi‐Chun Lai, Yih‐Shiou Hwang
Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study
Yu-Chi Su, Pei-Chun Hsieh, Edward Chia-Cheng Lai, Yu-Ching Lin
Diabetes & Metabolism.2024; 50(2): 101522. CrossRef
Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint
Sarita Jacob, George I. Varughese
Clinical Medicine.2024; 24(2): 100031. CrossRef
Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
Aikaterini Eleftheriadou, David Riley, Sizheng S. Zhao, Philip Austin, Gema Hernández, Gregory Y. H. Lip, Timothy L. Jackson, John P. H. Wilding, Uazman Alam
Diabetologia.2024; 67(7): 1271. CrossRef
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study
Karen M. Wai, Kapil Mishra, Euna Koo, Cassie Ann Ludwig, Ravi Parikh, Prithvi Mruthyunjaya, Ehsan Rahimy
American Journal of Ophthalmology.2024; 265: 39. CrossRef
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
Ophthalmology Retina.2024; 8(10): 943. CrossRef
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis
Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He
Expert Review of Clinical Pharmacology.2024; 17(10): 949. CrossRef
Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World Data
Masaya Koshizaka, Tomoaki Tatsumi, Fumiko Kiyonaga, Yoshinori Kosakai, Yoko Yoshinaga, Mami Shintani-Tachi
Diabetes Therapy.2024; 15(11): 2401. CrossRef
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY
Rithwick Rajagopal, Janet B. McGill
Retina.2024; 44(11): 1851. CrossRef
Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy
Bowen Zhao, Yin Zhao, Xufang Sun
Pharmacological Research.2024; 210: 107505. CrossRef
Diabetes Renders Photoreceptors Susceptible to Retinal Ischemia-Reperfusion Injury
David A. Antonetti, Cheng-Mao Lin, Sumathi Shanmugam, Heather Hager, Manjing Cao, Xuwen Liu, Alyssa Dreffs, Adam Habash, Steven F. Abcouwer
Investigative Ophthalmology & Visual Science.2024; 65(13): 46. CrossRef
Multi-omics in exploring the pathophysiology of diabetic retinopathy
Xinlu Li, XiaoJing Dong, Wen Zhang, Zhizhou Shi, Zhongjian Liu, Yalian Sa, Li Li, Ninghua Ni, Yan Mei
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Yih-Shiou Hwang
Diabetes & Metabolism Journal.2023; 47(4): 573. CrossRef
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
Jihee Ko, Sun Joon Moon
Diabetes & Metabolism Journal.2023; 47(4): 571. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
Fu-Shun Yen, James Cheng-Chung Wei, Teng-Shun Yu, Yu-Tung Hung, Chih-Cheng Hsu, Chii-Min Hwu
JAMA Network Open.2023; 6(12): e2348431. CrossRef

Complications
Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis: Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni; Diabetes Metab J. 2022;46(6):901-911. Published online April 12, 2022; DOI: https://doi.org/10.4093/dmj.2021.0314

11,924 View
321 Download
22 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
In addition to the metabolic effects in diabetes, glucagon-like peptide 1 receptor (GLP-1R) agonists lead to a small but substantial increase in heart rate (HR). However, the GLP-1R actions on the autonomic nervous system (ANS) in diabetes remain debated. Therefore, this meta-analysis evaluates the effect of GLP-1R agonist on measures of ANS function in diabetes.
Methods
According to the Cochrane Collaboration and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, we conducted a meta-analysis considering clinical trials in which the autonomic function was evaluated in diabetic subjects chronically treated with GLP-1R agonists. The outcomes were the change of ANS function measured by heart rate variability (HRV) and cardiac autonomic reflex tests (CARTs).
Results
In the studies enrolled, HR significantly increased after treatment (P<0.001), whereas low frequency/high frequency ratio did not differ (P=0.410); no changes in other measures of HRV were detected. Considering CARTs, only the 30:15 value derived from lying-to-standing test was significantly lower after treatment (P=0.002), but only two studies reported this measurement. No differences in other CARTs outcome were observed.
Conclusion
The meta-analysis confirms the HR increase but seems to exclude an alteration of the sympatho-vagal balance due to chronic treatment with GLP-1R agonists in diabetes, considering the available measures of ANS function.

Citations

Citations to this article as recorded by

Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review
Jelena Vekic, Aleksandra Zeljkovic, Viviana Maggio, Manfredi Rizzo, Sanja Medenica
Diabetes Therapy.2026;[Epub] CrossRef
Cardiac Autonomic Neuropathy in Diabetes Mellitus: Pathogenesis, Epidemiology, Diagnosis and Clinical Implications: A Narrative Review
Alexandra Gogan, Ovidiu Potre, Vlad-Florian Avram, Minodora Andor, Florina Caruntu, Bogdan Timar
Journal of Clinical Medicine.2025; 14(3): 671. CrossRef
Effect of the glucagon‐like peptide‐1 receptor agonists on diabetic peripheral neuropathy: A meta‐analysis
Shujin Fan, Yue Qiu, Jing Liu, Tianxin Zhu, Chuan Wang, Dan Liu, Li Yan, Meng Ren
Journal of Neurochemistry.2025;[Epub] CrossRef
Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference
Gregory J. Grosicki, Jeongeun Kim, Finn Fielding, Summer R. Jasinski, Christopher Chapman, William von Hippel, Kristen E. Holmes
American Journal of Physiology-Heart and Circulatory Physiology.2025; 328(2): H235. CrossRef
The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
Eman A. Toraih, Awwad Alenezy, Mohammad H. Hussein, Shahmeer Hashmat, Saitej Mummadi, Nawaf Farhan Alrawili, Ahmed Abdelmaksoud, Manal S. Fawzy
Biomedicines.2025; 13(5): 1049. CrossRef
Anorgasmia following initiation of GLP-1 agonist
Vidya Visvabharathy, Sally MacPhedran, Katie Shupp, Benjamin King
Sexual Medicine.2025;[Epub] CrossRef
Expanding the concept of pharma-cise: A graphical primer for clinicians, researchers and industry
Ross Arena, Jonathan Myers, Nicolaas P. Pronk
Current Problems in Cardiology.2025; 50(10): 103144. CrossRef
Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials
Mohammed El-Sheikh, Christina Dam Bjerregaard Sillassen, Frederik Dencker Wisborg, Jens Dahlgaard Hove, Carsten Dirksen, Matthew Meng Yang Lee, Janus C Jakobsen, Johannes Grand
BMJ Open.2025; 15(9): e103668. CrossRef
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation
Husam Abu-Nejim, Richard C. Becker
Current Atherosclerosis Reports.2025;[Epub] CrossRef
Genetic variation in the glucagon-like peptide-1 receptor protein encoding region is associated with higher heart rate variability, but not with neurodegeneration of the brain, retina, and peripheral nerves: The Maastricht study
Frank C. T. van der Heide, Indra L. M. Steens, Archana Singh-Manoux, Séverine Sabia, Tan Lai Zhou, Sebastian Köhler, Miranda T. Schram, Carla J. H. van der Kallen, Tos T. J. M. Berendschot, Carroll A. B. Webers, Marleen M. J. van Greevenbroek, Anke Wessel
Cardiovascular Diabetology.2025;[Epub] CrossRef
Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates
Magdy Abdelhamid, Mostafa M Abdrabou, Emanuel Faris, Sameh El Kafas, Mohamed Hosny, Ahmed Hassan
Cardiac Failure Review.2025;[Epub] CrossRef
GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
American Journal of Hypertension.2025;[Epub] CrossRef
Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
Qianyi Li, Chunxuan Wu, Shiqun Sun, Lingchao Yang, Yanyan Li, Yixin Niu, Li Zhang, Wei Li, Ying Yu
Journal of Diabetes.2024;[Epub] CrossRef
A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
Diabetes, Obesity and Metabolism.2024; 26(8): 3167. CrossRef
Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
Aikaterini Eleftheriadou, Vincenza Spallone, Abd A. Tahrani, Uazman Alam
Diabetologia.2024; 67(12): 2611. CrossRef
Autonomic Nervous System: A Therapeutic Target for Cardiac End-Organ Damage in Hypertension
Lisa A. Gottlieb, Felix Mahfoud, Stavros Stavrakis, Thomas Jespersen, Dominik Linz
Hypertension.2024; 81(10): 2027. CrossRef
Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics
Anthony J. Evans, Yu-Long Li
International Journal of Molecular Sciences.2024; 25(22): 12464. CrossRef
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh, Kyung Mook Choi
International Journal of Molecular Sciences.2023; 24(4): 3384. CrossRef
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Yi-lin Huang, Xiao-zhuo Xu, Jing Liu, Pin-yao Wang, Xue-li Wang, Hong-lin Feng, Cheng-jiang Liu, Xu Han
BMC Cardiovascular Disorders.2023;[Epub] CrossRef
Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023
Tiffany Lowe Clayton, Angela Fitch, Harold Edward Bays
Obesity Pillars.2023; 8: 100083. CrossRef
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
Diabetologia.2023; 66(10): 1832. CrossRef
Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis
Susumu Z. Sudo, Tadeu L. Montagnoli, Bruna de S. Rocha, Aimeé D. Santos, Mauro P. L. de Sá, Gisele Zapata-Sudo
Biomedicines.2022; 10(12): 3258. CrossRef

Basic Research
DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice: Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang; Diabetes Metab J. 2022;46(2):337-348. Published online January 21, 2022; DOI: https://doi.org/10.4093/dmj.2021.0056

12,026 View
384 Download
19 Web of Science
23 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated the antidiabetic effects of DA-1241, a novel G protein-coupled receptor (GPR) 119 agonist, in vitro and in vivo.
Methods
DA-1241 was administrated to high-fat diet (HFD)-fed C57BL/6J mice for 12 weeks after hyperglycaemia developed. Oral/intraperitoneal glucose tolerance test and insulin tolerance test were performed. Serum insulin and glucagon-like peptide-1 (GLP-1) levels were measured during oral glucose tolerance test. Insulinoma cell line (INS-1E) cells and mouse islets were used to find whether DA-1241 directly stimulate insulin secretion in beta cell. HepG2 cells were used to evaluate the gluconeogenesis and autophagic process. Autophagic flux was evaluated by transfecting microtubule-associated protein 1 light chain 3-fused to green fluorescent protein and monomeric red fluorescent (mRFP-GFP-LC3) expression vector to HepG2 cells.
Results
Although DA-1241 treatment did not affect body weight gain and amount of food intake, fasting blood glucose level decreased along with increase in GLP-1 level. DA-1241 improved only oral glucose tolerance test and showed no effect in intraperitoneal glucose tolerance test. No significant effect was observed in insulin tolerance test. DA-1241 did not increase insulin secretion in INS-1E cell and mouse islets. DA-1241 reduced triglyceride content in the liver thereby improved fatty liver. Additionally, DA-1241 reduced gluconeogenic enzyme expression in HepG2 cells and mouse liver. DA-1241 reduced autophagic flow in HepG2 cells.
Conclusion
These findings suggested that DA-1241 augmented glucose-dependent insulin release via stimulation of GLP-1 secretion, and reduced hepatic gluconeogenesis, which might be associated with autophagic blockage, leading to improved glycaemic control.

Citations

Citations to this article as recorded by

High‐Protein Diet Exacerbates Insulin Resistance via the JNK/IKKβ‐IRS‐1 Pathway
Junjun Li, Jinhua Xu, Jinmiao Tian, Lixia Chen, Lili Zhao, Yongming Yang, Jing Wang, Lei Yan, Yuxin Yang, Yuchen Jiang, Simin Chen, Binxuan Wang, Lulu Wang, Xihua Yang
Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119–AMPK signaling
Yangzheng He, Jing Li, Zhigang Wen, Yong Sun, Liufeng Zheng, Hongyan Li, Zeyuan Deng
Journal of Advanced Research.2026;[Epub] CrossRef
Discovery of 1,4-Disubstituted Cyclohexene Analogues as Selective GPR119 Agonists for the Treatment of Type 2 Diabetes
Hyunhwa La, Jinwoong Kim, Dae-Hoon Kim, Seong-Heon Kim, Pargat Singh, Gibeom Nam, Kyeongwon Moon, Ikyon Kim, In Su Kim
Journal of Medicinal Chemistry.2025; 68(4): 4619. CrossRef
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, Soumendra Rana
Comprehensive Physiology.2025;[Epub] CrossRef
Unraveling the Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions
Mohammad Muzaffar Mir, Mohammed Jeelani, Muffarah Hamid Alharthi, Syeda Fatima Rizvi, Shahzada Khalid Sohail, Javed Iqbal Wani, Zia Ul Sabah, Waad Fuad BinAfif, Partha Nandi, Abdullah M. Alshahrani, Jaber Alfaifi, Adnan Jehangir, Rashid Mir
International Journal of Molecular Sciences.2025; 26(6): 2770. CrossRef
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Barbara Gieroba, Adrianna Kryska, Anna Sroka-Bartnicka
Biochemistry and Biophysics Reports.2025; 42: 102037. CrossRef
DA-1241, a GPR119 Agonist, Ameliorates Fatty Liver Through the Upregulation of TFEB-Mediated Autophagy
Jin Yoo, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, Myung-Shik Lee, You-Cheol Hwang
Diabetes.2025; 74(7): 1107. CrossRef
Design, synthesis, and antidiabetic activities of 5-methoxypyrimidine derivatives targeting GPR119 and DPP-4
Fukang Yang, Sumei Shi, Shaobing Cheng, Huilan Li, Mai Zhang, Pei Hu, Zunhua Yang, Yuanying Fang
Bioorganic & Medicinal Chemistry.2025; 129: 118318. CrossRef
LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies
Seung Jin Kim, Won Seok Bang, Zhengri Li, Mi Hye Kwon, Dae Young Lee, Hee Eun Kang
Journal of Mass Spectrometry.2025;[Epub] CrossRef
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
Biomedicine & Pharmacotherapy.2024; 172: 116245. CrossRef
GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates
Deanne H Hryciw, Rhiannon K Patten, Raymond J Rodgers, Joseph Proietto, Dana S Hutchinson, Andrew J McAinch
Expert Opinion on Investigational Drugs.2024; 33(3): 183. CrossRef
Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Katarzyna Napiórkowska-Baran, Paweł Treichel, Marta Czarnowska, Magdalena Drozd, Kinga Koperska, Agata Węglarz, Oskar Schmidt, Samira Darwish, Bartłomiej Szymczak, Zbigniew Bartuzi
International Journal of Molecular Sciences.2024; 25(7): 3769. CrossRef
Advances in small-molecule insulin secretagogues for diabetes treatment
Jingqian Su, Jingran Xu, Shan Hu, Hui Ye, Lian Xie, Songying Ouyang
Biomedicine & Pharmacotherapy.2024; 178: 117179. CrossRef
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?
Khaled Al Smadi, Ammar Qureshi, Besher Ashouri, Zeid Kayali
Expert Opinion on Investigational Drugs.2024; 33(9): 877. CrossRef
Chronic metabolic effects of novel gut-oriented small-molecule GPR119 agonists in diet-induced obese mice
Mohan Patil, Dinesh Thapa, Leon N. Warne, Ricky R. Lareu, Elena Dallerba, Jerome Lian, Massimiliano Massi, Rodrigo Carlessi, Marco Falasca
Biomedicine & Pharmacotherapy.2024; 181: 117675. CrossRef
Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy
Yuxuan Zhang, Jiali Zhou, Lan Yang, Hang Xiao, Dongbo Liu, Xincong Kang
Antioxidants.2024; 13(12): 1501. CrossRef
Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists
Heecheol Kim, Minjung Kim, Kyujin Oh, Sohee Lee, Sunyoung Lim, Sangdon Lee, Young Hoon Kim, Kwee Hyun Suh, Kyung Hoon Min
European Journal of Medicinal Chemistry.2023; 258: 115584. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
Karolien Buyl, Martine Vrints, Ruani Fernando, Terry Desmae, Thomas Van Eeckhoutte, Mia Jans, Jan Van Der Schueren, Joost Boeckmans, Robim M. Rodrigues, Veerle De Boe, Vera Rogiers, Joery De Kock, Filip Beirinckx, Tamara Vanhaecke
European Journal of Pharmacology.2023; 957: 175989. CrossRef
GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling
Seung-Ho Lee, Hansu Park, Eun-Kyoung Yang, Bo Ram Lee, Il-Hoon Jung, Tae-Hyoung Kim, Moon Jung Goo, Yuna Chae, Mi-Kyung Kim
Biomedicine & Pharmacotherapy.2023; 166: 115345. CrossRef
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun
The Journal of Korean Diabetes.2023; 24(3): 148. CrossRef
DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice
Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang
Diabetes & Metabolism Journal.2022; 46(2): 337. CrossRef
Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
Chun-Liang Chen, Yu-Cheng Lin
International Journal of Molecular Sciences.2022; 23(17): 10055. CrossRef

Short Communication

Drug/Regimen
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study: Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee; Diabetes Metab J. 2022;46(4):658-662. Published online November 8, 2021; DOI: https://doi.org/10.4093/dmj.2021.0232

65,535 View
454 Download
10 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated the real-world efficacy and safety of the combination of SGLT2i and GLP-1RA in patients with type 2 diabetes mellitus in Korea. The medical records of 104 patients who maintained the combination for at least 1 year were retrospectively reviewed. The change in glycosylated hemoglobin (HbA1c) after 6 months and 1 year of treatment was evaluated. The mean age was 51 years, and 41% were female. The mean baseline HbA1c, body mass index, and duration of diabetes were 9.0%, 28.8 kg/m², and 11.7 years, respectively. Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74; P<0.001) after 6 months and by 1.4% (95% CI, 1.19 to 1.70; P<0.001) after 1 year. Over 1 year, the bodyweight change was −2.8 kg (95% CI, −4.21 to −1.47; P<0.001). The combination of SGLT2i and GLP-1RA is effective and tolerable in type 2 diabetes mellitus patients in real-world practice.

Citations

Citations to this article as recorded by

Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy
Hariballav Mahapatra, Piyush Kumar Gupta, Ajo Paul, Amit Nampalliwar, Manju Bansal, Baijnath Das, K. Parameswaran Namboothiri
Cureus.2026;[Epub] CrossRef
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Carlos A. Yepes-Cortés, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, Karen M. Feriz-Bonelo, Erica Yama-Mosquera, Alex H. Ramirez-Rincón, Gilberto A. Castillo-Barrios, Andres F. Suarez-Rodriguez, Johanna Carreño-Jiménez, Carlos E. Builes-Montaño
Diabetes Therapy.2025; 16(5): 813. CrossRef
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology.2024;[Epub] CrossRef
Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome
Fernando Cortés-Camacho, Oscar René Zambrano-Vásquez, Elena Aréchaga-Ocampo, Jorge Ismael Castañeda-Sánchez, José Guillermo Gonzaga-Sánchez, José Luis Sánchez-Gloria, Laura Gabriela Sánchez-Lozada, Horacio Osorio-Alonso
Antioxidants.2024; 13(7): 768. CrossRef
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
António Cabral Lopes, Olga Lourenço, Manuel Morgado
Expert Review of Clinical Pharmacology.2024; 17(11): 1081. CrossRef
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh, Kyung Mook Choi
International Journal of Molecular Sciences.2023; 24(4): 3384. CrossRef
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J. Cuthbertson, Gregory Y. H. Lip, Uazman Alam
Diabetes, Obesity and Metabolism.2023; 25(10): 2897. CrossRef
The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Hwi Seung Kim, Woo Je Lee
Diabetes & Metabolism Journal.2022; 46(4): 665. CrossRef
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Tomoyuki Kawada
Diabetes & Metabolism Journal.2022; 46(4): 663. CrossRef
Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef

Original Articles

Complications
Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus: Hua-Xing Huang, Liang-Lan Shen, Hai-Yan Huang, Li-Hua Zhao, Feng Xu, Dong-Mei Zhang, Xiu-Lin Zhang, Tong Chen, Xue-Qin Wang, Yan Xie, Jian-Bin Su; Diabetes Metab J. 2021;45(6):868-879. Published online March 23, 2021; DOI: https://doi.org/10.4093/dmj.2020.0149

9,921 View
193 Download
9 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Type 2 diabetes mellitus (T2DM) is characterized by elevated fasting glucagon and impaired suppression of postprandial glucagon secretion, which may participate in diabetic complications. Therefore, we investigated the associations of plasma glucagon with estimated glomerular filtration rate (eGFR), albuminuria and diabetic kidney disease (DKD) in T2DM patients.
Methods
Fasting glucagon and postchallenge glucagon (assessed by area under the glucagon curve [AUC_gla]) levels were determined during oral glucose tolerance tests. Patients with an eGFR <60 mL/min/1.73 m² and/or a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g who presented with diabetic retinopathy were identified as having DKD.
Results
Of the 2,436 recruited patients, fasting glucagon was correlated with eGFR and UACR (r=–0.112 and r=0.157, respectively; P<0.001), and AUC_gla was also correlated with eGFR and UACR (r=–0.267 and r=0.234, respectively; P<0.001). Moreover, 31.7% (n=771) presented with DKD; the prevalence of DKD was 27.3%, 27.6%, 32.5%, and 39.2% in the first (Q1), second (Q2), third (Q3), and fourth quartile (Q4) of fasting glucagon, respectively; and the corresponding prevalence for AUC_gla was 25.9%, 22.7%, 33.7%, and 44.4%, respectively. Furthermore, after adjusting for other clinical covariates, the adjusted odds ratios (ORs; 95% confidence intervals) for DKD in Q2, Q3, and Q4 versus Q1 of fasting glucagon were 0.946 (0.697 to 1.284), 1.209 (0.895 to 1.634), and 1.521 (1.129 to 2.049), respectively; the corresponding ORs of AUC_gla were 0.825 (0.611 to 1.114), 1.323 (0.989 to 1.769), and 2.066 (1.546 to 2.760), respectively. Additionally, when we restricted our analysis in patients with glycosylated hemoglobin <7.0% (n=471), we found fasting glucagon and AUC_gla were still independently associated with DKD.
Conclusion
Both increased fasting and postchallenge glucagon levels were independently associated with DKD in T2DM patients.

Citations

Citations to this article as recorded by

Acetylation of CPT1A reduces fatty acid oxidation and leads to dysfunctional renal tubular mitochondria in diabetic kidney disease
Siyao Sun, Sen Liu, Shiyan Ruan, Hongli Zhou, Xiangfei Cui, Ning Lu, Liu Hong, Miaomiao Lu
Biochemical Pharmacology.2026; 243: 117465. CrossRef
The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications
Song Wen, Chenglin Xu, Yue Yuan, Lijiao Chen, Yishu Ren, Zhimin Xu, Jianlan Jin, Jiyu Li, Ligang Zhou
Frontiers in Medicine.2026;[Epub] CrossRef
Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control
Seung Hee Lee, Hyeon Young Park, Ji Ho Yun, Eun Kyoung Do
Frontiers in Endocrinology.2025;[Epub] CrossRef
Prolonged glucagon exposure rewires lipid oxidation and drives diabetic kidney disease progression
Xingfeng Liu, Jingwen Chen, Shengying Gu, Yibing Chen, Ruiping Zhang, Qingce Zang, Ting Li, Hanwen Li, Dejin Lu, Shaocong Hou, Lijuan Kong, Qian Jiang, Caiyi Xing, Wenjia Fan, Yanjun Wan, Jiaqi Zhang, Linyuan Zhu, Chunxiao Ma, Qijin Zhao, Hai Yan, Zeper A
Nature Communications.2025;[Epub] CrossRef
Fasting glucagon as an independent risk indicator for CAD in patient with type 2 diabetes
Linlin Kong, Lina Chang, Jiamin Nie, Yian Gu, Xin Wang, Siyu Yan, Wantong Han, Hequn Sang, Shaofang Tang, Ming Liu, Qing He
Frontiers in Endocrinology.2025;[Epub] CrossRef
Random survival forest for predicting the combined effects of multiple physiological risk factors on all-cause mortality
Bu Zhao, Vy Kim Nguyen, Ming Xu, Justin A. Colacino, Olivier Jolliet
Scientific Reports.2024;[Epub] CrossRef
Endocrine Disorders in Nephrotic Syndrome—A Comprehensive Review
Maja Mizdrak, Bozo Smajic, Ivan Mizdrak, Tina Ticinovic Kurir, Marko Kumric, Ivan Paladin, Darko Batistic, Josko Bozic
Biomedicines.2024; 12(8): 1860. CrossRef
Glucagon in type 2 diabetes: Friend or foe?
Irene Caruso, Nicola Marrano, Giuseppina Biondi, Valentina Annamaria Genchi, Rossella D'Oria, Gian Pio Sorice, Sebastio Perrini, Angelo Cignarelli, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino
Diabetes/Metabolism Research and Reviews.2023;[Epub] CrossRef

Drug/Regimen
Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus: Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho; Diabetes Metab J. 2020;44(2):248-259. Published online November 4, 2019; DOI: https://doi.org/10.4093/dmj.2019.0018

14,468 View
283 Download
21 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To investigate the effects of a glucagon-like peptide-1 receptor agonist on functional brain activation in lean and obese individuals with type 2 diabetes mellitus (T2DM) in response to visual food cues.

Methods

In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period. We evaluated brain activation in response to pictures of high-calorie food, low-calorie food, and nonfood using functional magnetic resonance imaging and measured appetite and caloric intake in participants who were given access to an ad libitum buffet.

Results

Obese individuals with T2DM showed significantly greater activation of the hypothalamus, pineal gland, parietal cortex (high-calorie food vs. low-calorie food, P<0.05), orbitofrontal cortex (high-calorie food vs. nonfood, P<0.05), and visual cortex (food vs. nonfood, P<0.05) than lean individuals with T2DM. Lixisenatide injection significantly reduced the functional activation of the fusiform gyrus and lateral ventricle in obese individuals with T2DM compared with that in lean individuals with T2DM (nonfood vs. high-calorie food, P<0.05). In addition, in individuals who decreased their caloric intake after lixisenatide injection, there were significant interaction effects between group and treatment in the posterior cingulate, medial frontal cortex (high-calorie food vs. low-calorie food, P<0.05), hypothalamus, orbitofrontal cortex, and temporal lobe (food vs. nonfood, P<0.05).

Conclusion

Brain responses to visual food cues were different in lean and obese individuals with T2DM. In addition, acute administration of lixisenatide differentially affected functional brain activation in these individuals, especially in those who decreased their caloric intake after lixisenatide injection.

Citations

Citations to this article as recorded by

Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence
Cristian-Daniel Llach, Sebastian Badulescu, Aniqa Tabassum, Hiya Shah, Hartej Gill, Gia Han Le, Eduard Vieta, Roger S. McIntyre, Joshua D. Rosenblat, Rodrigo B. Mansur
Molecular Psychiatry.2026; 31(1): 456. CrossRef
Advancing Precision Nutrition Through Multimodal Data and Artificial Intelligence
Yuanqing Fu, Ke Zhang, Zelei Miao, Gaoyi Yang, Yujing Huang, Ju‐Sheng Zheng
Advanced Science.2026;[Epub] CrossRef
Lesions involving the insula are associated with reduced appetite and weight loss
Wanzhi Lyu, Joel Bruss, Emily R Dappen, Joseph C Griffis, Benjamin Pace, Brandon Neisewander, Kenneth Manzel, Daniel Tranel, Aaron D Boes, Nicholas T Trapp
Brain Communications.2026;[Epub] CrossRef
Bidirectional Regulation of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism in Obese Patients with Type 2 Diabetes Mellitus
钰琪王
Advances in Clinical Medicine.2026; 16(03): 253. CrossRef
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Xiaoke Dou, Lei Zhao, Jing Li, Yaqiu Jiang
Frontiers in Neuroscience.2025;[Epub] CrossRef
Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
Juliana West, Maggie Li, Sabrina Wong, Gia Han Le, Kayla M. Teopiz, Kyle Valentino, Christine E. Dri, Roger S. McIntyre
Neurology and Therapy.2025; 14(4): 1157. CrossRef
Neurovascular decoupling of frontoparietal cortex-putamen-cerebellum network in type 2 diabetes patient: Potential biomarker for abnormal eating patterns
Ying Yu, Bo Hu, Xin-Wen Yu, Yan-Yan Cui, Xin-Yu Cao, Min-Hua Ni, Si-Ning Li, Pan Dai, Qian Sun, Xiao-Yan Bai, Yao Tong, Xiao-Rui Jing, Ai-Li Yang, Sheng-Ru Liang, Li-Juan Du, Shuo Guo, Lin-Feng Yan, Bin Gao, Guang-Bin Cui
Diabetes Research and Clinical Practice.2025; 224: 112175. CrossRef
Regulation of the interaction between carboxymethyl starch and whey protein isolate by tannin: Effects on their colonic targeting and stimulation of satiety hormone secretion
Jinming Tan, Yingying Li, Zhibing Zhang, Xiaoxi Li
Food Research International.2025; 217: 116839. CrossRef
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Joon Seok Park, Kyu Sik Kim, Hyung Jin Choi
Diabetes & Metabolism Journal.2025; 49(3): 333. CrossRef
Fibroblast Growth Factor 21 Levels Are Associated With Perception and Neural Responses to Sweetness in Type 2 Diabetes Mellitus
Piao Kang, Ying Zhang, Dian Zeng, Dan Liu, Rui Han, Yuwei Lu, Di Cheng, Qinyi Wang, Silin Liu, Liang Wu, Qian Wu, Shujie Yu, Anran Chen, Jingyi Guo, Wenli Ge, Jiacheng Ni, Jingyi Yang, Xiaomeng Wu, Lifei Ma, Weiping Jia, Qichen Fang, Yuehua Li, Huating Li
Diabetes & Metabolism Journal.2025; 49(4): 893. CrossRef
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Susanna Fang, Fiona Cui, Daniel J. Drucker
Cell Reports Medicine.2025; 6(12): 102511. CrossRef
The Potential Effects of Exercise Training on Cortical Glutamatergic Synapse, Retrograde Endocannabinoid Signaling, and the Oxytocin Signaling Pathway in the Diabetic–Obesity Cortex: An In Silico Study
Yin-Yu Chiang, Michael Anekson Widjaya, Shin-Da Lee
International Journal of Molecular Sciences.2025; 27(1): 266. CrossRef
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
Jae Hyun Bae
Diabetes & Metabolism Journal.2024; 48(1): 157. CrossRef
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kyu Sik Kim, Joon Seok Park, Eunsang Hwang, Min Jung Park, Hwa Yun Shin, Young Hee Lee, Kyung Min Kim, Laurent Gautron, Elizabeth Godschall, Bryan Portillo, Kyle Grose, Sang-Ho Jung, So Lin Baek, Young Hyun Yun, Doyeon Lee, Eunseong Kim, Jason Ajwani, Seo
Science.2024; 385(6707): 438. CrossRef
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Sebastian Badulescu, Aniqa Tabassum, Gia Han Le, Sabrina Wong, Lee Phan, Hartej Gill, Cristian-Daniel Llach, Roger S. McIntyre, Joshua Rosenblat, Rodrigo Mansur
Physiology & Behavior.2024; 283: 114622. CrossRef
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Ryan J Jalleh, Mark P Plummer, Chinmay S Marathe, Mahesh M Umapathysivam, Daniel R Quast, Christopher K Rayner, Karen L Jones, Tongzhi Wu, Michael Horowitz, Michael A Nauck
The Journal of Clinical Endocrinology & Metabolism.2024; 110(1): 1. CrossRef
Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
Ryan J Jalleh, Chinmay S Marathe, Christopher K Rayner, Karen L Jones, Mahesh M Umapathysivam, Tongzhi Wu, Daniel R Quast, Mark P Plummer, Michael A Nauck, Michael Horowitz
Endocrinology.2024;[Epub] CrossRef
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial
Natalia McInnes, Stephanie Hall, Heather A. Lochnan, Stewart B. Harris, Zubin Punthakee, Ronald J. Sigal, Irene Hramiak, Mohammed Azharuddin, Joanne F. Liutkus, Jean‐François Yale, Farah Sultan, Ada Smith, Rose E. Otto, Diana Sherifali, Yan Yun Liu, Hertz
Diabetes, Obesity and Metabolism.2023; 25(11): 3347. CrossRef
Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy
Hussein Zaitoon, Ronit Lubetzky, Achiya Z. Amir, Hadar Moran-Lev, Liora Sagi, Michal Yacobi-Bach, Ophir Borger, Efrat Chorna, Yael Lebenthal, Avivit Brener
Acta Diabetologica.2023; 60(8): 1099. CrossRef
What can functional brain imaging teach us about remission of type 2 diabetes?
Dhruti Hirani, Shahd Alabdulkader, Alexander. D. Miras, Victoria Salem
Diabetic Medicine.2023;[Epub] CrossRef
Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward‐ and attention‐related brain centres in response to visual food cues in adults with obesity: A cross‐sectional functional MRI study
Nikolaos Perakakis, Olivia M. Farr, Christos S. Mantzoros
Diabetes, Obesity and Metabolism.2021; 23(5): 1202. CrossRef
Aberrant Brain Functional Connectivity Strength and Effective Connectivity in Patients with Type 2 Diabetes Mellitus
Xi Guo, Su Wang, Yu-Chen Chen, Heng-Le Wei, Gang-Ping Zhou, Yu-Sheng Yu, Xindao Yin, Kun Wang, Hong Zhang, Eusebio Chiefari
Journal of Diabetes Research.2021; 2021: 1. CrossRef

Obesity and Metabolic Syndrome
Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals: Chang Ho Ahn, Jae Hyun Bae, Young Min Cho; Diabetes Metab J. 2019;43(6):879-892. Published online June 25, 2019; DOI: https://doi.org/10.4093/dmj.2018.0202

12,745 View
130 Download
6 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

A premeal load of protein can increase satiety and reduce energy intake. Dietary fiber also conveys metabolic benefits by modulating energy intake. We made a protein-enriched, dietary fiber-fortified bar (PFB) and aimed to investigate its effects on food intake and gut hormone secretion in healthy individuals.

Methods

Twenty subjects with normal glucose tolerance were enrolled. On three separate visits, the subjects received, in a randomized order, one of the following: a PFB containing 73 kcal with 10.7 g of protein and 12.7 g of dietary fiber; a usual bar (UB) containing the same calories as the PFB but only 0.9 g of protein and no dietary fiber; or water (control). After 15 minutes, the subjects had ad libitum intake of a test meal. Food consumption, appetite, and plasma gut hormone levels were measured.

Results

Total energy intake, including the bar and the test meal, was significantly reduced with the PFB preload compared to the water (904.4±534.9 kcal vs. 1,075.0±508.0 kcal, P=0.016). With the UB preload, only the intake of the test meal was reduced (P=0.044) but not the total energy intake (P=0.471) than the water. Fullness was also significantly increased after the PFB. In addition, postprandial glucose levels decreased and glucagon-like peptide-1 levels increased with the PFB compared with both the UB and water.

Conclusion

In healthy individuals, a premeal supplementation of PFB reduced total energy intake and decreased postprandial glucose excursion. This finding necessitates long-term studies regarding clinical use in obesity.

Citations

Citations to this article as recorded by

Egg white rice-shaped analogue enhances satiety hormones and glycemic control in healthy men: a randomized unblinded crossover trial
Nitchakan Chaiprukmalakan, Waralee Joymak, Siriyakorn Chantieng, Mutthatinee Tangmongkhonsuk, Charoonsri Chusak, Praew Chantarasinlapin, Tanyawan Suantawee, Sathaporn Ngamukote, Sirichai Adisakwattana
Food Production, Processing and Nutrition.2026;[Epub] CrossRef
Obesity-driven hunger: From pathophysiology to intervention
Ahmad Khusairi Azemi, Yahkub Babatunde Mutalub, Monsurat Abdulwahab, Aida Hanum Ghulam Rasool, Sagir Mustapha, Siti Qusyasyiah Ahmad Suhaimi, Siti Safiah Mokhtar
Obesity Medicine.2025; 54: 100588. CrossRef
Effects of Whey Protein, Carbohydrate, and Fibre Combination on Health Indicators: A Systematic Review
Martín Pratto-Burgos, María Belén Gutiérrez-Barrutia, Ximena Otegui, Miriam Ortega-Heras, Sonia Cozzano, Inmaculada Gómez
Applied Sciences.2025; 15(23): 12645. CrossRef
Citrus pectin protects mice from burn injury by modulating intestinal microbiota, GLP-1 secretion and immune response
Ji-Wei Hao, Hong-Sheng Liu, Ling-Ying Liu, Qing-Hong Zhang
International Immunopharmacology.2024; 131: 111912. CrossRef
Effect of Two Different Meal Compositions on 1-hour Plasma Ghrelin Levels in Young Men
Brinnell Annette Caszo, Sangeetha Shyam, Purushotham Krishnappa, Justin Vijay Gnanou
Malaysian Journal of Medicine and Health Sciences.2023; 19(5): 185. CrossRef
Intake of Fibre-Associated Foods and Texture Preferences in Relation to Weight Status Among 9–12 Years Old Children in 6 European Countries
Marlies Hörmann-Wallner, Raphaela Krause, Begoña Alfaro, Hannah Jilani, Monica Laureati, Valérie L. Almli, Mari Sandell, Pernilla Sandvik, Gertrude G. Zeinstra, Lisa Methven
Frontiers in Nutrition.2021;[Epub] CrossRef
Response: Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals (Diabetes Metab J 2019;43:879–92)
Chang Ho Ahn, Jae Hyun Bae, Young Min Cho
Diabetes & Metabolism Journal.2020; 44(1): 207. CrossRef
Letter: Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals (Diabetes Metab J 2019;43:879–92)
Mi-kyung Kim
Diabetes & Metabolism Journal.2020; 44(1): 203. CrossRef
Spent coffee (Coffea arabicaL.) grounds promote satiety and attenuate energy intake: A pilot study
Rocio Campos‐Vega, Andrea Arreguín‐Campos, Miguel A. Cruz‐Medrano, María Dolores Castillo Bilbao
Journal of Food Biochemistry.2020;[Epub] CrossRef

Pathophysiology
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus: Soyeon Yoo, Eun-Jin Yang, Gwanpyo Koh; Diabetes Metab J. 2019;43(4):495-503. Published online February 20, 2019; DOI: https://doi.org/10.4093/dmj.2018.0105

6,248 View
45 Download

Abstract PDF PubReader ePub: Background
We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM).
Methods
We cross-sectionally analyzed 336 patients with T2DM. Intact glucagon-like peptide 1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 minutes after ingestion of a standard mixed meal. The differences between 30 and 0 minute iGLP-1 and iGIP levels were indicated as ΔiGLP-1 and ΔiGIP.
Results
In simple correlation analyses, fasting iGLP-1 was positively correlated with glucose, C-peptide, creatinine, and triglyceride levels, and negatively correlated with estimated glomerular filtration rate. ΔiGLP-1 was positively correlated only with ΔC-peptide levels. Fasting iGIP showed positive correlations with glycosylated hemoglobin (HbA1c) and fasting glucose levels, and negative correlations with ΔC-peptide levels. ΔiGIP was negatively correlated with diabetes duration and HbA1c levels, and positively correlated with Δglucose and ΔC-peptide levels. In multivariate analyses adjusting for age, sex, and covariates, fasting iGLP-1 levels were significantly related to fasting glucose levels, ΔiGLP-1 levels were positively related to ΔC-peptide levels, fasting iGIP levels were related to fasting C-peptide levels, and ΔiGIP levels were positively related to ΔC-peptide and Δglucose levels.
Conclusion
Taken together, intact incretin levels are primarily related to C-peptide and glucose levels. This result suggests that glycemia and insulin secretion are the main factors associated with intact incretin levels in T2DM patients.

Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials: Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck; Diabetes Metab J. 2019;43(4):410-421. Published online December 27, 2018; DOI: https://doi.org/10.4093/dmj.2018.0070

10,652 View
175 Download
26 Web of Science
26 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by

Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Tianzuo Wang, Yuying Cui, Lin Liao
Diabetes Therapy.2025;[Epub] CrossRef
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or O
Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, Yu Mi Kang, Martin K. Rutter, Hertzel C. Gerstein, Darren K. McGuire, Naveed Sattar
Diabetes Care.2025; 48(3): 489. CrossRef
Expert Opinion on the Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Established or High‑risk Atherosclerotic Cardiovascular Disease in Thailand
Wanwarang Wongcharoen, Rungroj Krittayaphong, Wacin Buddhari, Songsak Kiatchoosakun, Apiradee Sriwijitkamol, Taweesak Wannachalee, Arintaya Phrommintikul
Journal of Asian Pacific Society of Cardiology.2025;[Epub] CrossRef
Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review
Pulwasha Iftikhar, Chander P Khatri, Sri Ratna Divya Nanduri, Minahil Ramzan, Krishna Sai Kiran Sakalabaktula
Cureus.2025;[Epub] CrossRef
Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
Yuzi Cao, Indah Widyahening, Xiaodong Sun, Sheyu Li
Diabetes, Obesity and Metabolism.2025; 27(S10): 3. CrossRef
Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
Wenxuan Li, Linyan Huang, Ruixue Wang, Peiyan Peng, Aowen Song, Yi Zeng, Zhen Zhang
Diabetes, Obesity and Metabolism.2025; 27(11): 6727. CrossRef
Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(3): 418. CrossRef
Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials
Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
Journal of Clinical Lipidology.2024; 18(4): e588. CrossRef
A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
Diabetes, Obesity and Metabolism.2024; 26(8): 3167. CrossRef
Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
Current Problems in Cardiology.2023; 48(8): 101228. CrossRef
Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
Journal of Cardiovascular Development and Disease.2023; 10(4): 176. CrossRef
Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
L. Yu. Khamnueva, L. S. Andreeva
Problems of Endocrinology.2023; 69(2): 38. CrossRef
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
Obesity Pillars Roundtable: Obesity and East Asians
Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
Obesity Pillars.2022; 2: 100011. CrossRef
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
Nature Reviews Endocrinology.2022; 18(7): 413. CrossRef
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
Cardiovascular Diabetology.2022;[Epub] CrossRef
Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
Xiaoling Cai, Linong Ji
Diabetes Therapy.2021; 12(7): 1861. CrossRef
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
Metabolism.2021; 123: 154838. CrossRef
Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub] CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
Frontiers in Endocrinology.2021;[Epub] CrossRef
Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456. CrossRef
Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
Current Diabetes Reports.2020;[Epub] CrossRef
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Christopher S. Wilcox
Hypertension.2020; 75(4): 894. CrossRef
Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
Diabetes Therapy.2020; 11(9): 2121. CrossRef
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
Journal of the Chinese Medical Association.2020; 83(7): 587. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef

Reviews

Complications
Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet: Vincenza Spallone; Diabetes Metab J. 2019;43(1):3-30. Published online November 2, 2018; DOI: https://doi.org/10.4093/dmj.2018.0259

40,152 View
671 Download
210 Web of Science
221 Crossref

Abstract PDF PubReader ePub

The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase due to the diabetes epidemic and its early and widespread appearance. CAN has a definite prognostic role for mortality and cardiovascular morbidity. Putative mechanisms for this are tachycardia, QT interval prolongation, orthostatic hypotension, reverse dipping, and impaired heart rate variability, while emerging mechanisms like inflammation support the pervasiveness of autonomic dysfunction. Efforts to overcome CAN under-diagnosis are on the table: by promoting screening for symptoms and signs; by simplifying cardiovascular reflex tests; and by selecting the candidates for screening. CAN assessment allows for treatment of its manifestations, cardiovascular risk stratification, and tailoring therapeutic targets. Risk factors for CAN are mainly glycaemic control in type 1 diabetes mellitus (T1DM) and, in addition, hypertension, dyslipidaemia, and obesity in type 2 diabetes mellitus (T2DM), while preliminary data regard glycaemic variability, vitamin B12 and D changes, oxidative stress, inflammation, and genetic biomarkers. Glycaemic control prevents CAN in T1DM, whereas multifactorial intervention might be effective in T2DM. Lifestyle intervention improves autonomic function mostly in pre-diabetes. While there is no conclusive evidence for a disease-modifying therapy, treatment of CAN manifestations is available. The modulation of autonomic function by SGLT2i represents a promising research field with possible clinical relevance.

Citations

Citations to this article as recorded by

Impact of cardiovascular autonomic neuropathy on cardiopulmonary, sympathoadrenal and metabolic responses to physical exercise in adults with type 1 diabetes
Olivia M. McCarthy, Rasmus B. Brødsgaard, Sandra Tawfik, Sissel Banner Lundemose, Emilie B. Lindkvist, Sara H. Naaman, Christian Stevns Hansen, Richard M. Bracken, Kirsten Nørgaard
Diabetologia.2026; 69(3): 618. CrossRef
Echocardiographic insights into cardiovascular autonomic dysfunction in Parkinson's disease
Zihao Li, Xiaohong Li, Wenlin Huang, Ziqi Gao, Piao Zhang, Chentao He, Siming Rong, Mengfei Cai, Zhenzhen Chen, Yan Li, Ruixue Xu, Lijuan Wang, Zhichao Zheng, Hongwen Fei, Yuhu Zhang
Journal of Parkinson’s Disease.2026; 16(1): 146. CrossRef
Recent Advances in the Study of Diabetic Cardiac Autonomic Neuropathy
Nan Wang, Jie Zhang
Reviews in Cardiovascular Medicine.2026;[Epub] CrossRef
Cutoffs, sensitivity and specificity of the Ewing battery in evaluating autonomic nervous system disorders: a systematic review
Theodora R. Barkoula, Christiana Ioannou, Martina Rekatsina, Kassiani Theodoraki, Panagiotis Zis
Clinical Autonomic Research.2026;[Epub] CrossRef
Association between metabolic dysfunction-associated fatty liver disease and cardiovascular autonomic neuropathy in type 2 diabetes
Rong Peng, Yaoyun Ao, Enni Cen, Junnian Chen, Zeshan Huang, Xiaoying Fu, Jian Kuang, Shuiqing Lai, Shuting Zhang
Frontiers in Endocrinology.2026;[Epub] CrossRef
SDNN predicts 90-day disability after intravenous thrombolysis: autonomic dysfunction as a novel predictors in acute ischemic stroke
Xiaoyan Wu, Jianping Wang, Liumeng Jian, Li Shi, Jie Li, Jianqiang Zhong, Guoyou Peng, Jianjun Guo
Frontiers in Neurology.2026;[Epub] CrossRef
Normative data on measures of cardiovascular autonomic neuropathy and the effect of pretest conditions in a large Danish non-diabetic CVD-free population from the Lolland-Falster Health Study
Christian S. Hansen, Marie Mathilde Bjerg Christensen, Dorte Vistisen, Randi Jepsen, Christina Ellervik, Marit Eika Jørgensen, Jesper Fleischer
Clinical Autonomic Research.2025; 35(1): 101. CrossRef
Comparative study of autonomic function in diabetics and yoga practitioners using Ewing’s battery
Tasneem Amadawala, Charushila Rukadikar, Dileep Deshpande
Journal of Family Medicine and Primary Care.2025; 14(1): 121. CrossRef
A call to action for peripheral neuropathy research funding—Time to consolidate funding under one NIH initiative?
Stéphanie A. Eid, Kristy L. Townsend, Vincenza Spallone, Daniela M. Menichella, Emily J. Koubek, Eva L. Feldman
Journal of the Peripheral Nervous System.2025;[Epub] CrossRef
Electrodiagnostic assessment of autonomic nervous system in diabetic autonomic neuropathy: Case series in 72 diabetes patients
Suchitra Dube, Sandip M. Hulke, Santosh L. Wakode, Sagar Khadanga
Journal of Family Medicine and Primary Care.2025; 14(1): 452. CrossRef
Disorders of circadian rhythms of heart rate variability in diabetic cardiac autonomic neuropathy: mechanisms and consequences
V.A. Serhiyenko, M.I. Dolynay, V.B. Sehin, Y.V. Lazur, A.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 20(8): 549. CrossRef
Cardiac Autonomic Neuropathy in Diabetes Mellitus: Pathogenesis, Epidemiology, Diagnosis and Clinical Implications: A Narrative Review
Alexandra Gogan, Ovidiu Potre, Vlad-Florian Avram, Minodora Andor, Florina Caruntu, Bogdan Timar
Journal of Clinical Medicine.2025; 14(3): 671. CrossRef
Cardiovascular autonomic neuropathy is associated with SLEDAI in patients with systemic lupus erythematosus
Simin Guo, Yujiao Wang, Lingyun Sun
Clinical Rheumatology.2025; 44(3): 1103. CrossRef
Correlation between Sirtuin 1 downregulation and reduced vitamin D receptor expression in patients with diabetic neuropathy
Andrea Latini, Giada De Benedittis, Chiara Morgante, Beatrice Gasperini, Ilenia D’Ippolito, Davide Lauro, Giuseppe Novelli, Cinzia Ciccacci, Vincenza Spallone, Paola Borgiani
Acta Diabetologica.2025; 62(9): 1395. CrossRef
Obesity Class and Severity of Metabolic Emergencies: A Single-Center Retrospective Five-Year Study
Iulia Najette Crintea, Alexandru Cristian Cindrea, Teodor Florin Fulga, Cosmin Iosif Trebuian, Adina Maria Marza, Alina Petrica, Ovidiu Alexandru Mederle, Romulus Timar
Healthcare.2025; 13(6): 617. CrossRef
Sequential classification approach for enhancing the assessment of cardiac autonomic neuropathy
Moustafa Abdelwanis, Karim Moawad, Shahmir Mohammed, Ammar Hummieda, Shayaan Syed, Maher Maalouf, Herbert F. Jelinek
Computers in Biology and Medicine.2025; 190: 109999. CrossRef
Pooled prevalence and associated factors of ECG abnormality among type 2 diabetic patients in the last ten years: Systematic review and meta-analysis
Mihret Getnet, Habtu Kifle Negash, Hailu Aragie, Hiwot Tezera Endale, Tseganesh Asefa, Winta Tesfaye, Yibeltal Yismaw Gela, Gaetano Santulli
PLOS ONE.2025; 20(3): e0319173. CrossRef
Resident Macrophages in the Cervical Sympathetic Ganglia Participate in P2Y12 Receptor Mediated Diabetic Cardiac Autonomic Neuropathy
Junpei Du, Yuxin Yang, Jingan Rao, Xiaoqian Ma, Shanshan Tang, Jian Liu, Yeqing Liu, Shipan Liu, Guodong Li, Shangdong Liang, Yun Gao
Molecular Neurobiology.2025; 62(8): 9744. CrossRef
Heart Rate Variability, Microvascular Dysfunction, and Inflammation: Exploring the Potential of taVNS in Managing Heart Failure in Type 2 Diabetes Mellitus
Serge C. Thal, Sergey Shityakov, Ellaine Salvador, Carola Y. Förster
Biomolecules.2025; 15(4): 499. CrossRef
Corneal confocal microscopy identifies early and definite diabetic cardiac autonomic neuropathy
Shazli Azmi, Maryam Ferdousi, Alise Kalteniece, Ioannis N Petropoulos, Uazman Alam, Georgios Ponirakis, Omar Asghar, Andrew Marshall, Andrew JM Boulton, Nathan Efron, Rayaz A Malik
Diabetes Research and Clinical Practice.2025; 224: 112172. CrossRef
Diabetic neuropathy: cutting-edge research and future directions
Yang Yang, Bing Zhao, Yuanzhe Wang, Hongli Lan, Xinyu Liu, Yue Hu, Peng Cao
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
External validation of a clinical risk score for the presence of cardiovascular autonomic neuropathy in type 1 diabetes
Pietro Pertile, Ilenia D'Ippolito, Beatrice De Santis, Aikaterini Andreadi, Davide Lauro, Vincenza Spallone
Journal of Diabetes and its Complications.2025; 39(7): 109066. CrossRef
ВПЛИВ ВИМУШЕНОГО ПЕРЕСЕЛЕННЯ НА СТАН ХРОНІЧНОГО ЗАПАЛЕННЯ ТА ІНСУЛІНОВОЇ РЕЗИСТЕНТНОСТІ ПРИ ДІАБЕТИЧНІЙ КАРДІАЛЬНІЙ АВТОНОМНІЙ НЕЙРОПАТІЇ
Вікторія Сергієнко, Володимир Сегін, Олександр Сергієнко
PROBLEMS OF ENDOCRINE PATHOLOGY.2025; 82(1): 33. CrossRef
Features of short-term heart rate variability in internally displaced people with type 2 diabetes mellitus
V.A. Serhiyenko, V.B. Sehin, V.I. Pankiv, A.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(3): 243. CrossRef
Autonomic function and hemodynamic changes in type 2 diabetes: insights into sympathetic activation and vascular stiffness
Larissa Morete Caieiro da Costa, Tatiana Palotta Minari, Luciana Pellegrini Pisani, Tatiane de Azevedo Rubio, Louise Bounalume Tácito Yugar, Luis Gustavo Sedenho-Prado, Milene Ribeiro, Lúcia Helena Bonalume Tacito, Luciana Neves Cosenso-Martin, Antônio Ca
Diabetes Research and Clinical Practice.2025; 225: 112266. CrossRef
NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy
Raffaele Galiero, Amel Rezki, Vittorio Simeon, Domenico Beccia, Maria Alfano, Alfredo Caturano, Ferdinando Carlo Sasso, Paul Valensi
Journal of Diabetes and its Complications.2025; 39(9): 109107. CrossRef
High Diagnostic Performance of the Indicator Plaster Neuropad for the Detection of Established Diabetic Autonomic Neuropathy
Ioanna Zografou, Panagiotis Doukelis, Theocharis Koufakis, Evangelia Kotzakioulafi, Polykarpos Evripidou, Zisis Kontoninas, Christos Savopoulos, Michael Doumas, Triantafyllos Didangelos, Konstantinos Kantartzis
Diabetology.2025; 6(6): 55. CrossRef
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
Diabetes & Metabolism Journal.2025; 49(4): 582. CrossRef
Cross-cultural adaptation and validation of the Ukrainian version of the Type 2 Diabetes Distress Assessment System
V.A. Serhiyenkо, V.B. Sehin, S.Y. Holovach, A.A. Serhiyenko
INTERNATIONAL NEUROLOGICAL JOURNAL.2025; 21(4): 266. CrossRef
Diabetic distress, low-grade chronic inflammation, and cardiac autonomic neuropathy in internally displaced people (literature review and own observations)
V.A. Serhiyenkо
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(4): 381. CrossRef
Initial Evaluation of Patients with Diabetes Mellitus according to Clinical Guidelines
Dughyun Choi
The Journal of Korean Diabetes.2025; 26(2): 69. CrossRef
Long-term prediction of mortality by heart rate turbulence in hemodialysis patients and the impact of diabetes mellitus–a longitudinal observational study
Nora Hannane, Christopher C. Mayer, Julia Matschkal, Felix Bormann, Axel Krieter, Jürgen R. Braun, Claudius Küchle, Lutz Renders, Roman Günthner, Georg Schmidt, Alexander Müller, Siegfried Wassertheurer, Uwe Heemann, Bernhard Haller, Marek Malik, Christop
Journal of Nephrology.2025; 38(8): 2261. CrossRef
Assessing the impact of supervised interval training on cardiovascular autonomic neuropathy in type 2 diabetes patients
Laura Stirane, Karlis Stirans, Leonora Pahirko, Janis Mednieks, Karina Ostrovska, Aija Kļavina, Leo Selavo, Jelizaveta Sokolovska
Physiological Reports.2025;[Epub] CrossRef
Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy
Tina Okdahl, Anne-Marie Wegeberg, Marie Møller Jensen, Jonas Salling Quist, Christina Brock
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Obstructive Sleep Apnea and Type 2 Diabetes: An Update
Sandro Gentile, Vincenzo Maria Monda, Giuseppina Guarino, Ersilia Satta, Maria Chiarello, Giuseppe Caccavale, Edi Mattera, Raffaele Marfella, Felice Strollo
Journal of Clinical Medicine.2025; 14(15): 5574. CrossRef
Comparison of Diabetic Polyneuropathy and Cardiac Autonomic Neuropathy in Type 1 and Type 2 Diabetes Mellitus
Laura Šiaulienė, Ieva Sereikė, Juozas Rimantas Lazutka, Joana Semigrejeviene, Žydrūnė Visockienė
Diabetology.2025; 6(8): 74. CrossRef
Bioprospecting the antidiabetic potential of aqueous seed extract of Allanblackia floribunda Oliv. (Clusiaceae)
John Alake, Wisdom Ahlidja, Isaac Tabiri Henneh, Augustine Kwabil, Kwabena Darko Adu, Samuel Ansong Asiamah, Du-Bois Asante, Francis Ackah Armah
Food Chemistry Advances.2025; 8: 101071. CrossRef
Diabetes mellitus and postural hypotension in prehospital care
William Young
Journal of Paramedic Practice.2025; 17(9): 1. CrossRef
The prevalence of diabetic neuropathy in Greenland and its association with Inuit genetic ancestry – a cross-sectional study
Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Ninna Senftleber, Frederik Filip Stæger, Torben Hansen, Daniel R. Witte, Marit Eika Jørgensen
Journal of Diabetes and its Complications.2025; 39(11): 109179. CrossRef
Cardiac Autonomic Neuropathy and Its Impact on Progression of Diabetic Kidney Disease in Type 1 and Type 2 Diabetes
Kywe Kywe Soe, Dinesh Selvarajah
Kidney Medicine.2025; 7(12): 101149. CrossRef
SPARC-modified mesenchymal stem cells promote recovery of β-cells and insulin secretion by calcium ion homeostasis
Jiaqi Gao, Balun Li, Hongkai Tian, Chenchen Li, Nikita Merzlikin, Dongyao Han, Zixi Ling, Zengyu Zhang, Wenlong zhu, Jianqi Dai, Lydmila Gerunova, Changrong Lv, Na Li, Jinlian Hua
Stem Cell Research & Therapy.2025;[Epub] CrossRef
Association between physical activity propensity and cardiovascular autonomic neuropathy in type 1 diabetes: evidence from a single-centre study
Simona Zaccaria, Laura Giurato, Isabella Nardone, Sium Wolde Sellasie, Innocenza Tripicchio, Marco Meloni, Pasquale Di Perna, Luigi Uccioli
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Physical Exercise Before Long‐Term Electrocardiogram May Enhance the Assessment of Nocturnal Heart Rate Variability in Young Individuals With Type 1 Diabetes Melltius
Cecilia Fridolfsson, Peter Blomstrand, Jan Engvall, Johanna Thegerström
Annals of Noninvasive Electrocardiology.2025;[Epub] CrossRef
Rectal sensitivity correlated with gastrointestinal‐mediated glucose disposal, but not the incretin effect
Sondre Meling, Erling Tjora, Heike Eichele, Rasmus B. Nedergaard, Filip K. Knop, Niels Ejskjaer, Siri Carlsen, Pål R. Njølstad, Christina Brock, Eirik Søfteland
Endocrinology, Diabetes & Metabolism.2024;[Epub] CrossRef
Glucose metabolism and autonomic function in healthy individuals and patients with type 2 diabetes mellitus at rest and during exercise
Takuto Hamaoka, Urs A. Leuenberger, Rachel C. Drew, Matthew Murray, Cheryl Blaha, Jonathan Carter Luck, Lawrence I. Sinoway, Jian Cui
Experimental Physiology.2024; 109(2): 214. CrossRef
Quantification of lipoproteins by proton nuclear magnetic resonance spectroscopy (1H-NMRS) improves the prediction of cardiac autonomic dysfunction in patients with type 1 diabetes
L. Nattero-Chávez, M. Insenser, N. Amigó, S. Samino, N. Martínez-Micaelo, B. Dorado Avendaño, A. Quintero Tobar, H. F. Escobar-Morreale, M. Luque-Ramírez
Journal of Endocrinological Investigation.2024; 47(8): 2075. CrossRef
Predictors of pacemaker requirement in patients with implantable loop recorder and unexplained syncope: A systematic review and meta‐analysis
Moein Zangiabadian, Kiarash Soltani, Yasaman Gholinejad, Reyhane Yahya, Shayan Bastami, Mohammad Ali Akbarzadeh, Mohammad Sharifian Ardestani, Azadeh Aletaha
Clinical Cardiology.2024;[Epub] CrossRef
Impaired Cardiovagal Activity as a Link Between Hyperglycemia and Arterial Stiffness in Adults With Type 2 Diabetes Mellitus Among an Eastern Indian Population: A Cross-sectional Study
Nibedita Priyadarsini, Devineni Likhitha, Madumathy Ramachandran, Kishore Kumar Behera
Canadian Journal of Diabetes.2024; 48(3): 147. CrossRef
No clear evidence of neuropathy among patients with high risk for the development of prediabetes/diabetes—a pilot study
Anna E. Körei, Magdolna Békeffy, Adrienn Menyhárt, Karola Osgyán, Ildikó Istenes, Viktor J. Horváth, Péter Kempler
Frontiers in Endocrinology.2024;[Epub] CrossRef
Effects of Physical Cues on Stem Cell-Derived Extracellular Vesicles toward Neuropathy Applications
Danyale Berry, Justice Ene, Aakash Nathani, Mandip Singh, Yan Li, Changchun Zeng
Biomedicines.2024; 12(3): 489. CrossRef
Oxidative Stress, Endothelial Dysfunction, and N-Acetylcysteine in Type 2 Diabetes Mellitus
Xin Li, Junyong Zou, Aiping Lin, Jingshu Chi, Hong Hao, Hong Chen, Zhenguo Liu
Antioxidants & Redox Signaling.2024; 40(16-18): 968. CrossRef
High dose cholecalciferol supplementation causing morning blood pressure reduction in patients with type 1 diabetes mellitus and cardiovascular autonomic neuropathy
João Felício, Lorena Moraes, Gabriela Lemos, Ícaro Souza, Giovana Vieira, Lilian Silva, Natércia Queiroz, Ana Carolina Souza, Franciane Melo, João Felício Abrahão Neto, Hana Britto, Manuela Lemos, Márcia Santos, Priscila Figueiredo, Ana Regina Motta, Meli
Scientific Reports.2024;[Epub] CrossRef
Transcutaneous vagal nerve stimulation for treating gastrointestinal symptoms in individuals with diabetes: a randomised, double-blind, sham-controlled, multicentre trial
Ditte S. Kornum, Davide Bertoli, Huda Kufaishi, Anne-Marie Wegeberg, Tina Okdahl, Esben B. Mark, Katrine L. Høyer, Jens B. Frøkjær, Birgitte Brock, Klaus Krogh, Christian S. Hansen, Filip K. Knop, Christina Brock, Asbjørn M. Drewes
Diabetologia.2024; 67(6): 1122. CrossRef
Independent and interactive associations of heart rate and obesity with type 2 diabetes mellites: A population‐based study
Tianxin Zhu, Qingyu Chen, Hongxing Chen, Lili You, Dan Liu, Xiaoyun Zhang, Feng Li, Hongshi Wu, Juying Tang, Diaozhu Lin, Kan Sun, Li Yan, Meng Ren
Journal of Diabetes.2024;[Epub] CrossRef
Bladder dysfunction in adolescents with type 1 diabetes
Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Mette Madsen, Esben Thyssen Vestergaard, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Konstantinos Kamperis, Kurt Kristensen
Journal of Pediatric Urology.2024; 20(4): 564.e1. CrossRef
Genetic markers of cardiac autonomic neuropathy in the Kazakh population
Nazira Bekenova, Ainur Sibagatova, Alisher Aitkaliyev, Tamara Vochshenkova, Balzhan Kassiyeva, Valeriy Benberin
BMC Cardiovascular Disorders.2024;[Epub] CrossRef
Acompanhamento e rastreamento de pacientes com Diabetes Mellitus Tipo 2 em uma unidade de saúde: prevenção de complicações macro e microvasculares
Maria Helena Cordeiro de Oliveira, Milena Nunes Alves de Sousa
Cuadernos de Educación y Desarrollo.2024; 16(5): e4145. CrossRef
POST-TRAUMATIC STRESS DISORDER, INSOMNIA, HEART RATE VARIABILITY AND METABOLIC SYNDROME (NARRATIVE REVIEW)
Alexandr Serhiyenko, Myroslav Baitsar, Volodymyr Sehin, Ludmila Serhiyenko, Vitaliy Kuznets, Victoria Serhiyenko
Proceeding of the Shevchenko Scientific Society. Medical Sciences.2024;[Epub] CrossRef
Determinants of Orthostatic Hypotension in Type 2 Diabetes: Is Cardiac Autonomic Neuropathy the Main Factor?
Ilenia D'Ippolito, Myriam Angelica Carlucci, Cinzia D'Amato, Davide Lauro, Vincenza Spallone
Endocrine Practice.2024; 30(9): 802. CrossRef
New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial
Sofie Hecquet, Søren Ballegaard, Ebbe Eldrup, Christian Hansen, Tine Hansen, Gitte Harboe, Peter Rossing, Caroline Pichat, Torquil Watt, Finn Gyntelberg, Nanna Ørsted, Jens Faber
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 2519. CrossRef
Exploring heart rate variability in polycystic ovary syndrome: implications for cardiovascular health: a systematic review and meta-analysis
Seyedeh Tarlan Mirzohreh, Padideh Panahi, Fariba Heidari
Systematic Reviews.2024;[Epub] CrossRef
Predicting the dynamics of heart rate variability in patients with type 1 diabetes against improving glycemic control
N.O. Pertseva, K.I. Moshenets
Medicni perspektivi.2024; 29(2): 87. CrossRef
Neurophysiological assessment of peripheral neuropathy through whole plantar nerve conduction in type 2 diabetes mellitus and healthy control subjects
Dario Ricciardi, Raffaele Galiero, Vincenzo Todisco, Gioacchino Tedeschi, Giuseppe Loffredo, Alfredo Caturano, Luca Rinaldi, Giovanni Cirillo, Ferdinando Carlo Sasso
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Glycemic variability and diabetic cardiac autonomic neuropathy
A.A. Serhiyenko, T.V. Tsaryk, Y.I. Pavlovskiy, V.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(4): 225. CrossRef
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
Diabetes & Metabolism Journal.2024; 48(4): 546. CrossRef
Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
Aikaterini Eleftheriadou, Vincenza Spallone, Abd A. Tahrani, Uazman Alam
Diabetologia.2024; 67(12): 2611. CrossRef
Prevalence of cardiovascular autonomic neuropathy in an admixed population of patients with type 1 diabetes. Lessons from a pioneer multicentre study in Brazil
Lucianne Righeti Monteiro Tannus, Hermelinda Cordeiro Pedrosa, Cejana Hamu Aguiar, Karla Guerra Drummond, André Pinheiro, Franz Schubert Leal, Carlos Antonio Negrato, Marilia Brito Gomes
Primary Care Diabetes.2024; 18(5): 539. CrossRef
Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Parthena Giannoulaki, Zisis Kontoninas, Anastasia Kontana, Polykarpos Evripidou, Christos Savopoulos, Andreas L. Birkenfeld, Konstantinos Kantartzis
Nutrients.2024; 16(18): 3045. CrossRef
Cardiovascular Autonomic Dysfunction Before and After Chemotherapy in Cancer Patients
So Young Yoon, Jeeyoung Oh
Journal of Clinical Neurology.2024; 20(6): 551. CrossRef
Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics
Anthony J. Evans, Yu-Long Li
International Journal of Molecular Sciences.2024; 25(22): 12464. CrossRef
Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy in Individuals with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Xin Huang, Yun Bao, Jie Wang, Limin Tian
Reviews in Cardiovascular Medicine.2024;[Epub] CrossRef
The impact of working night shifts on cardiac autonomic nervous regulation during the six-minute walk test in nurses
Taihe Zhan, Xiumei Wei, Ziying Zhang, Zhimin Shi, Hongyan Xie, Xiaotao Ma, Suyue Pan, Daogang Zha
BMC Nursing.2024;[Epub] CrossRef
D1S-Neuro Program: Frequency and Risk Factors for the Development of Diabetic Neuropathy in Pediatric Patients with Type 1 Diabetes Mellitus, a Single Center Study
Marco Piccoli, Joaquin Gutierrez de Rubalcava Doblas, Patrizia Furlan, Silvia Cocchio, Alessandro Zamberlan, Gloria Panzeri, Vincenzo Baldo, Carlo Moretti
Biomedicines.2024; 13(1): 19. CrossRef
Опитувальник «Композитна оцінка вегетативних симптомів 31» (COMPASS 31): валідація та можливості застосування в діагностиці вегетативної дисфункції у хворих на цукровий діабет 2-го типу
V.A. Serhiyenko, V.B. Sehin, A.A.
Endokrynologia.2024; 29(4): 338. CrossRef
Mortality risk factors in newly diagnosed diabetic cardiac autonomic neuropathy
Bruce A. Chase, Sylwia Pocica, Roberta Frigerio, Katerina Markopoulou, Demetrius M. Maraganore, Navamon Aunaetitrakul, Alexander Epshteyn, Alexandru C. Barboi
Clinical Autonomic Research.2023; 33(6): 903. CrossRef
Autonomic symptoms and associated factors in patients with chronic heart failure
Hellen Da Silva, Sofie Pardaens, Marc Vanderheyden, Johan De Sutter, Heleen Demeyer, Michel De Pauw, Laurent Demulier, Jan Stautemas, Patrick Calders
Acta Cardiologica.2023; 78(2): 203. CrossRef
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
Diabetologia.2023; 66(10): 1832. CrossRef
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings
Eleonora Galosi, Luca Leonardi, Pietro Falco, Giuseppe Di Pietro, Alessandra Fasolino, Nicoletta Esposito, Caterina Leone, Giulia Di Stefano, Maurizio Inghilleri, Marco Luigetti, Antonini Giovanni, Andrea Truini
Amyloid.2023; 30(1): 59. CrossRef
In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross‐sectional 68 Ga‐RGD‐PET study
Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt‐Møller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa
Diabetic Medicine.2023;[Epub] CrossRef
Cardiac innervations in diabetes mellitus—Anatomical evidence of neuropathy
Natalija Filipović, Maja Marinović Guić, Vana Košta, Katarina Vukojević
The Anatomical Record.2023; 306(9): 2345. CrossRef
Clinical Predictors of Pacing Device Implantation in Implantable Cardiac Monitor Recipients for Unexplained Syncope
Reina Tonegawa-Kuji, Yuko Y. Inoue, Michikazu Nakai, Koshiro Kanaoka, Yoko Sumita, Yuichiro Miyazaki, Akinori Wakamiya, Keiko Shimamoto, Nobuhiko Ueda, Kenzaburo Nakajima, Naoya Kataoka, Mitsuru Wada, Kenichiro Yamagata, Kohei Ishibashi, Koji Miyamoto, Sa
CJC Open.2023; 5(4): 259. CrossRef
Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia
Laura Blok-Husum, Milka Ane Rank Brcelic, Hanin Kawa Farman Kawal Bassi, Svend Eggert Jensen, Rene Ernst Nielsen, Kristian Kragholm, Jesper Fleischer, Esben Laugesen, Christoffer Polcwiartek
American Heart Journal Plus: Cardiology Research and Practice.2023; 26: 100252. CrossRef
Causal association between vitamin D and diabetic neuropathy: a Mendelian randomization analysis
Wei Huang, Lei Gu, Jingwen Wang, Yiqi Wang, Fangzheng Cao, Tianyu Jin, Yifan Cheng
Endocrine.2023; 80(2): 328. CrossRef
Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis
Life.2023; 13(2): 497. CrossRef
Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes
Lía Nattero-Chávez, María Insenser, Alejandra Quintero Tobar, Elena Fernández-Durán, Beatriz Dorado Avendaño, Tom Fiers, Jean-Marc Kaufman, Manuel Luque-Ramírez, Héctor F. Escobar-Morreale
Cardiovascular Diabetology.2023;[Epub] CrossRef
Early Gastrointestinal Neuropathy Assessed by Wireless Motility Capsules in Adolescents with Type 1 Diabetes
Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Ann-Margrethe Rønholt Christensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Christina Brock, Klaus Krogh
Journal of Clinical Medicine.2023; 12(5): 1925. CrossRef
Heart rate variability in people with metabolic syndrome
Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
Ageing and Longevity.2023; 4(1): 1. CrossRef
Heart rate variability in people with metabolic syndrome
Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE.2023; (1 2023): 1. CrossRef
Potential of electronic devices for detection of health problems in older adults at home: A systematic review and meta-analysis
Yu-ting Cao, Xin-xin Zhao, Yi-ting Yang, Shi-jie Zhu, Liang-dong Zheng, Ting Ying, Zhou Sha, Rui Zhu, Tao Wu
Geriatric Nursing.2023; 51: 54. CrossRef
Diabetes mellitus in der Akut- und Notfallmedizin
Leo Benning, Julian Krehl, Felix Patricius Hans
Notfallmedizin up2date.2023; 18(01): 45. CrossRef
Correlation between Heart rate recovery and Left Atrial phasic functions evaluated by 2D speckle-tracking Echocardiography after Acute Myocardial infarction
Behruz Mashayekhi, Reza Mohseni-Badalabadi, Ali Hosseinsabet, Tahereh Ahmadian
BMC Cardiovascular Disorders.2023;[Epub] CrossRef
Pancreatic sympathetic innervation disturbance in type 1 diabetes
Senlin Li, Huimin Yuan, Keshan Yang, Qing Li, Ming Xiang
Clinical Immunology.2023; 250: 109319. CrossRef
A Nonrandomized Trial of the Effects of Passive Simulated Jogging on Short-Term Heart Rate Variability in Type 2 Diabetic Subjects
Jose A. Adams, Jose R. Lopez, Veronica Banderas, Marvin A. Sackner, Mark Yorek
Journal of Diabetes Research.2023; 2023: 1. CrossRef
Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review
Jasmine KaiLi Goh, Leroy Koh
Diabetology International.2023; 14(3): 224. CrossRef
Autonomic neuropathic symptoms in patients with diabetes: practical tools for screening in daily routine
Ana Raquel Souza de Azevedo Vieira, Lara Benigno Porto-Dantas, Flaviene Alves do Prado Romani, Patrícia Souza Carvalho, Rodica Pop-Busui, Hermelinda Cordeiro Pedrosa
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
“Arterial stiffness is not associated with changes in the circadian pattern of blood pressure in patients with type 1 diabetes mellitus and cardiovascular autonomic dysfunction”
Lía Nattero-Chávez, Ane Bayona Cebada, Elena Fernández-Durán, Alejandra Quintero Tobar, Beatriz Dorado Avendaño, Héctor Escobar-Morreale, Manuel Luque-Ramírez
Diabetes and Vascular Disease Research.2023;[Epub] CrossRef
Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN)
Sanjeev Sharma, Gerry Rayman
Frontiers in Endocrinology.2023;[Epub] CrossRef
In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum
Jens Faber, Søren Ballegaard, Nanna Ørsted, Ebbe Eldrup, Benny Karpatschof, Finn Gyntelberg, Sofie Korsgaard Hecquet, Albert Gjedde
Frontiers in Neuroscience.2023;[Epub] CrossRef
Functional status associated with postural dizziness, but not postural hypotension, in older adults: a community-based study
Hsiang-Ju Cheng, Zih-Jie Sun, Feng-Hwa Lu, Yi-Ching Yang, Chih-Jen Chang, Jin-Shang Wu
BMC Geriatrics.2023;[Epub] CrossRef
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial
Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt‐Møller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J. L. Heerspink, Christian Stevns Hansen, Peter Ros
Diabetes, Obesity and Metabolism.2023; 25(10): 3064. CrossRef
The Retinal Nerve Fiber Layer Thickness Is Associated with Systemic Neurodegeneration in Long-Term Type 1 Diabetes
Christina Brock, Anne-Marie Wegeberg, Thomas Arendt Nielsen, Bassam Karout, Per M. Hellström, Asbjørn Mohr Drewes, Henrik Vorum
Translational Vision Science & Technology.2023; 12(6): 23. CrossRef
The Use of Empirical Mode Decomposition on Heart Rate Variability Signals to Assess Autonomic Neuropathy Progression in Type 2 Diabetes
Sandra Cossul, Felipe Rettore Andreis, Mateus Andre Favretto, Jefferson Luiz Brum Marques
Applied Sciences.2023; 13(13): 7824. CrossRef
Topical Capsaicin for the Management of Painful Diabetic Neuropathy: A Narrative Systematic Review
Brandon Goodwin, Maanas Chiplunkar, Ryan Salerno, Kylon Coombs, Umar Sannoh, Vrushank Shah, Nicholas Averell, Usmaan Al-Shebab, Deanna Janora
Pain Management.2023; 13(5): 309. CrossRef
Adynamic response to cold pain reflects dysautonomia in type 1 diabetes and polyneuropathy
Thomas Arendt Nielsen, Søren Lundbye-Christensen, Yoanna Krasimirova Dimitrova, Sam Riahi, Birgitte Brock, Asbjørn Mohr Drewes, Christina Brock
Scientific Reports.2023;[Epub] CrossRef
Autonomic Nerve Function Tests in Patients with Diabetes
Heung Yong Jin, Tae Sun Park
The Journal of Korean Diabetes.2023; 24(2): 71. CrossRef
Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies
Mandeep Kaur, Sakshi Misra, Priyanka Swarnkar, Preeti Patel, Balak Das Kurmi, Ghanshyam Das Gupta, Amrita Singh
Biochemical Pharmacology.2023; 215: 115723. CrossRef
A three-month physical training program improves cardiovascular autonomic function in patients with metabolic syndrome with and without diabetes – a pilot study
Anna Vágvölgyi, Judit Erzsébet Ábrahám, Éva Máthéné Köteles, Andrea Korom, Mária Barnai, Mónika Szűcs, Andrea Orosz, Péter Kempler, Adrienn Menyhárt, Attila Nemes, Tamás Várkonyi, István Baczkó, István Kósa, Csaba Lengyel
Frontiers in Endocrinology.2023;[Epub] CrossRef
Cardiovascular autonomic neuropathy in patients with type 2 diabetes with and without sensorimotor polyneuropathy
Emil Peters, Mustapha Itani, Alexander G. Kristensen, Astrid Juhl Terkelsen, Thomas Krøigård, Hatice Tankisi, Troels S. Jensen, Nanna B. Finnerup, Sandra Sif Gylfadottir
Journal of the Peripheral Nervous System.2023; 28(3): 450. CrossRef
Cardiac Autonomic Neuropathy in Prediabetes: A Case-Control Study
Pavan Gujjar, Y. S. Ravikumar, Lakshmi Nagendra, Hiya Boro, Saptarshi Bhattacharya
Indian Journal of Endocrinology and Metabolism.2023; 27(4): 325. CrossRef
Diabetic Neuropathies
Melissa A. Elafros, Brian C. Callaghan
Continuum.2023; 29(5): 1401. CrossRef
Determinants of the heart rate variability in type 1 diabetes mellitus
Máté Hajdu, Konstandia Garmpis, Vivien Vértes, Noémi Vorobcsuk-Varga, Gergő Attila Molnár, László Hejjel, István Wittmann, Réka Faludi
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Effect of Exercise on Cardiovascular Autonomic Nervous Function in Patients with Diabetes: A Systematic Review
Hidetaka Hamasaki
Healthcare.2023; 11(19): 2668. CrossRef
Influence of Fibrinogen/Albumin Ratio and Fibrinogen/Pre-Albumin Ratio on Cardiac Autonomic Neuropathy in Type 2 Diabetes
Subei Zhao, Zheng Yang, Meng Yu, Linyu Xiang, Yuhuan Lv, Chunyan Tian, Rong Li
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3249. CrossRef
In Ischemic Heart Disease, Reduced Sensitivity to Pressure at the Sternum Accompanies Lower Mortality after Five Years: Evidence from a Randomized Controlled Trial
Søren Ballegaard, Jens Faber, Christian Selmer, Finn Gyntelberg, Svend Kreiner, Benny Karpatschof, Tobias Wirenfeldt Klausen, Åke Hjalmarson, Albert Gjedde
Journal of Clinical Medicine.2023; 12(24): 7585. CrossRef
Assessment of the relationship of systemic vascular dysfunction and cardiac autonomic neuropathy (CAN) with diabetic retinopathy
KJ Hari Prakash, Sucheta Parija, Manisha Kar
Journal of Family Medicine and Primary Care.2023; 12(12): 3236. CrossRef
Autonomic Neuropathy in Ambulatory Type 2 Diabetes Mellitus Patients: A Single-arm Prospective, Observational Study
Kaustav Saha, Shatavisa Mukherjee, Animesh Maiti, Santanu Kumar Tripathi
Journal of the Practice of Cardiovascular Sciences.2023; 9(3): 178. CrossRef
Insomnia and type 2 diabetes: how to help the patient. Modern view of a neurologist
E. S. Akarachkova, O. V. Kotova, V. L. Klimov, D. I. Lebedeva
FOCUS. Endocrinology.2023; 4(4): 12. CrossRef
Carvedilol improves heart rate variability indices, biomarkers but not cardiac nerve density in streptozotocin-induced T2DM model of diabetic cardiac autonomic neuropathy
Olawale Mathias Akinlade, Bamidele Owoyele, Olufemi Ayodele Soladoye
Journal of Basic and Clinical Physiology and Pharmacology.2022; 33(2): 213. CrossRef
Cardiovascular autonomic responses during head-up tilt test in newly diagnosed type 2 diabetes
Esteban Jorge-Galarza, Margarita Torres-Tamayo, María del Rocío Martínez-Alvarado, Berenice Peña-Aparicio, Carmen González-Salazar, Juan Reyes-Barrera, Manuel Sierra-Beltrán, Erika Fajardo-Flores, Andrey Kostin, J. Antonio González-Hermosillo
Irish Journal of Medical Science (1971 -).2022; 191(5): 2077. CrossRef
Cardiovascular autonomic neuropathy and incident diabetic kidney disease in patients with type 2 diabetes
Ji Eun Jun, Min Sun Choi, Jae Hyeon Kim
Diabetes Research and Clinical Practice.2022; 184: 109181. CrossRef
Kardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1
Young Hee Lee-Barkey, Bernd Stratmann, Diethelm Tschöpe
Der Diabetologe.2022; 18(2): 131. CrossRef
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants
Francesca Romana Prandi, Isabella Evangelista, Domenico Sergi, Alberto Palazzuoli, Francesco Romeo
Heart Failure Reviews.2022; 28(3): 597. CrossRef
Comparison of Risk Assessment Strategies for Patients with Diabetes Mellitus and Stable Chest Pain: A Coronary Computed Tomography Angiography Study
Jia Zhao, Shuo Wang, Pengyu Zhao, Yong Huo, Chunjie Li, Jia Zhou, Pawel Kleczynski
Journal of Diabetes Research.2022; 2022: 1. CrossRef
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy
Gidon J Bönhof, Gundega Sipola, Alexander Strom, Christian Herder, Klaus Strassburger, Birgit Knebel, Claudia Reule, Jan-Christoph Wollmann, Andrea Icks, Hadi Al-Hasani, Michael Roden, Oliver Kuss, Dan Ziegler
BMJ Open.2022; 12(2): e057142. CrossRef
Pragmatic Clinic-Based Investigation of Glycemic Variability in Patients With Type 1 Diabetes in Routine Clinical Practice and Its Association With Cardiovascular Autonomic Neuropathy: A Pilot Study
Lucianne R.M. Tannus, Marilia B. Gomes
Endocrine Practice.2022; 28(5): 465. CrossRef
Longitudinal effects of one‐leg standing time on neuropathy outcomes in association with glycemic control in non‐elderly patients with type 2 diabetes
Kazuhiro Sugimoto, Takashi Sozu, Takehiko Hoshino, Yuko Watanabe, Akira Tamura, Toshiro Yamazaki, Setsu Ohta, Susumu Suzuki, Takuro Shimbo
Journal of Diabetes Investigation.2022; 13(6): 1039. CrossRef
Thermal quantitative sensory testing as a screening tool for cardiac autonomic neuropathy in patients with diabetes mellitus
Veronika Potockova, Sarka Mala, Lucie Hoskovcova, Vaclav Capek, Tomas Nedelka, Lucie Riedlbauchova, Daniel Baumgartner, Livie Mensova, Radim Mazanec
Brain and Behavior.2022;[Epub] CrossRef
Cardiovascular Autonomic Reflex Tests and 7 Heart Rate Variability Indices for Early Diagnosis of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Individuals
Yeelen Ballesteros Atala, Mozânia Reis De Matos, Denise Engelbrecht Zantut-Wittmann, Alejandro Rosell Castillo, Daniele P Santos-Bezerra, Maria Lucia Correa-Giannella, Maria Cândida Ribeiro Parisi
Current Diabetes Reviews.2022;[Epub] CrossRef
Design, synthesis, in vitro and in silico studies of naproxen derivatives as dual lipoxygenase and α-glucosidase inhibitors
Asma Sardar, Obaid-ur-Rahman Abid, Saima Daud, M. Fakhar-e-Alam, Muhammad Hussnain Siddique, Muhammad Ashraf, Wardah Shahid, Syeda Abida Ejaz, M. Atif, Shafiq Ahmad, Sulman Shafeeq, Muhammad Afzal
Journal of Saudi Chemical Society.2022; 26(3): 101468. CrossRef
Clinical manifestations and evaluation of cardiac autonomic neuropathy in diabetes mellitus and metabolic syndrome
L. S. Moshkhoeva, A. N. Barinov
Neurology, Neuropsychiatry, Psychosomatics.2022; 14(2): 71. CrossRef
The relationship between vitamin B12 levels and electrocardiographic ventricular repolarization markers
Emre Yılmaz, Devrim Kurt, Aslı Vural, Ertan Aydın, Sencer Çamcı, Ercan Aydın
Nutrición Hospitalaria.2022;[Epub] CrossRef
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double‐blinded, placebo‐controlled trial
Suvanjaa Sivalingam, Emilie Hein Zobel, Christian S. Hansen, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Jacob K. Jensen, Tine W. Hansen, Peter Rossing
Diabetes, Obesity and Metabolism.2022; 24(8): 1638. CrossRef
Heart Rate Variability and Chronic Kidney Disease in Patients with Type 2 Diabetes
Wei Shi, Jing Zhang, Dan Chen, Xiaolei Chen, Wei Duan, Hongmei Zhang, Fahd Abd Algalil
Applied Bionics and Biomechanics.2022; 2022: 1. CrossRef
Spectrum of Cardiac Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
Prativa Priyadarshani Sethi, Basavraj Jatteppanavar, Ravi Kant, Monika Pathania, Mukesh Chand Bairwa
Journal of Cardio-diabetes and Metabolic Disorders.2022; 2(1): 23. CrossRef
Cardiac Autonomic Dysfunction Is Associated With Risk of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus
Haixia Zeng, Jianmo Liu, Zheng Chen, Peng Yu, Jianping Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Gidon J. Bönhof, Christian Herder, Dan Ziegler
Current Diabetes Reviews.2022;[Epub] CrossRef
Triglyceride glucose index is related with cardiac autonomic dysfunction in patients with metabolic syndrome
Akif Serhat Balcıoğlu, Ekrem Aksu, Ahmet Çağrı Aykan
Kardiologiia.2022; 62(6): 45. CrossRef
Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes
Sasha Smith, Pasha Normahani, Tristan Lane, David Hohenschurz-Schmidt, Nick Oliver, Alun Huw Davies
Life.2022; 12(7): 1074. CrossRef
Correlation between impaired hemodynamic response and cardiopulmonary fitness in middle-aged type 2 diabetes mellitus patients: a case–control study
Jinjin Xie, Lianhua Yin, Jia Huang, Ying Xu, Yannan Chen, Jiawei Qin, Zhizhen Liu, Jing Tao
European Journal of Applied Physiology.2022; 122(10): 2295. CrossRef
Higher frequency of cardiovascular autonomic neuropathy in youth with type 2 compared to type 1 diabetes: Role of cardiometabolic risk factors
Benjamin J. Varley, Megan L. Gow, Yoon Hi Cho, Paul Benitez‐Aguirre, Janine Cusumano, Alison Pryke, Albert Chan, Vallimayil Velayutham, Kim C. Donaghue, Maria E. Craig
Pediatric Diabetes.2022; 23(7): 1073. CrossRef
The role of protein kinase C in diabetic microvascular complications
Deng Pan, Lin Xu, Ming Guo
Frontiers in Endocrinology.2022;[Epub] CrossRef
Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Dimitrios Patoulias, Alexandra Katsimardou, Nikolaos Fragakis, Christodoulos Papadopoulos, Michael Doumas
Acta Diabetologica.2022; 60(1): 1. CrossRef
Association between blood glucose levels and autonomic symptoms in Peru
Gabriel Angeles-Zurita, Margorie Narro-Fuentes, Antonio Bernabe-Ortiz
Primary Care Diabetes.2022; 16(5): 709. CrossRef
Clinical scoring systems for the risk of cardiovascular autonomic neuropathy in type 1 and type 2 diabetes: A simple tool
Marika Menduni, Cinzia D'Amato, Martina Leoni, Valentina Izzo, Mariateresa Staltari, Carla Greco, Andrea Abbatepassero, Giuseppe Seminara, Ilenia D'Ippolito, Davide Lauro, Vincenza Spallone
Journal of the Peripheral Nervous System.2022; 27(4): 259. CrossRef
Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study
Amanda Hempel Zinglersen, Ida Lynghøj Drange, Katrine Aagaard Myhr, Andreas Fuchs, Mogens Pfeiffer-Jensen, Christina Brock, Søren Jacobsen
BMJ Open.2022; 12(9): e064552. CrossRef
To the interpretation of frequency components of the heart rate variability
N. V. Kuzmenko, V. A. Tsyrlin, M. G. Pliss
Translational Medicine.2022; 9(3): 35. CrossRef
Protein pyrrole adducts are associated with elevated glucose indices and clinical features of diabetic diffuse neuropathies
Xiao Chen, Zhuyi Jiang, Lianjing Zhang, Wei Liu, Xiaohu Ren, Luling Nie, Desheng Wu, Zhiwei Guo, Weimin Liu, Xifei Yang, Yan Wu, Zhen Liang, Peter Spencer, Jianjun Liu
Journal of Diabetes.2022; 14(10): 646. CrossRef
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Scott Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Marshall, Emily Brown, Uazman Alam
Clinical Therapeutics.2022; 44(10): 1394. CrossRef
Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview
Victoria A. Serhiyenko, Ludmila M. Serhiyenko, Volodymyr B. Sehin, Alexandr A. Serhiyenko
Endocrine Regulations.2022; 56(4): 284. CrossRef
Heart rate-corrected QT interval prolongation is associated with decreased heart rate variability in patients with type 2 diabetes
Seon-Ah Cha
Medicine.2022; 101(45): e31511. CrossRef
Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
Diabetes & Metabolism Journal.2022; 46(6): 901. CrossRef
Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis
Susumu Z. Sudo, Tadeu L. Montagnoli, Bruna de S. Rocha, Aimeé D. Santos, Mauro P. L. de Sá, Gisele Zapata-Sudo
Biomedicines.2022; 10(12): 3258. CrossRef
The Relationship Between Orthostatic Hypotension and Vitamin D Deficiency in Patients with Uncontrolled Type 2 Diabetes Mellitus
Ece YİĞİT, Ridvan SİVRİTEPE, Dilay KARABULUT, Umut KARABULUT
Online Türk Sağlık Bilimleri Dergisi.2022; 7(2): 313. CrossRef
A study of heart rate variability in diabetic mellitus patients
Srinivasa Jayachandra, Satyanath Reddy Kodidala
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 153. CrossRef
Oxidative Damage and Anti-Inflammatory Activity of Myricetin from Berries in Streptozotocin-Induced Diabetic Rats
Shuling Wang, Jing Zhang
International Journal of Pharmacology.2022; 18(4): 753. CrossRef
Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients
Hantao Jiang, Jinping Feng, Chao Feng, Pei Ren, Kai Ren, Ying Jin, Jia Zhou
Reviews in Cardiovascular Medicine.2022;[Epub] CrossRef
The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
Aikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, Emily Brown, Rebecca Roylance, John P. H. Wilding, Daniel J. Cuthbertson, Uazman Alam
Diabetologia.2021; 64(2): 288. CrossRef
Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A cross‐sectional study
Ernesto Maddaloni, Chiara Moretti, Rossella Del Toro, Sara Sterpetti, Maria Vittoria Ievolella, Gabriele Arnesano, Rocky Strollo, Silvia Irina Briganti, Luca D'Onofrio, Paolo Pozzilli, Raffaella Buzzetti
Diabetic Medicine.2021;[Epub] CrossRef
Effects of lunar cycle on fasting plasma glucose, heart rate and blood pressure in type 2 diabetic patients
Sutanu Dutta Chowdhury, Subhasish Pramanik, Koena Bhattacharjee, Lakshmi Kanta Mondal
Chronobiology International.2021; 38(2): 270. CrossRef
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
Yaling Tang, Hetal Shah, Carlos Roberto Bueno Junior, Xiuqin Sun, Joanna Mitri, Maria Sambataro, Luisa Sambado, Hertzel C. Gerstein, Vivian Fonseca, Alessandro Doria, Rodica Pop-Busui
Diabetes Care.2021; 44(1): 164. CrossRef
Decreased glomerular filtration rate and increased albuminuria for identification of cardiovascular autonomic neuropathy in subjects with and without diabetes
Ying-Chuen Lai, Hung-Yuan Li, Yi-Dier Jiang, Tien-Jyun Chang, Lee-Ming Chuang
Autonomic Neuroscience.2021; 230: 102757. CrossRef
Exposures influencing the developing central autonomic nervous system
Sarah D. Schlatterer, Adre J. du Plessis
Birth Defects Research.2021; 113(11): 845. CrossRef
Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial
Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Eleni Margariti, Parthena Giannoulaki, Georgios Batanis, Solomon Tesfaye, Kοnstantinos Kantartzis
Nutrients.2021; 13(2): 395. CrossRef
The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes
Min Young Kim, Gyuri Kim, Ji Yun Park, Min Sun Choi, Ji Eun Jun, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2021; 23(6): 434. CrossRef
Insulin resistance is independently associated with cardiovascular autonomic neuropathy in type 2 diabetes
Yingshan Liu, Yu Peng, Jing Jin, Yanshan Chen, Chuna Chen, Zhenguo Chen, Haishan Huang, Lingling Xu
Journal of Diabetes Investigation.2021; 12(9): 1651. CrossRef
SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
Vincenza Spallone, Paul Valensi
Diabetes & Metabolism.2021; 47(4): 101224. CrossRef
Reduction of Pressure Pain Sensitivity as Novel Non-pharmacological Therapeutic Approach to Type 2 Diabetes: A Randomized Trial
Jens Faber, Ebbe Eldrup, Christian Selmer, Caroline Pichat, Sofie Korsgaard Hecquet, Torquil Watt, Svend Kreiner, Benny Karpatschof, Finn Gyntelberg, Søren Ballegaard, Albert Gjedde
Frontiers in Neuroscience.2021;[Epub] CrossRef
Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes
M. Serdarova, R. Dimova, N. Chakarova, G. Grozeva, A. Todorova, T. Tankova
Diabetes Research and Clinical Practice.2021; 174: 108721. CrossRef
Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review
Mar Sempere-Bigorra, Iván Julián-Rochina, Omar Cauli
Journal of Personalized Medicine.2021; 11(3): 230. CrossRef
Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
Ditte S. Kornum, Astrid J. Terkelsen, Davide Bertoli, Mette W. Klinge, Katrine L. Høyer, Huda H. A. Kufaishi, Per Borghammer, Asbjørn M. Drewes, Christina Brock, Klaus Krogh
Journal of Clinical Medicine.2021; 10(7): 1392. CrossRef
Diabetic heart disease: A clinical update
Jake Rajbhandari, Cornelius James Fernandez, Mayuri Agarwal, Beverly Xin Yi Yeap, Joseph M Pappachan
World Journal of Diabetes.2021; 12(4): 383. CrossRef
Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy
Anne Marshall, Uazman Alam, Andreas Themistocleous, Nigel Calcutt, Andrew Marshall
Clinical Therapeutics.2021; 43(9): 1441. CrossRef
Cardiac Autonomic Neuropathy Is Not Reversed by Euglycemia Following Islet Transplantation
Tejas Deshmukh, Peter Emerson, Patricia Anderson, Eddy Kizana, Philip J. O’Connell, D. Jane Holmes-Walker, James J.H. Chong
Transplantation.2021; 105(5): 1125. CrossRef
Attenuation of Muscle Mass and Density Is Associated With Poor Outcomes Among Patients Undergoing Major Gynecologic Surgery: A Retrospective Cohort Study
Lu Che, Yan Zhang, Jiawen Yu, Li Xu, Yuguang Huang
Anesthesia & Analgesia.2021; 132(6): 1692. CrossRef
Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy
Min Sun Choi, Ji Eun Jun, Sung Woon Park, Jee Hee Yoo, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee, Jae Hyeon Kim
Diabetes & Metabolism Journal.2021; 45(3): 349. CrossRef
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Gordon Sloan, Dinesh Selvarajah, Solomon Tesfaye
Nature Reviews Endocrinology.2021; 17(7): 400. CrossRef
Heart Rate Variability as a Potential Non-invasive Marker of Blood Glucose Level
L. R. Jarman, J. L. Elliott, T. Lees, R. Clifton-Bligh, A. M. Simpson, N. Nassif, S. Lal
Human Physiology.2021; 47(2): 209. CrossRef
Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
Alice Duque, Mauro Felippe Felix Mediano, Andrea De Lorenzo, Luiz Fernando Rodrigues Jr
World Journal of Diabetes.2021; 12(6): 855. CrossRef
Gaussian process-based kernel as a diagnostic model for prediction of type 2 diabetes mellitus risk using non-linear heart rate variability features
R. Shashikant, Uttam Chaskar, Leena Phadke, Chetankumar Patil
Biomedical Engineering Letters.2021; 11(3): 273. CrossRef
Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
Advances in Therapy.2021; 38(8): 4195. CrossRef
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus
Amanda Hempel Zinglersen, Katrine Kjær Iversen, Henrik Christian Bidstrup Leffers, Esben Laugesen, Jesper Fleischer, Søren Jacobsen
Lupus Science & Medicine.2021; 8(1): e000507. CrossRef
Impaired vagal adaptation to an exercise task in women with gestational diabetes mellitus versus women with uncomplicated pregnancies
Marieta P. Theodorakopoulou, Areti Triantafyllou, Andreas Zafeiridis, Afroditi Κ. Boutou, Iris Grigoriadou, Evangelia Kintiraki, Stella Douma, Dimitrios G. Goulis, Konstantina Dipla
Hormones.2021; 20(4): 753. CrossRef
Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis
Lucas Silva Sousa, Felipe de Araújo Nascimento, Juliano Rocha, Michelle Rocha-Parise
International Journal of Cardiovascular Sciences.2021;[Epub] CrossRef
Management of diabetic neuropathy
Simona Cernea, Itamar Raz
Metabolism.2021; 123: 154867. CrossRef
Large fibre, small fibre and autonomic neuropathy in adolescents with type 1 diabetes: A systematic review
Vinni Faber Rasmussen, Troels Staehelin Jensen, Hatice Tankisi, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen
Journal of Diabetes and its Complications.2021; 35(11): 108027. CrossRef
Cardiovascular Risk Management in Type 1 Diabetes
I. H. Teoh, P. Elisaus, J. D. Schofield
Current Diabetes Reports.2021;[Epub] CrossRef
Disturbances in the intraventricular conduction system in teenagers with type 1 diabetes. A pilot study
Agnieszka Zubkiewicz-Kucharska, Anna Noczyńska, Małgorzata Sobieszczańska, Małgorzata Poręba, Joanna Chrzanowska, Rafał Poręba, Monika Seifert, Anna Janocha, Krystyna Laszki-Szcząchor
Journal of Diabetes and its Complications.2021; 35(11): 108043. CrossRef
Peripheral and Autonomic Neuropathy Status of Young Patients With Type 1 Diabetes Mellitus at the Time of Transition From Pediatric Care to Adult-Oriented Diabetes Care
Anna Vágvölgyi, Ágnes Maróti, Mónika Szűcs, Csongor Póczik, Dóra Urbán-Pap, István Baczkó, Attila Nemes, Éva Csajbók, Krisztián Sepp, Péter Kempler, Andrea Orosz, Tamás Várkonyi, Csaba Lengyel
Frontiers in Endocrinology.2021;[Epub] CrossRef
Pancreatic exocrine insufficiency in diabetes is associated with autonomic dysfunction
Dag André Sangnes, Elisabeth Sandvik Bergmann, Rose Marie Moss, Trond Engjom, Eirik Søfteland
Scandinavian Journal of Gastroenterology.2021; 56(10): 1222. CrossRef
Dependence of Heart Rate Variability Indices on the Mean Heart Rate in Women with Well-Controlled Type 2 Diabetes
Adriana Robles-Cabrera, José M. Torres-Arellano, Ruben Fossion, Claudia Lerma
Journal of Clinical Medicine.2021; 10(19): 4386. CrossRef
Normative data on cardiovascular autonomic function in Greenlandic Inuit
Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Dorte Vistisen, Stine Byberg, Trine Larsen, Jens Christian Laursen, Marit Eika Jørgensen
BMJ Open Diabetes Research & Care.2021; 9(1): e002121. CrossRef
What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs
V. Spallone, C. Ciccacci, A. Latini, P. Borgiani, Karim Gariani
Journal of Diabetes Research.2021; 2021: 1. CrossRef
Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes
O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev
Neurology, Neuropsychiatry, Psychosomatics.2021; 13(5): 116. CrossRef
Manifestazioni cliniche della neuropatia autonomica diabetica: valutazione dei sintomi
Carla Greco, Chiara Pacchioni, Manuela Simoni
L'Endocrinologo.2021; 22(6): 514. CrossRef
Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
Xiaochun Zhang, Xue Yang, Bao Sun, Chunsheng Zhu
Communications Biology.2021;[Epub] CrossRef
The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
Jens Christian Laursen, Ida Kirstine B. Rasmussen, Emilie H. Zobel, Philip Hasbak, Bernt Johan von Scholten, Lene Holmvang, Rasmus S. Ripa, Christian S. Hansen, Marie Frimodt-Moeller, Andreas Kjaer, Peter Rossing, Tine W. Hansen
Frontiers in Endocrinology.2021;[Epub] CrossRef
Dependence of heart rate variability on indicators of type 1 diabetes mellitus control.
N. O. Pertseva, O. V. Gurzhiy, K. I. Moshenets
Medicni perspektivi (Medical perspectives).2020; 25(1): 88. CrossRef
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef
Diabetes mellitus and comorbidities: A bad romance
Niki Katsiki, Dimitrios Tousoulis
Hellenic Journal of Cardiology.2020; 61(1): 23. CrossRef
Features of the glucose influence on the heart activity and the changes in the potentials of the stomach and the intestines at the heart insufficiency conditions
V. V. Soltanov, L. M. Komarovskaya
Doklady of the National Academy of Sciences of Belarus.2020; 63(6): 736. CrossRef
Living Day to Day
Gerald Kayingo, Virginia McCoy Hass
Physician Assistant Clinics.2020; 5(2): 213. CrossRef
Source specific PM2.5 associated with heart rate variability in the elderly with coronary heart disease: A community-based panel study
Xi Chen, Bing Qiu, Qinpei Zou, Tian Qiu, Runkui Li, Ashley Truong, Yanmin Qi, Tao Liu, Limin Han, Tiebing Liu, Junrui Chang, Qi Sun, Ying Zhu, Dongqun Xu
Chemosphere.2020; 260: 127399. CrossRef
The Association of Autonomic Nervous System Function With Ischemic Stroke, and Treatment Strategies
Mengxi Zhao, Ling Guan, Yilong Wang
Frontiers in Neurology.2020;[Epub] CrossRef
Cardiac diabetic autonomic neuropathy
L. T. Akhmedzhanova, T. A. Belyakova, Yu. A. Podkovko, Yu. M. Shor
Medical Council.2020; (21): 94. CrossRef
Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions
Liliana Espinoza, Carie R Boychuk
Current Opinion in Pharmacology.2020; 54: 18. CrossRef
Morning blood pressure surge is associated with autonomic neuropathy and peripheral vascular disease in patients with diabetes
Federica Di Gennaro, Cinzia D’Amato, Roberto Morganti, Carla Greco, Susanna Longo, Diana Corradini, Davide Lauro, Vincenza Spallone
Journal of Human Hypertension.2020; 34(7): 495. CrossRef
The Compound Expression of HSP90 and INOS in the Testis of Diabetic Rats as Cellular and Pathologic Adverse Effects of Diabetes
Ali Alsarhan, Kawther Faisal Amawi, Inas Saleh Al-Mazari, Hashem Abu Hurirah, Ahed J. Alkhatib
Analytical Cellular Pathology.2020; 2020: 1. CrossRef
Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine
Yogender Aggarwal, Joyani Das, Papiya Mitra Mazumder, Rohit Kumar, Rakesh Kumar Sinha
Biocybernetics and Biomedical Engineering.2020; 40(3): 1002. CrossRef
Distal Symmetric and Cardiovascular Autonomic Neuropathies in Brazilian Individuals with Type 2 Diabetes Followed in a Primary Health Care Unit: A Cross-Sectional Study
Mozania Reis de Matos, Daniele Pereira Santos-Bezerra, Cristiane das Graças Dias Cavalcante, Jacira Xavier de Carvalho, Juliana Leite, Jose Antonio Januario Neves, Sharon Nina Admoni, Marisa Passarelli, Maria Candida Parisi, Maria Lucia Correa-Giannella
International Journal of Environmental Research and Public Health.2020; 17(9): 3232. CrossRef
Awareness of hypoglycemia and spectral analysis of heart rate variability in type 1 diabetes
Ticiana Paes, L. Clemente Rolim, Celso Sallum Filho, João Roberto de Sa, Sérgio A. Dib
Journal of Diabetes and its Complications.2020; 34(8): 107617. CrossRef
Is there cardiac autonomic neuropathy in prediabetes?
Lindsay A. Zilliox, James W. Russell
Autonomic Neuroscience.2020; 229: 102722. CrossRef
Chronic Microvascular Complications in Prediabetic States—An Overview
Angelika Baranowska-Jurkun, Wojciech Matuszewski, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2020; 9(10): 3289. CrossRef
Cardiac vagal tone as a novel screening tool to recognize asymptomatic cardiovascular autonomic neuropathy: Aspects of utility in type 1 diabetes
Anne-Marie Wegeberg, Elin D Lunde, Sam Riahi, Niels Ejskjaer, Asbjørn M Drewes, Birgitte Brock, Rodica Pop-Busui, Christina Brock
Diabetes Research and Clinical Practice.2020; 170: 108517. CrossRef
Assessment of baroreceptor reflex sensitivity in young obese Saudi males at rest and in response to physiological challenges
Abdullah N. AlShahrani, Lubna I. Al‐Asoom, Ahmed A. Alsunni, Nabil S. Elbahai, Talay Yar
Physiological Reports.2020;[Epub] CrossRef
The relationship between QT interval indices with cardiac autonomic neuropathy in diabetic patients: a case control study
Maryam Vasheghani, Farzaneh Sarvghadi, Mohammad Reza Beyranvand, Habib Emami
Diabetology & Metabolic Syndrome.2020;[Epub] CrossRef
Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options
Péter Bencsik, Kamilla Gömöri, Tamara Szabados, Péter Sántha, Zsuzsanna Helyes, Gábor Jancsó, Péter Ferdinandy, Anikó Görbe
British Journal of Pharmacology.2020; 177(23): 5336. CrossRef
Biological Activity of c-Peptide in Microvascular Complications of Type 1 Diabetes—Time for Translational Studies or Back to the Basics?
Aleksandra Ryk, Aleksandra Łosiewicz, Arkadiusz Michalak, Wojciech Fendler
International Journal of Molecular Sciences.2020; 21(24): 9723. CrossRef
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Aman Sharma, Shweta Mittal, Rohan Aggarwal, Meenakshi K. Chauhan
Future Journal of Pharmaceutical Sciences.2020;[Epub] CrossRef
Diabetic Autonomic Neuropathy: A Clinical Update
Jugal Kishor Sharma, Anshu Rohatgi, Dinesh Sharma
Journal of the Royal College of Physicians of Edinburgh.2020; 50(3): 269. CrossRef
Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2019; 25(18): 2051. CrossRef
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
Scott M. Williams, Aikaterini Eleftheriadou, Uazman Alam, Daniel J. Cuthbertson, John P. H. Wilding
Diabetes Therapy.2019; 10(6): 1995. CrossRef

Clinical Diabetes & Therapeutics
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association: Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi; Diabetes Metab J. 2017;41(6):423-429. Published online December 19, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.6.423

10,132 View
86 Download
5 Web of Science
6 Crossref

Abstract PDF PubReader ePub

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by

Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
European Journal of Pharmacology.2022; 933: 175269. CrossRef
Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
Journal of Healthcare Engineering.2021; 2021: 1. CrossRef
Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11. CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Ju-Ming Lu
Advances in Therapy.2019; 36(4): 798. CrossRef
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
Diabetes Therapy.2019; 10(1): 5. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
The Journal of Korean Diabetes.2018; 19(1): 35. CrossRef

Islet Studies and Transplantation
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass: Suk Chon, Jean-François Gautier; Diabetes Metab J. 2016;40(2):99-114. Published online April 25, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.2.99

13,291 View
180 Download
49 Web of Science
47 Crossref

Abstract PDF PubReader ePub

Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.

Citations

Citations to this article as recorded by

The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
Mighty Kemelo, Phillip Moseki
Results in Chemistry.2025; 14: 102139. CrossRef
Cyanidin-3-O-glucoside enhances GLP-1 secretion via PPARβ/δ-β-catenin-TCF-4 pathway in type 2 diabetes mellitus
Xiang Ye, Wen Chen, Fujie Yan, Xiaodong Zheng, Pengcheng Tu
npj Science of Food.2025;[Epub] CrossRef
Local Insulin for Local Needs? Insights into Retinal Insulin Signaling and RPE Metabolism
Matilde Balbi, Alessandra Puddu, Andrea Amaroli, Davide Maggi, Isabella Panfoli, Silvia Ravera
Biomolecules.2025; 15(11): 1570. CrossRef
Scars of oxidative stress: protein carbonylation and beta cell dysfunction in diabetes
Ashley Ling, Katherine R. Schultz, Jefferson D. Knight, Colin T. Shearn, Sharon Baumel-Alterzon
Frontiers in Endocrinology.2025;[Epub] CrossRef
GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes
Joana Moreira Marques, Rute Nunes, Ana Margarida Carvalho, Helena Florindo, Domingos Ferreira, Bruno Sarmento
ACS Pharmacology & Translational Science.2024; 7(5): 1650. CrossRef
Bisphenol a accelerates the glucolipotoxicity-induced dysfunction of rat insulinoma cell lines: An implication for a potential risk of environmental bisphenol a exposure for individuals susceptible to type 2 diabetes
Chengmeng Huang, Xiaolin Chen, Zedong Ouyang, Lingxue Meng, Jian Liu, Qihua Pang, Ruifang Fan
Toxicology in Vitro.2024; 99: 105866. CrossRef
Harnessing gut cells for functional insulin production: Strategies and challenges
Kelvin Baafi, John C. March
Biotechnology Notes.2023; 4: 7. CrossRef
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho
Endocrinology and Metabolism.2023; 38(1): 1. CrossRef
Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function
Simon B. K. Jensen, Christian R. Juhl, Charlotte Janus, Julie R. Lundgren, Christoffer Martinussen, Christoffer Wiingaard, Cecilie Knudsen, Ruth Frikke‐Schmidt, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad, Signe S. Torekov
Obesity.2023; 31(4): 977. CrossRef
How do parasitic worms prevent diabetes? An exploration of their influence on macrophage and β-cell crosstalk
Inah Camaya, Bronwyn O’Brien, Sheila Donnelly
Frontiers in Endocrinology.2023;[Epub] CrossRef
An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review
Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard Ing
Obesity Surgery.2023; 33(9): 2927. CrossRef
Therapeutic Dilemma in Personalized Medicine
Ehab S. EL Desoky
Current Reviews in Clinical and Experimental Pharmacology.2022; 17(2): 94. CrossRef
Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment
Amar Abderrahmani, Cécile Jacovetti, Romano Regazzi
Trends in Endocrinology & Metabolism.2022; 33(6): 378. CrossRef
Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Diabetes, Obesity and Metabolism.2022; 24(12): 2353. CrossRef
A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes
Chih-Yuan Wang, Kuo-Chin Huang, Chia-Wen Lu, Chih-Hsun Chu, Chien-Ning Huang, Harn-Shen Chen, I-Te Lee, Jung-Fu Chen, Ching-Chu Chen, Chung-Sen Chen, Chang-Hsun Hsieh, Kai-Jen Tien, Hung-Yu Chien, Yu-Yao Huang, Jui-Pao Hsu, Guang-Tzuu Shane, Ai-Ching Chan
The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4063. CrossRef
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
Tao Tao, Yi Zhang, Yu-Chen Zhu, Jia-Rong Fu, Yu-Ying Wang, Jie Cai, Jing-Yu Ma, Yu Xu, Yi-Ning Gao, Yun Sun, WuQiang Fan, Wei Liu
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1420. CrossRef
The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study
Tuccinardi Dario, Giorgino Riccardo, Pieralice Silvia, Watanabe Mikiko, Maggi Daria, Palermo Andrea, Defeudis Giuseppe, Fioriti Elvira, Pozzilli Paolo, Manfrini Silvia
Acta Diabetologica.2021; 58(4): 411. CrossRef
Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy
E. V. Biryukova, I. A. Morozova, S. V. Rodionova
Meditsinskiy sovet = Medical Council.2021; (21): 160. CrossRef
Emerging Role of Caveolin-1 in GLP-1 Action
Alessandra Puddu, Davide Maggi
Frontiers in Endocrinology.2021;[Epub] CrossRef
Improvements in HOMA indices and pancreatic endocrinal tissues in type 2-diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans
Heera Ram, Pramod Kumar, Ashok Purohit, Priya Kashyap, Suresh Kumar, Shivani Kumar, Garima Singh, Abdulaziz A. Alqarawi, Abeer Hashem, Elsayed Fathi Abd-Allah, Al-Bandari Fahad Al-Arjani, Bhim Pratap Singh
Nutrition & Metabolism.2021;[Epub] CrossRef
Chop / Ddit3 depletion in β cells alleviates ER stress and corrects hepatic steatosis in mice
Jing Yong, Vishal S. Parekh, Shannon M. Reilly, Jonamani Nayak, Zhouji Chen, Cynthia Lebeaupin, Insook Jang, Jiangwei Zhang, Thazha P. Prakash, Hong Sun, Sue Murray, Shuling Guo, Julio E. Ayala, Leslie S. Satin, Alan R. Saltiel, Randal J. Kaufman
Science Translational Medicine.2021;[Epub] CrossRef
Assessment of Insulin Secretion and Insulin Resistance in Human
So Young Park, Jean-François Gautier, Suk Chon
Diabetes & Metabolism Journal.2021; 45(5): 641. CrossRef
Targeted pharmacological therapy restores β-cell function for diabetes remission
Stephan Sachs, Aimée Bastidas-Ponce, Sophie Tritschler, Mostafa Bakhti, Anika Böttcher, Miguel A. Sánchez-Garrido, Marta Tarquis-Medina, Maximilian Kleinert, Katrin Fischer, Sigrid Jall, Alexandra Harger, Erik Bader, Sara Roscioni, Siegfried Ussar, Annett
Nature Metabolism.2020; 2(2): 192. CrossRef
The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes
Kristina S. Boye, Reema Mody, Maureen J. Lage, Raleigh E. Malik
Clinical Therapeutics.2020; 42(9): 1812. CrossRef
Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study
Valentina K. Bayrasheva, Ivan Y. Pchelin, Vladimir A. Dobronravov, Alina Yu. Babenko, Svetlana G. Chefu, Ivan S. Shatalov, Volha N. Vasilkova, Natalia V. Hudiakova, Alexandra N. Ivanova, Pavel A. Andoskin, Elena N. Grineva
Archives of Endocrinology and Metabolism.2020;[Epub] CrossRef
A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity
Jennifer Vogel, Jianning Yin, Liansheng Su, Sharon X. Wang, Richard Zessis, Sena Fowler, Chun-Hao Chiu, Aaron C. Wilson, Amy Chen, Frederic Zecri, Gordon Turner, Thomas M. Smith, Brian DeChristopher, Heming Xing, Deborah M. Rothman, Xinming Cai, Alina Ber
Diabetes.2020; 69(5): 1032. CrossRef
Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice
Gaëtan Prévost, Arnaud Arabo, Marie-Anne Le Solliec, Justine Bons, Marie Picot, Julie Maucotel, Hind Berrahmoune, Mouna El Mehdi, Saloua Cherifi, Alexandre Benani, Emmanuelle Nédélec, Moïse Coëffier, Jérôme Leprince, Anneli Nordqvist, Valéry Brunel, Pierr
American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E147. CrossRef
Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues
Krister Bokvist, Ying Ding, William H. Landschulz, Vikram Sinha, Aleksandra Pastrak, Ruth M. Belin
Diabetes, Obesity and Metabolism.2019; 21(7): 1606. CrossRef
Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
Phytomedicine.2019; 62: 152946. CrossRef
The future of new drugs for diabetes management
Clifford J. Bailey, Caroline Day
Diabetes Research and Clinical Practice.2019; 155: 107785. CrossRef
Compact fluidic system for functional assessment of pancreatic islets
Takeshi Hori, Kei Yamane, Takayuki Anazawa, Osamu Kurosawa, Hiroo Iwata
Biomedical Microdevices.2019;[Epub] CrossRef
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison, Nigel H. Greig
Scientific Reports.2019;[Epub] CrossRef
Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot Glotfelty, Lital Rachmany, Hee Kyung Kim, Ho-Il Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig, Dong Seok Kim
Neurobiology of Disease.2019; 124: 439. CrossRef
Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
N.M. Pathak, V. Pathak, V.A. Gault, S. McClean, N. Irwin, P.R. Flatt
Biochemical Pharmacology.2018; 155: 264. CrossRef
Human EndoC-βH1 β-cells form pseudoislets with improved glucose sensitivity and enhanced GLP-1 signaling in the presence of islet-derived endothelial cells
Michael G. Spelios, Lauren A. Afinowicz, Regine C. Tipon, Eitan M. Akirav
American Journal of Physiology-Endocrinology and Metabolism.2018; 314(5): E512. CrossRef
Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice
Tatiana Yu. Demidova
Problems of Endocrinology.2018; 64(5): 336. CrossRef
Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss
Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Teresa Guagnano, Armando Tartaro, Riccardo C. Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli, Francesca Santilli
Nutrients.2018; 10(12): 1872. CrossRef
Nutrient regulation of β-cell function: what do islet cell/animal studies tell us?
R Carlessi, K N Keane, C Mamotte, P Newsholme
European Journal of Clinical Nutrition.2017; 71(7): 890. CrossRef
Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice
You-Cheol Hwang, Ari Kim, Euna Jo, Yeoree Yang, Jae-Hyoung Cho, Byung-Wan Lee
BMC Endocrine Disorders.2017;[Epub] CrossRef
Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
Diabetes, Obesity and Metabolism.2017; 19(5): 654. CrossRef
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi
Cardiovascular Diabetology.2017;[Epub] CrossRef
Recent Advances in Effect‐directed Enzyme Assays based on Thin‐layer Chromatography
Sarah Bräm, Evelyn Wolfram
Phytochemical Analysis.2017; 28(2): 74. CrossRef
Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
Diabetes, Obesity and Metabolism.2017; 19(5): 635. CrossRef
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
The Korean Journal of Internal Medicine.2017; 32(6): 947. CrossRef
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
Diabetes & Metabolism Journal.2017; 41(5): 337. CrossRef
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Eun Ju Bae
Archives of Pharmacal Research.2016; 39(8): 1114. CrossRef
Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet ß-cell Function in Severe Non-obese Diabetic Mice
Li-rong Li, Jing Lu, Xiao-lei Jia, Hui Hui, Jie Zhang, Ying Liu, Wei-juan Cui, Qian-yue Xu, Da-long Zhu
Molecular Medicine.2016; 22(1): 800. CrossRef

Original Article

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus: Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho; Diabetes Metab J. 2015;39(4):335-341. Published online July 17, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.4.335

7,424 View
40 Download
4 Web of Science
3 Crossref

Abstract PDF PubReader ePub

Background

This study aimed to evaluate the effect of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, on insulin secretion and glucagon suppression in Korean subjects with type 2 diabetes mellitus.

Methods

Twenty-four subjects underwent a 75-g oral glucose tolerance test (OGTT) before and after 6 months of sitagliptin treatment. Sitagliptin, insulin, and sulfonylurea were withdrawn for 3 days before OGTT to eliminate any acute effects on β-cell insulin or α-cell glucagon secretion. Venous samples were drawn five times during each OGTT to measure plasma glucose, insulin, and glucagon. Indices on insulin secretion and resistance were calculated.

Results

Early phase insulin secretion, measured by the insulinogenic index significantly increased after 6 months of sitagliptin treatment, especially in the higher baseline body mass index group and higher baseline glycosylated hemoglobin (HbA1c) group. There were no significant differences in the insulin resistance indices before and after sitagliptin treatment. Although no significant differences were observed in the absolute levels of glucagon and the glucagon-to-insulin ratio, there was a significant reduction in the percentile change of glucagon-to-insulin ratio at 30- and 120-minute during the OGTT.

Conclusion

Although the HbA1c level did not decrease significantly after 6 months of sitagliptin treatment, an increase in insulin secretion and reduction in early phase postprandial plasma glucagon-to-insulin ratio excursion was confirmed in Korean subjects with type 2 diabetes.

Citations

Citations to this article as recorded by

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
Eugene Han, Hye Sun Park, Obin Kwon, Eun Yeong Choe, Hye Jin Wang, Yong-ho Lee, Sang-Hak Lee, Chul Hoon Kim, Lee-Kyung Kim, Soo Heon Kwak, Kyong Soo Park, Chul Sik Kim, Eun Seok Kang
Medicine.2016; 95(44): e5155. CrossRef
Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial
Mingyuan Tian, Zerong Liang, Rui Liu, Ke Li, Xinrong Tan, Yong Luo, Mengliu Yang, Harvest F Gu, Hua Liu, Ling Li, Gangyi Yang
European Journal of Endocrinology.2016; 174(2): 147. CrossRef
Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
Ji Hyun Kim
Diabetes & Metabolism Journal.2015; 39(4): 304. CrossRef

Reviews

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea: Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang; Diabetes Metab J. 2015;39(3):177-187. Published online June 15, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.3.177

8,369 View
63 Download
4 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(3): 418. CrossRef
Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
Diabetes & Metabolism Journal.2017; 41(5): 337. CrossRef
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
The Korean Journal of Internal Medicine.2017; 32(6): 947. CrossRef

Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block: Jun Sung Moon, Kyu Chang Won; Diabetes Metab J. 2015;39(1):1-9. Published online February 16, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.1.1

11,522 View
121 Download
43 Web of Science
43 Crossref

Abstract PDF PubReader ePub

Type 2 diabetes (T2D) has been known as 'bi-hormonal disorder' since decades ago, the role of glucagon from α-cell has languished whereas β-cell taking center stage. Recently, numerous findings indicate that the defects of glucagon secretion get involve with development and exacerbation of hyperglycemia in T2D. Aberrant α-cell responses exhibit both fasting and postprandial states: hyperglucagonemia contributes to fasting hyperglycemia caused by inappropriate hepatic glucose production, and to postprandial hyperglycemia owing to blunted α-cell suppression. During hypoglycemia, insufficient counter-regulation response is also observed in advanced T2D. Though many debates still remained for exact mechanisms behind the dysregulation of α-cell in T2D, it is clear that the blockade of glucagon receptor or suppression of glucagon secretion from α-cell would be novel therapeutic targets for control of hyperglycemia. Whereas there have not been remarkable advances in developing new class of drugs, currently available glucagon-like peptide-1 and dipeptidyl peptidase-IV inhibitors could be options for treatment of hyperglucagonemia. In this review, we focus on α-cell dysfunction and therapeutic potentials of targeting α-cell in T2D.

Citations

Citations to this article as recorded by

The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Siham Accacha, Julia Barillas-Cerritos, Liana Gabriel, Ankita Srivastava, Shelly Gulkarov, Jennifer A. Apsan, Joshua De Leon, Allison B. Reiss
Biomedicines.2026; 14(1): 198. CrossRef
Transcriptomic heterogeneity of non-beta islet cells is associated with type 2 diabetes development in mouse models
Pascal Gottmann, Thilo Speckmann, Mandy Stadion, Prateek Chawla, Judith Saurenbach, Nikolay Ninov, Heiko Lickert, Annette Schürmann
Diabetologia.2025; 68(1): 166. CrossRef
The Role of the Gut Microbiome in the Development and Progression of Type 2 Diabetes and Liver Disease
Asha Guraka, Sreejesh Sreedharan, Ramesh Arasaradnam, Gyan Tripathi, Ali Kermanizadeh
Nutrition Reviews.2025; 83(7): e2025. CrossRef
Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics
Abdulbasit Amin, Toyin Mohammed Salman
Journal of Basic and Clinical Physiology and Pharmacology.2025; 36(2-3): 139. CrossRef
Prolonged glucagon exposure rewires lipid oxidation and drives diabetic kidney disease progression
Xingfeng Liu, Jingwen Chen, Shengying Gu, Yibing Chen, Ruiping Zhang, Qingce Zang, Ting Li, Hanwen Li, Dejin Lu, Shaocong Hou, Lijuan Kong, Qian Jiang, Caiyi Xing, Wenjia Fan, Yanjun Wan, Jiaqi Zhang, Linyuan Zhu, Chunxiao Ma, Qijin Zhao, Hai Yan, Zeper A
Nature Communications.2025;[Epub] CrossRef
An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect
Vijaya Subramanian, Jonatan I. Bagger, Vinayak Harihar, Jens J. Holst, Filip K. Knop, Tina Villsbøll
American Journal of Physiology-Endocrinology and Metabolism.2024; 326(2): E182. CrossRef
Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2024; 39(1): 98. CrossRef
Effect of probiotic-fermented milk containing Lactiplantibacillus pentoses strain HBUAS 53657 on serum glutathione peroxidase activity and pancreatic histopathology in hyperglycemic rats
Rita Yaswir, Eti Yerizel, Netti Suharti, Cimi Ilmiawati
Acta Biochimica Indonesiana.2024; 7(2): 174. CrossRef
Childhood Obesity, Diabetes, and Cardiovascular Disease Risk
Mostafa Salama, Babu Balagopal, Ilene Fennoy, Seema Kumar
The Journal of Clinical Endocrinology & Metabolism.2023; 108(12): 3051. CrossRef
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum
Diabetes.2022; 71(1): 1. CrossRef
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum
Diabetes Care.2022; 45(1): 3. CrossRef
Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum
Marek Skrzypski, Paweł A. Kołodziejski, Ewa Pruszyńska-Oszmałek, Tatiana Wojciechowicz, Paulina Janicka, Małgorzata Krążek, Emilian Małek, Mathias Z. Strowski, Krzysztof W. Nowak
International Journal of Molecular Sciences.2022; 23(17): 9807. CrossRef
A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
Vijaya Subramanian, Jonatan I. Bagger, Jens J. Holst, Filip K. Knop, Tina Vilsbøll
Frontiers in Physiology.2022;[Epub] CrossRef
Increased serum cystatin C levels and responses of pancreatic α- and β-cells in type 2 diabetes
Hui-qing Yuan, Jia-xi Miao, Jia-ping Xu, Su-xiang Zhu, Feng Xu, Xiao-hua Wang, Chun-hua Wang, Chao Yu, Xue-qin Wang, Jian-bin Su, Dong-mei Zhang
Endocrine Connections.2022;[Epub] CrossRef
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
Soyeon Yoo, Dongkyu Kim, Gwanpyo Koh
Journal of Clinical Medicine.2021; 10(11): 2487. CrossRef
Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes
Hong Wang, Jie Cao, Jian-bin Su, Xue-qin Wang, Xing Wang, Dong-mei Zhang, Xiao-hua Wang
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
Angiopoietins stimulate pancreatic islet development from stem cells
Soujanya S. Karanth, Shuofei Sun, Huanjing Bi, Kaiming Ye, Sha Jin
Scientific Reports.2021;[Epub] CrossRef
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 3567. CrossRef
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
María Sofía Martínez, Alexander Manzano, Luis Carlos Olivar, Manuel Nava, Juan Salazar, Luis D’Marco, Rina Ortiz, Maricarmen Chacín, Marion Guerrero-Wyss, Mayela Cabrera de Bravo, Clímaco Cano, Valmore Bermúdez, Lisse Angarita
International Journal of Molecular Sciences.2021; 22(17): 9504. CrossRef
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum, Norman Rosenblum, William Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christine Dhara, Stephen P. Jame
Canadian Journal of Diabetes.2021; 45(8): 697. CrossRef
The role of GIP in α-cells and glucagon secretion
Kimberley El, Jonathan E. Campbell
Peptides.2020; 125: 170213. CrossRef
Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes
Muhammad Yazid Jalaludin, Margarita Barrientos-Pérez, Mona Hafez, Jane Lynch, Naim Shehadeh, Serap Turan, Daniel Weghuber
Clinical Trials.2020; 17(1): 87. CrossRef
Recent advances in understanding the role of glucagon-like peptide 1
Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi
F1000Research.2020; 9: 239. CrossRef
Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study
Irene Roncero-Ramos, Juan F. Alcala-Diaz, Oriol A. Rangel-Zuñiga, Francisco Gomez-Delgado, Rosa Jimenez-Lucena, Antonio García-Rios, Cristina Vals-Delgado, Cristina Romero-Baldonado, Raul M. Luque, Jose M. Ordovas, Pablo Perez-Martinez, Antonio Camargo, J
Clinical Nutrition.2020; 39(2): 492. CrossRef
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
Diabetes, Obesity and Metabolism.2020; 22(2): 173. CrossRef
Pathophysiology of Type 2 Diabetes in Children and Adolescents
Badhma Valaiyapathi, Barbara Gower , Ambika P. Ashraf
Current Diabetes Reviews.2020; 16(3): 220. CrossRef
Decellularized Tissue Matrix Enhances Self-Assembly of Islet Organoids from Pluripotent Stem Cell Differentiation
Huanjing Bi, Soujanya S. Karanth, Kaiming Ye, Roland Stein, Sha Jin
ACS Biomaterials Science & Engineering.2020; 6(7): 4155. CrossRef
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Dipeeka K. Mandaliya, Sriram Seshadri
Pancreatology.2019; 19(4): 617. CrossRef
A contemporary biological pathway of islet amyloid polypeptide for the management of diabetic dementia
Sushil Kumar Sah, Vijaya Paul Samuel, Sunita Dahiya, Yogendar Singh, Ritu M. Gilhotra, Gaurav Gupta, Anurag Mishra, Rakesh Kumar Sharma, Gubbiyappa Shiva Kumar, Nagaraja SreeHarsha, Dinesh Kumar Chellappan, Kamal Dua
Chemico-Biological Interactions.2019; 306: 117. CrossRef
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Dipeeka K. Mandaliya, Sriram Seshadri
Pancreatology.2019; 19(2): 280. CrossRef
Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients
Minyoung Lee, Minkyung Kim, Jong Suk Park, Sangbae Lee, Jihong You, Chul Woo Ahn, Kyung Rae Kim, Shinae Kang
The Korean Journal of Internal Medicine.2019; 34(5): 1068. CrossRef
Insulin regulates glucagon-like peptide-1 secretion by pancreatic alpha cells
Pan Liu, Jia Song, He Liu, Fei Yan, Tianyi He, Lingshu Wang, Huying Shen, Xinguo Hou, Li Chen
Endocrine.2018; 62(2): 394. CrossRef
Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential
Ana Marta de Matos, Maria Paula de Macedo, Amélia Pilar Rauter
Medicinal Research Reviews.2018; 38(1): 261. CrossRef
Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes
Irene Roncero-Ramos, Rosa Jimenez-Lucena, Juan F. Alcala-Diaz, Cristina Vals-Delgado, Antonio P. Arenas-Larriva, Oriol A. Rangel-Zuñiga, Ana Leon-Acuña, María M. Malagon, Javier Delgado-Lista, Pablo Perez-Martinez, Jose M. Ordovas, Antonio Camargo, Jose L
The Journal of Nutritional Biochemistry.2018; 62: 247. CrossRef
Targetting PED/PEA-15 for diabetes treatment
Francesca Fiory, Rosa Spinelli, Gregory Alexander Raciti, Luca Parrillo, Vittoria D’esposito, Pietro Formisano, Claudia Miele, Francesco Beguinot
Expert Opinion on Therapeutic Targets.2017; 21(6): 571. CrossRef
PANCREATIC ALPHA CELL DYSFUNCTION IN DIABETES MELLITUS AND ITS MANAGEMENT STRATEGIES
Butungeshwar Pradhan, Chakradhar Majhi
Journal of Evidence Based Medicine and Healthcare.2017; 4(45): 2775. CrossRef
Glucagon and heart in type 2 diabetes: new perspectives
Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda
Cardiovascular Diabetology.2016;[Epub] CrossRef
Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes
Sivaram Pillarisetti
Trends in Pharmacological Sciences.2016; 37(3): 207. CrossRef
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Nicolai J Wewer Albrechtsen, Rune E Kuhre, Jens Pedersen, Filip K Knop, Jens J Holst
Biomarkers in Medicine.2016; 10(11): 1141. CrossRef
Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
Chloé Amouyal, Fabrizio Andreelli
Journal of Diabetes Research.2016; 2016: 1. CrossRef
Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1
Toya M Albury-Warren, Veethika Pandey, Lina P Spinel, Michal M Masternak, Deborah A Altomare
Journal of Endocrinology.2016; 228(1): 49. CrossRef
Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Hao Liu, Yun Hu, Feng-fei Li, Bing-li Liu, Xiao-fei Su, Jian-hua Ma
Diabetes Therapy.2016; 7(4): 743. CrossRef

Original Articles

Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients: Hye-Jin Yoon, Youn-Zoo Cho, Ji-young Kim, Byung-Joon Kim, Keun-Young Park, Gwan-Pyo Koh, Dae-Ho Lee, Dong-Mee Lim; Diabetes Metab J. 2012;36(5):379-387. Published online October 18, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.5.379

12,173 View
72 Download
25 Crossref

Abstract PDF PubReader ePub

Background

This study aimed to investigate whether stimulated C-peptide is associated with microvascular complications in type 2 diabetes mellitus (DM).

Methods

A cross-sectional study was conducted in 192 type 2 diabetic patients. Plasma basal C-peptide and stimulated C-peptide were measured before and 6 minutes after intravenous injection of 1 mg glucagon. The relationship between C-peptide and microvascular complications was statistically analyzed.

Results

In patients with retinopathy, basal C-peptide was 1.9±1.2 ng/mL, and stimulated C-peptide was 2.7±1.6 ng/mL; values were significantly lower compared with patients without retinopathy (P=0.031 and P=0.002, respectively). In patients with nephropathy, basal C-peptide was 1.6±0.9 ng/mL, and stimulated C-peptide was 2.8±1.6 ng/mL; values were significantly lower than those recorded in patients without nephropathy (P=0.020 and P=0.026, respectively). Stimulated C-peptide level was associated with increased prevalence of microvascular complications. Age-, DM duration-, and hemoglobin A1c-adjusted odds ratios for retinopathy in stimulated C-peptide value were 4.18 (95% confidence interval [CI], 1.40 to 12.51) and 3.35 (95% CI, 1.09 to 10.25), respectively. The multiple regression analysis between nephropathy and C-peptide showed that stimulated C-peptide was statistically correlated with nephropathy (P=0.03).

Conclusion

In patients with type 2 diabetes, the glucagon stimulation test was a relatively simple method of short duration for stimulating C-peptide response. Stimulated C-peptide values were associated with microvascular complications to a greater extent than basal C-peptides.

Citations

Citations to this article as recorded by

Postprandial C-Peptide to Glucose Ratio as a Promising Systemic Marker of Diabetic Retinopathy in Type 2 Diabetes
Zhaoxia Zheng, Nianen Liu, Yue Zhang, Xiaoya Gu, Hui Li, Xiaobing Yu
Translational Vision Science & Technology.2025; 14(7): 27. CrossRef
The effect of sacubitril/valsartan on urinary C-peptide excretion and endogenous insulin secretory capacity in a patient with type 2 diabetes: a case report
Shun Onodera, Masashi Miyamae, Issei Higuchi, Shunsuke Nashimoto, Akinobu Nakamura, Mitsuru Sugawara, Yoh Takekuma
Journal of Pharmaceutical Health Care and Sciences.2025;[Epub] CrossRef
A Nomogram for Predicting Vision-Threatening Diabetic Retinopathy Among Mild Diabetic Retinopathy Patients: A Case–Control and Prospective Study of Type 2 Diabetes
Jing Ke, Kun Li, Bin Cao
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 275. CrossRef
The average 30-minute post-prandial C-peptide predicted diabetic retinopathy progress: a retro-prospective study
Ting Pan, Jie Gao, Xinghua Cai, Huihui Zhang, Jun Lu, Tao Lei
BMC Endocrine Disorders.2023;[Epub] CrossRef
Dysregulation of miR-374a is involved in the progression of diabetic retinopathy and regulates the proliferation and migration of retinal microvascular endothelial cells
Zhanhong Wang, Xiao Zhang, Yanjun Wang, Dailing Xiao
Clinical and Experimental Optometry.2022; 105(3): 287. CrossRef
The Relationship between the Lipid Accumulation Product and Beta-cell Function in Korean Adults with or without Type 2 Diabetes Mellitus: The 2015 Korea National Health and Nutrition Examination Survey
Hye Eun Cho, Seung Bum Yang, Mi Young Gi, Ju Ae Cha, so Young Park, Hyun Yoon
Endocrine Research.2022; 47(2): 80. CrossRef
Effects of Serum C‐Peptide Level on Blood Lipid and Cardiovascular and Cerebrovascular Injury in Patients with Type 2 Diabetes Mellitus: A Meta‐Analysis
Juan Qin, Rongli Sun, Ding Ding, Yuvaraja Teekaraman
Contrast Media & Molecular Imaging.2022;[Epub] CrossRef
Investigation of Diabetes Complication Risk Perception and Diabetes Self-Management Skills in Individuals with Diabetes
Mehmet AYTEMUR, Bahar İNKAYA
Turkish Journal of Diabetes and Obesity.2022; 6(2): 121. CrossRef
Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness
Eli Ipp
Frontiers in Endocrinology.2021;[Epub] CrossRef
Association of C-peptide with diabetic vascular complications in type 2 diabetes
Y. Wang, H. Wan, Y. Chen, F. Xia, W. Zhang, C. Wang, S. Fang, K. Zhang, Q. Li, N. Wang, Y. Lu
Diabetes & Metabolism.2020; 46(1): 33. CrossRef
Variations in glucose/C-peptide ratio in patients with type 2 diabetes associated with renal function
John A. D'Elia, Christopher Mulla, Jiankang Liu, Larry A. Weinrauch
Diabetes Research and Clinical Practice.2019; 150: 1. CrossRef
The pharmacokinetics of porcine C‐peptide after intraperitoneal injection
Naho Iizuka, Masuhiro Nishimura, Yasutaka Fujita, Osamu Sawamoto, Shinichi Matsumoto
Xenotransplantation.2019;[Epub] CrossRef
Association of KCNJ11(RS5219) gene polymorphism with biochemical markers of glycemic status and insulin resistance in gestational diabetes mellitus
Lenin M, Ramesh Ramasamy, Sweta Kulkarani, Seetesh Ghose, Srinivasan A.R.S., Sathish Babu M
Meta Gene.2018; 16: 134. CrossRef
Glucagon secretion is increased in patients with Type 2 diabetic nephropathy
Xiaoyu Wang, Juhong Yang, Baocheng Chang, Chunyan Shan, Yanguang Xu, Miaoyan Zheng, Ying Wang, Huizhu Ren, Liming Chen
Journal of Diabetes and its Complications.2016; 30(3): 488. CrossRef
Relationship between serum C-peptide level and diabetic retinopathy according to estimated glomerular filtration rate in patients with type 2 diabetes
Jin Ook Chung, Dong Hyeok Cho, Dong Jin Chung, Min Young Chung
Journal of Diabetes and its Complications.2015; 29(3): 350. CrossRef
Independent association between serum C‐peptide levels and fat mass‐to‐lean mass ratio in the aging process
Ying Li, Lian Shun Zheng, Yue Li, Duo Duo Zhao, Lu Meng
Geriatrics & Gerontology International.2015; 15(7): 918. CrossRef
Relationship Between β-Cell Function, Metabolic Control, and Microvascular Complications in Type 2 Diabetes Mellitus
Lihua Zhao, Jing Ma, Shaoxin Wang, Yun Xie
Diabetes Technology & Therapeutics.2015; 17(1): 29. CrossRef
Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes
Jane Z Kuo, Xiuqing Guo, Ronald Klein, Barbara E Klein, Robert N Weinreb, Pauline Genter, Fone-Ching Hsiao, Mark O Goodarzi, Jerome I Rotter, Yii-Der Ida Chen, Eli Ipp
BMJ Open Diabetes Research & Care.2014; 2(1): e000027. CrossRef
Association between physical activity and serum C‐peptide levels among the elderly
Ying Li, Lu Meng, QianQian Miao, Yasuto Sato
Geriatrics & Gerontology International.2014; 14(3): 647. CrossRef
Age at Diagnosis and C-Peptide Level Are Associated with Diabetic Retinopathy in Chinese
Xiaoling Cai, Xueyao Han, Simin Zhang, Yingying Luo, Yingli Chen, Linong Ji, Alfred S. Lewin
PLoS ONE.2014; 9(3): e91174. CrossRef
Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset Type 1 and Type 2 Diabetes
Ramachandran Rajalakshmi, Anandakumar Amutha, Harish Ranjani, Mohammed K. Ali, Ranjit Unnikrishnan, Ranjit Mohan Anjana, K.M. Venkat Narayan, Viswanathan Mohan
Journal of Diabetes and its Complications.2014; 28(3): 291. CrossRef
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Kenjiro Imai, Tetsuro Tsujimoto, Atsushi Goto, Maki Goto, Miyako Kishimoto, Ritsuko Yamamoto-Honda, Hiroshi Noto, Hiroshi Kajio, Mitsuhiko Noda
Diabetology & Metabolic Syndrome.2014;[Epub] CrossRef
The Association between the Serum C-Peptide Level and Bone Mineral Density
Ying Li, Hua Liu, Yasuto Sato, Bin He
PLoS ONE.2013; 8(12): e83107. CrossRef
C-Peptide and Its Career from Innocent Bystander to Active Player in Diabetic Atherogenesis
Corinna Lebherz, Nikolaus Marx
Current Atherosclerosis Reports.2013;[Epub] CrossRef
C-Peptide and Vascular Complications in Type 2 Diabetic Subjects
Seok Man Son
Diabetes & Metabolism Journal.2012; 36(5): 345. CrossRef

Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study: Juyoung Shin, Jin-Sun Chang, Hun-Sung Kim, Sun-Hee Ko, Bong-Yun Cha, Ho-Young Son, Kun-Ho Yoon, Jae-Hyoung Cho; Diabetes Metab J. 2012;36(5):364-370. Published online October 18, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.5.364

7,192 View
45 Download
11 Crossref

Abstract PDF PubReader ePub

Background

While many studies have shown the good efficacy and safety of exenatide in patients with diabetes, limited information is available about exenatide in clinical practice in Korean populations. Therefore, this retrospective cohort study was designed to analyze the effects of exenatide on blood glucose level and body weight in Korean patients with type 2 diabetes mellitus.

Methods

We reviewed the records of the patients with diabetes who visited Seoul St. Mary's Hospital and for whom exenatide was prescribed from June 2009 to October 2011. After excluding subjects based on their race/ethnicity, medical history, whether or not they changed more than 2 kinds of oral hypoglycemic agents with exenatide treatment, loss to follow-up, or whether they stopped exenatide therapy within 6 months, a total of 52 subjects were included in the final analysis.

Results

The mean glycated hemoglobin (HbA1c) level and weight remarkably decreased from 8.5±1.7% to 6.7±1.0% (P<0.001) and from 82.3±15.8 kg to 78.6±16.3 kg (P<0.001), respectively. The multiple regression analysis indicated that the reduction in HbA1c level was significantly associated with a shorter duration of diabetes, a higher baseline HbA1c level, and greater weight reduction, whereas weight loss had no significant correlation with other factors. No severe adverse events were observed.

Conclusion

These results suggest that a 6-month exenatide injection therapy significantly improved patients' HbA1c levels and body weights without causing serious adverse effects in Korean patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Mehrnaz Abbasi, Kai Sun, Kevin W. Huggins, Braeden Heath, Hannah DeLoit, Lauren McGinness, Kate Mccamy
Acta Pharmaceutica Sinica B.2026;[Epub] CrossRef
Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study
Celine B.E. Busch, Suzanne Meiring, Annieke C.G. van Baar, Frits Holleman, Max Nieuwdorp, Jacques J.G.H.M. Bergman
Gastrointestinal Endoscopy.2024; 100(5): 896. CrossRef
Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
Artemis Kyriakidou, Angeliki V. Kyriazou, Theocharis Koufakis, Yiannis Vasilopoulos, Maria Grammatiki, Xanthippi Tsekmekidou, Iakovos Avramidis, Stefanos Baltagiannis, Dimitrios G. Goulis, Pantelis Zebekakis, Kalliopi Kotsa
Journal of Personalized Medicine.2022; 12(3): 424. CrossRef
Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells
Nunzia Caporarello, Cristina Parrino, Vincenzo Trischitta, Lucia Frittitta, Claudia Miele
PLOS ONE.2017; 12(8): e0181190. CrossRef
Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
Kun-Ho Yoon, Elise Hardy, Jenny Han
Diabetes & Metabolism Journal.2017; 41(1): 69. CrossRef
Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool
Oliver Schnell, Jianping Weng, Wayne H.-H. Sheu, Hirotaka Watada, Sanjay Kalra, Sidartawan Soegondo, Noriyuki Yamamoto, Rahul Rathod, Cheryl Zhang, Wladyslaw Grzeszczak
Journal of Diabetes and its Complications.2016; 30(4): 628. CrossRef
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Muhammad Khan, Jing Ouyang, Karen Perkins, Sunil Nair, Franklin Joseph
Journal of Diabetes Research.2015; 2015: 1. CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang
Diabetes & Metabolism Journal.2015; 39(3): 177. CrossRef
Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 554. CrossRef
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?
C.-Y. Chen, C.-Y. Tsai
Rheumatology.2014; 53(2): 205. CrossRef
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Stuart A. Ross, Jane Ballantine
Current Medical Research and Opinion.2013; 29(12): 1617. CrossRef

Reviews

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease: Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Lee; Diabetes Metab J. 2012;36(4):262-267. Published online August 20, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.4.262

16,047 View
164 Download
73 Crossref

Abstract PDF PubReader ePub

Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.

Citations

Citations to this article as recorded by

Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease
Menglei Ding, Zihan Xiao, Xionglin Hou, Zichen Luo, Zepeng Zhang, Manman Guo, Cheng Xu, Ruimin Xu, Jinjun Shan, Huiping Peng
Chinese Medicine.2026;[Epub] CrossRef
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
Brandon Havranek, Rebecca Loh, Beatriz Torre, Rachel Redfield, Dina Halegoua-DeMarzio
Scientific Reports.2025;[Epub] CrossRef
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
Abdelilah Arredouani
Pharmacology & Therapeutics.2025; 269: 108824. CrossRef
Effects of Phytosterols on Growth Performance, Serum Indexes, and Fecal Microbiota in Finishing Pigs
Renjie Xie, Zhenxing Guo, Haiqing Gan, Dexing Hou, Guang Chen, Chao Deng, Hongkun Li, Jiajie Ouyang, Qiyu Tian, Xingguo Huang
Animals.2025; 15(9): 1188. CrossRef
Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions
Carolina Jiménez-González, Marta Alonso-Peña, Paula Argos Vélez, Javier Crespo, Paula Iruzubieta
Nutrients.2025; 17(9): 1580. CrossRef
Evolving Role of GLP-1 Therapies in Liver Disease
Mark Lindsay, Gretchen Arndt, Amanda Wieland, Thomas Jensen
Current Gastroenterology Reports.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
Giovanna Gallo, Gabriele Nalli, Francesco Baratta, Giovambattista Desideri, Carmine Savoia
International Journal of Molecular Sciences.2025; 26(16): 8081. CrossRef
Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance
Shakila Jahan Shimu, Jawad Ul Karim Mahir, Fardin Al Fahad Shakib, Arafath Amin Ridoy, Ratin Al Samir, Nadia Jahan, Md Fahim Hasan, Sadman Sazzad, Shamima Akter, Mohammad Sarif Mohiuddin, Md Jalal Ahmed Shawon, Mohammad Hossain Shariare, Mohammad Mohabbul
Medical Sciences.2025; 13(3): 180. CrossRef
The effect of exenatide (GLP-1a) and sitagliptin (DPP-4i) on paraoxonase 1 (PON1) activity and expression in normal and fructose-fed rats
G. Wójcicka, A. Pradiuch, L. Guz, M. Wójciak, M. Rusek, A. Jamroz-Wiśniewska, G. Czechowska, S. Marciniak, A. Góralczyk, J. Bełtowski
European Journal of Pharmacology.2025; 1007: 178197. CrossRef
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Jia Nuo Feng, Tianru Jin
Medical Review.2024; 4(4): 312. CrossRef
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
Subhodip Pramanik, Partha Pal, Sayantan Ray
World Journal of Methodology.2024;[Epub] CrossRef
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
Frontiers in Endocrinology.2024;[Epub] CrossRef
Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats
Onrapak Reamtong, Rattiya Waeonukul, Pattaneeya Prangthip
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef
Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease
Samradhi Singh, Mona Kriti, Roberto Catanzaro, Francesco Marotta, Mustafa Malvi, Ajay Jain, Vinod Verma, Ravinder Nagpal, Rajnarayan Tiwari, Manoj Kumar
Livers.2024; 4(3): 435. CrossRef
Second Generation Anti-Obesity Medications
Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
Current Pediatrics Reports.2024; 12(4): 138. CrossRef
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 784. CrossRef
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
International Journal of Molecular Sciences.2023; 24(2): 1703. CrossRef
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
Avilene Rodríguez-Lara, Ascensión Rueda-Robles, María José Sáez-Lara, Julio Plaza-Diaz, Ana I. Álvarez-Mercado
Pathogens.2023; 12(7): 940. CrossRef
Investigating the Opposing Effect of Two Different Green Tea Supplements on Oxidative Stress, Mitochondrial Function and Cell Viability in HepG2 Cells
Aparna Shil, Chris Davies, Lata Gautam, Justin Roberts, Havovi Chichger
Journal of Dietary Supplements.2022; 19(4): 459. CrossRef
Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors
Bong Gyu Park, Gyeong Min Kim, Hye‐Jin Lee, Jae Ha Ryu, Dong‐Hoon Kim, Jae‐Young Seong, Soojeong Kim, Zee‐Yong Park, Young‐Joon Kim, Jaemin Lee, Jae Il Kim
Diabetes, Obesity and Metabolism.2022; 24(1): 50. CrossRef
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
Juan Pang, Jia Nuo Feng, Wenhua Ling, Tianru Jin
Acta Pharmaceutica Sinica B.2022; 12(11): 4040. CrossRef
Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes
Jinsoo Song, In-Jeoung Baek, Sujeong Park, Jinjoo Oh, Deokha Kim, Kyung Song, Mi Kyung Kim, Hye Won Lee, Byoung Kuk Jang, Eun-Jung Jin
iScience.2022; 25(10): 105135. CrossRef
Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
Salvatore Pezzino, Maria Sofia, Gloria Faletra, Chiara Mazzone, Giorgia Litrico, Gaetano La Greca, Saverio Latteri
Biology.2022; 11(11): 1622. CrossRef
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Anastassia Amaro, Danny Sugimoto, Sean Wharton
Postgraduate Medicine.2022; 134(sup1): 5. CrossRef
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański
Nutrients.2021; 13(2): 351. CrossRef
Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
Julio Plaza-Díaz, Patricio Solis-Urra, Jerónimo Aragón-Vela, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Ana I. Álvarez-Mercado
Biomedicines.2021; 9(2): 145. CrossRef
A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases
Changlu Qi, Ping Wang, Tongze Fu, Minke Lu, Yiting Cai, Xu Chen, Liang Cheng
Briefings in Functional Genomics.2021; 20(1): 42. CrossRef
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Maka Siamashvili, Stephen N. Davis
Expert Review of Clinical Pharmacology.2021; 14(9): 1081. CrossRef
Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
Manisha Gupta, Pawan Krishan, Amarjot Kaur, Sandeep Arora, Nirupma Trehanpati, Thakur Gurjeet Singh, Onkar Bedi
Inflammation Research.2021; 70(7): 765. CrossRef
Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India
Nithyanantham Kamalraj, Madhanagopal Sathishkumar, Mani Arunvignesh, Viswanathan Baskar, Saravanan Jebarani, Anandakumar Amutha, Mohan Deepa, Coimbatore Subramanyam Shanthi Rani, Sundaramoorthy Chandru, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Mardavada
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102261. CrossRef
Gastrointestinal Hormones in Healthy Adults: Reliability of Repeated Assessments and Interrelations with Eating Habits and Physical Activity
Silke M. Wortha, Katharina A. Wüsten, Veronica A. Witte, Nicole Bössel, Wolfram Keßler, Antje Vogelgesang, Agnes Flöel
Nutrients.2021; 13(11): 3809. CrossRef
Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao
Molecular Metabolism.2020; 34: 16. CrossRef
Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials
Amir Hadi, Ehsan Ghaedi, Saman Khalesi, Makan Pourmasoumi, Arman Arab
European Journal of Nutrition.2020; 59(7): 2857. CrossRef
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv, Yongqiang Dong, Lingling Hu, Feiyu Lu, Changyu Zhou, Shaoyou Qin
Endocrinology, Diabetes & Metabolism.2020;[Epub] CrossRef
Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
Jong Youl Lee, Taehoon Park, Eunmi Hong, Reeju Amatya, Kyung-Ah Park, Young-Hoon Park, Kyoung Ah Min, Minki Jin, Sumi Lee, Seungmi Hwang, Gu Seob Roh, Meong Cheol Shin
Biomaterials.2020; 257: 120250. CrossRef
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Rebecca K. Vincent, David M. Williams, Marc Evans
Diabetes, Obesity and Metabolism.2020; 22(12): 2227. CrossRef
A systematic review and meta-analysis of probiotic consumption and metabolic status of athletes
Atefeh As’Habi, Maryam Nazari, Hossein Hajianfar, Arman Arab, Zeinab Faghfoori
International Journal of Food Properties.2020; 23(1): 941. CrossRef
The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage
Julio Plaza-Díaz, Patricio Solís-Urra, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Miguel Navarro-Oliveros, Francisco Abadía-Molina, Ana I. Álvarez-Mercado
International Journal of Molecular Sciences.2020; 21(21): 8351. CrossRef
Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská
Frontiers in Endocrinology.2020;[Epub] CrossRef
Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of diabetes
Michael J. Ryan
Clinical Science.2020; 134(23): 3119. CrossRef
Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
Maite Martínez-Uña, Yaiza López-Mancheño, Carlos Diéguez, Manuel A. Fernández-Rojo, Marta G. Novelle
International Journal of Molecular Sciences.2020; 21(24): 9368. CrossRef
The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
Cindy G. Avalos-de León, Mónica B. Jiménez-Castro, María Eugenia Cornide-Petronio, Araní Casillas-Ramírez, Carmen Peralta
Cells.2019; 8(12): 1599. CrossRef
LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet
Tao Hao, Hongying Chen, Sisi Wu, Haoming Tian
Molecular Medicine Reports.2019;[Epub] CrossRef
Liraglutide alters hepatic metabolism in high-fat fed obese mice: A bioinformatic prediction and functional analysis
Isabelle Arruda Barbosa, Eloá Mangabeira Santos, Alanna Fernandes Paraíso, Pablo Vinicyus Ferreira Chagas, Luís Paulo Oliveira, João Marcus Oliveira Andrade, Lucyana Conceição Farias, Bruna Mara Aparecida de Carvalho, Alfredo Maurício Batista de Paula, An
Meta Gene.2019; 20: 100553. CrossRef
Dipeptidyl peptidase‐4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
Nagat Younan, Samah Elattar, Mira Farouk, Laila Rashed, Suzanne Estaphan
Physiological Reports.2019;[Epub] CrossRef
Microbial Metabolites Determine Host Health and the Status of Some Diseases
Panida Sittipo, Jae-won Shim, Yun Lee
International Journal of Molecular Sciences.2019; 20(21): 5296. CrossRef
Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats
Yoo-Cheol Hwang, Da-Hee Oh, Moon Chan Choi, Sang Yeoul Lee, Kyu-Jeong Ahn, Ho-Yeon Chung, Sung-Jig Lim, Sung Hyun Chung, In-Kyung Jeong
The Korean Journal of Internal Medicine.2018; 33(2): 347. CrossRef
Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers
Ahmed A. Abdelsameea, Noha A.T. Abbas, Samar M. Abdel Raouf
Naunyn-Schmiedeberg's Archives of Pharmacology.2017; 390(3): 311. CrossRef
Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis
Yong Rao, Hong Yu, Lin Gao, Yu‐Ting Lu, Zhao Xu, Hong Liu, Lian‐Quan Gu, Ji‐Ming Ye, Zhi‐Shu Huang
British Journal of Pharmacology.2017; 174(15): 2457. CrossRef
Non-alcoholic fatty liver disease and dyslipidemia: An update
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros
Metabolism.2016; 65(8): 1109. CrossRef
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
PLOS ONE.2016; 11(12): e0166913. CrossRef
The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter
Young Eun Chon, Kwang Joon Kim, Kyu Sik Jung, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Jae Bock Chung, Kyeong Hye Park, Ji Cheol Bae, Kwang-Hyub Han
Yonsei Medical Journal.2016; 57(4): 885. CrossRef
The role of the gut microbiota in NAFLD
Christopher Leung, Leni Rivera, John B. Furness, Peter W. Angus
Nature Reviews Gastroenterology & Hepatology.2016; 13(7): 412. CrossRef
Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR)
Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard
Physiological Reports.2016;[Epub] CrossRef
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence
Jonathan Temple, Paul Cordero, Jiawei Li, Vi Nguyen, Jude Oben
International Journal of Molecular Sciences.2016; 17(6): 947. CrossRef
Extrapancreatic Effect of Glucagon like Peptide-1
In-Kyung Jeong
The Korean Journal of Medicine.2015; 89(4): 404. CrossRef
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet
Aline B. Santamarina, Juliana L. Oliveira, Fernanda P. Silva, June Carnier, Laís V. Mennitti, Aline A. Santana, Gabriel H. I. de Souza, Eliane B. Ribeiro, Cláudia M. Oller do Nascimento, Fábio S. Lira, Lila M. Oyama, Patricia Aspichueta
PLOS ONE.2015; 10(11): e0141227. CrossRef
Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1
Mark F McCarty, James J DiNicolantonio
Open Heart.2015; 2(1): e000205. CrossRef
The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease
Huiting Gao, Zhigang Zeng, Han Zhang, Xiaoli Zhou, Lichang Guan, Weiping Deng, Lishu Xu
Biological & Pharmaceutical Bulletin.2015; 38(5): 694. CrossRef
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Sri Harsha Tella, Marc S. Rendell
Therapeutic Advances in Endocrinology and Metabolism.2015; 6(3): 109. CrossRef
Gut Microbiota: Association with NAFLD and Metabolic Disturbances
E. Lau, D. Carvalho, P. Freitas
BioMed Research International.2015; 2015: 1. CrossRef
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes
James J DiNicolantonio, Jaikrit Bhutani, James H O'Keefe
Open Heart.2015; 2(1): e000327. CrossRef
Nonalcoholic fatty liver disease and bariatric surgery in adolescents
AiXuan Holterman, Juan Gurria, Smita Tanpure, Nerina DiSomma
Seminars in Pediatric Surgery.2014; 23(1): 49. CrossRef
Pediatric non-alcoholic fatty liver disease: New insights and future directions
Pierluigi Marzuillo
World Journal of Hepatology.2014; 6(4): 217. CrossRef
4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics
Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci, Guglielmo M Trovato
EPMA Journal.2014;[Epub] CrossRef
The Role of Medications for the Management of Patients with NAFLD
Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti, Giulio Marchesini
Clinics in Liver Disease.2014; 18(1): 73. CrossRef
Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis
A. Alisi, G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, V. Nobili
Alimentary Pharmacology & Therapeutics.2014; 39(11): 1276. CrossRef
The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
Mark F McCarty, James J DiNicolantonio
Open Heart.2014; 1(1): e000103. CrossRef
Pediatric non-alcoholic fatty liver disease: an increasing public health issue
S. Berardis, E. Sokal
European Journal of Pediatrics.2014; 173(2): 131. CrossRef
Glucagon‐like peptide‐1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
H. Kahal, G. Abouda, A. S. Rigby, A. M. Coady, E. S. Kilpatrick, S. L. Atkin
Clinical Endocrinology.2014; 81(4): 523. CrossRef
Comparative analysis of plasma metabolomics response to metabolic challenge tests in healthy subjects and influence of the FTO obesity risk allele
Simone Wahl, Susanne Krug, Cornelia Then, Anna Kirchhofer, Gabi Kastenmüller, Tina Brand, Thomas Skurk, Melina Claussnitzer, Cornelia Huth, Margit Heier, Christa Meisinger, Annette Peters, Barbara Thorand, Christian Gieger, Cornelia Prehn, Werner Römisch-
Metabolomics.2014; 10(3): 386. CrossRef
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Eugene Chang, Cheol‐Young Park, Sung Woo Park
Journal of Diabetes Investigation.2013; 4(6): 517. CrossRef
Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions
Pietro Vajro, Selvaggia Lenta, Claudio Pignata, Mariacarolina Salerno, Roberta D’Aniello, Ida De Micco, Giulia Paolella, Giancarlo Parenti
Italian Journal of Pediatrics.2012; 38(1): 55. CrossRef

The Role of the Sweet Taste Receptor in Enteroendocrine Cells and Pancreatic β-Cells: Itaru Kojima, Yuko Nakagawa; Diabetes Metab J. 2011;35(5):451-457. Published online October 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.5.451

10,649 View
149 Download
56 Crossref

Abstract PDF PubReader ePub

The sweet taste receptor is expressed in taste cells located in taste buds of the tongue. This receptor senses sweet substances in the oral cavity, activates taste cells, and transmits the taste signals to adjacent neurons. The sweet taste receptor is a heterodimer of two G protein-coupled receptors, T1R2 and T1R3. Recent studies have shown that this receptor is also expressed in the extragustatory system, including the gastrointestinal tract, pancreatic β-cells, and glucose-responsive neurons in the brain. In the intestine, the sweet taste receptor regulates secretion of incretin hormones and glucose uptake from the lumen. In β-cells, activation of the sweet taste receptor leads to stimulation of insulin secretion. Collectively, the sweet taste receptor plays an important role in recognition and metabolism of energy sources in the body.

Citations

Citations to this article as recorded by

Effect of Sucralose on Cardiometabolic Health: A Review on Possible Mechanisms
David Ni, Aisha Parihar, Sabyasachi Sen
Metabolic Syndrome and Related Disorders.2026; 24(1): 1. CrossRef
The Oral Microbiota: Implications in Mucosal Health and Systemic Disease—Crosstalk with Gut and Brain
Vincenzo Miranda, Kamilia Laarej, Carlo Cavaliere
Cells.2026; 15(1): 82. CrossRef
Glycemic Impact of Non-Nutritive Sweeteners in Health and Type 2 Diabetes
Braden D Rose, Denise Kreuch, Tongzhi Wu, Michael Horowitz, Christopher K Rayner, Amanda J Page, Caroline L Miller, Richard L Young
Nutrition Reviews.2026;[Epub] CrossRef
Nonnutritive Sweetener Consumption, Metabolic Risk Factors, and Inflammatory Biomarkers Among Adults in the Cancer Prevention Study-3 Diet Assessment Sub-Study
Allison C Sylvetsky, Ying Wang, Ananya G Reddy, Caroline Y Um, Rebecca A Hodge, Cari Lichtman, Diane Mitchell, Anuj Nanavati, Michael Pollak, Ye Wang, Alpa V Patel, Marjorie L McCullough
The Journal of Nutrition.2025; 155(6): 1952. CrossRef
Integration of signal transduction pathways in sensory epithelial enteroendocrine cells
Shreya S. Bellampalli, Vikram Joshi, Gennadiy Fonar, Arthur Beyder, Keith Kozminski
Molecular Biology of the Cell.2025;[Epub] CrossRef
Potential of non-digestible polysaccharides as GLP-1 secretagogues: action mechanisms, structure-activity relationships and clinical applications
Zhen-Zi Shang, Hui-Yu Ye, Qiang-Ming Li, Xue-Qiang Zha, Jian-Ping Luo
Carbohydrate Polymers.2025; 367: 124024. CrossRef
Sugar type and route of delivery influence insulin and glucose-dependent insulinotropic polypeptide responses in rats
A. Valentina Nisi, Myrtha M. L. Arnold, Ginger D. Blonde, Lindsey A. Schier, Graciela Sanchez-Watts, Alan G. Watts, Wolfgang Langhans, Alan C. Spector
American Journal of Physiology-Endocrinology and Metabolism.2025; 329(2): E210. CrossRef
Potential Effects of Low-Calorie Sweeteners on Human Health
Huang-Pin Chen, Yuan Kao, Meng-Wei Lin, Chun-Te Lee, Hung-Tsung Wu, Hsin-Yu Kuo
Nutrients.2025; 17(17): 2726. CrossRef
Glucose tasting depletes intracellular calcium stores and impairs macrophage functionality
Laura Schlautmann, Daniel Burgdorf, Shaunak Ghosh, Alina Schieren, Linda Klümpen, Isabel Stötzel, Julia Bremser, Michael Döngi, Elvira Mass, Valentin Stein, Thomas Quast, Waldemar Kolanus, Thorsten Lang, Eva Kiermaier, Marie-Christine Simon, Sven Burgdorf
iScience.2025; 28(11): 113770. CrossRef
Targeting T2Rs, a feasible approach for natural bitter agents from traditional Chinese medicine modulate ABC transporters to treat respiratory diseases
Qi Liang, Ruo-Lan Li, Dan-Dan Tang, Ting Zhang, Lian Zhong, Chun-Jie Wu, Wei Peng
Arabian Journal of Chemistry.2024; 17(1): 105377. CrossRef
Impact of Some Natural and Artificial Sweeteners Consumption on Different Hormonal Levels and Inflammatory Cytokines in Male Rats: In Vivo and In Silico Studies
Dina Mostafa Mohammed, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, Abdulaziz Alhossan, Rasha Hamed Al-Serwi, Amr Farouk
ACS Omega.2024; 9(28): 30364. CrossRef
The involvement of T1R family receptors expressed outside the oral cavity in the regulation of metabolism
V. O. Murovets, E. A. Sozontov, V. A. Zolotarev
Uspehi fiziologičeskih nauk.2024; 55(4): 91. CrossRef
Impact of dietary sucralose and sucrose-sweetened water intake on lipid and glucose metabolism in male mice
Xinyi Wu, Le Cui, Haoquan Wang, Jinhong Xu, Zhaozhao Zhong, Xibei Jia, Jiaqi Wang, Huahua Zhang, Yanteng Shi, Yuhang Tang, Qianhui Yang, Qiongdan Liang, Yujing Zhang, Jing Li, Xiaohong Jiang
European Journal of Nutrition.2023; 62(1): 199. CrossRef
How dietary amino acids and high protein diets influence insulin secretion
Yuuki Yanagisawa
Physiological Reports.2023;[Epub] CrossRef
The elusive cephalic phase insulin response: triggers, mechanisms, and functions
Wolfgang Langhans, Alan G. Watts, Alan C. Spector
Physiological Reviews.2023; 103(2): 1423. CrossRef
Trace Amine-Associated Receptors and Monoamine-Mediated Regulation of Insulin Secretion in Pancreatic Islets
Anastasia N. Vaganova, Taisiia S. Shemyakova, Karina V. Lenskaia, Roman N. Rodionov, Charlotte Steenblock, Raul R. Gainetdinov
Biomolecules.2023; 13(11): 1618. CrossRef
Gene expression analyses of TAS1R taste receptors relevant to the treatment of cardiometabolic disease
Mariah R Stavrou, Sean Souchiart So, Angela M Finch, Sara Ballouz, Nicola J Smith
Chemical Senses.2023;[Epub] CrossRef
Dysgeusia
Davis C. Thomas, Deepti Chablani, Srishti Parekh, Reshmy Chellam Pichammal, Karpagavalli Shanmugasundaram, Priyanka Kodaganallur Pitchumani
The Journal of the American Dental Association.2022; 153(3): 251. CrossRef
Oral Microbiota-Host Interaction Mediated by Taste Receptors
Hao Dong, Jiaxin Liu, Jianhui Zhu, Zhiyan Zhou, Marco Tizzano, Xian Peng, Xuedong Zhou, Xin Xu, Xin Zheng
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
New frontiers in the hunger management involving GLP‐1, taste and oestrogen
Maja Baretić
Diabetic Medicine.2022;[Epub] CrossRef
The Impact of Artificial Sweeteners on Body Weight Control and Glucose Homeostasis
Michelle D. Pang, Gijs H. Goossens, Ellen E. Blaak
Frontiers in Nutrition.2021;[Epub] CrossRef
TAS1R2 sweet taste receptor genetic variation and dietary intake in Korean females
Jeong-Hwa Choi
Appetite.2021; 164: 105281. CrossRef
Sweet Taste Is Complex: Signaling Cascades and Circuits Involved in Sweet Sensation
Elena von Molitor, Katja Riedel, Michael Krohn, Mathias Hafner, Rüdiger Rudolf, Tiziana Cesetti
Frontiers in Human Neuroscience.2021;[Epub] CrossRef
Hazardous Hyperglisemic Effect of Facial Ischemia Following Subarachnoid Hemorrhage: An Experimental Study
Mehmet Dumlu Aydin, Ozgur Caglar, Mehmet Nuri Kocak, Erdem Karadeniz, Nazan Aydin, Irem Ates, Sevilay Ozmen
Archives of Neuroscience.2020;[Epub] CrossRef
Determinants of Sweetness Preference: A Scoping Review of Human Studies
Carolina Venditti, Kathy Musa-Veloso, Han Youl Lee, Theresa Poon, Alastair Mak, Maryse Darch, Justine Juana, Dylan Fronda, Daniel Noori, Erika Pateman, Maia Jack
Nutrients.2020; 12(3): 718. CrossRef
Allelic variation of the Tas1r3 taste receptor gene affects sweet taste responsiveness and metabolism of glucose in F1 mouse hybrids
Vladimir O. Murovets, Ekaterina A. Lukina, Egor A. Sozontov, Julia V. Andreeva, Raisa P. Khropycheva, Vasiliy A. Zolotarev, Keiko Abe
PLOS ONE.2020; 15(7): e0235913. CrossRef
Effect of sucralose and aspartame on glucose metabolism and gut hormones
Samar Y Ahmad, James K Friel, Dylan S Mackay
Nutrition Reviews.2020; 78(9): 725. CrossRef
Maternal low protein exposure alters glucose tolerance and intestinal nutrient-responsive receptors and transporters expression of rat offspring
Nan Wang, Bo Lv, Limin Guan, Hu Qiao, Bo Sun, Xiao Luo, Ru Jia, Ke Chen, Jianqun Yan
Life Sciences.2020; 243: 117216. CrossRef
Sugar Reduction in Dairy Food: An Overview with Flavoured Milk as an Example
Dipendra Kumar Mahato, Russell Keast, Djin Gie Liem, Catherine Georgina Russell, Sara Cicerale, Shirani Gamlath
Foods.2020; 9(10): 1400. CrossRef
Electrophysiology of the pancreatic islet β-cell sweet taste receptor TIR3
Juan V. Sanchez-Andres, Willy J. Malaisse, Itaru Kojima
Pflügers Archiv - European Journal of Physiology.2019; 471(4): 647. CrossRef
A Single 48 mg Sucralose Sip Unbalances Monocyte Subpopulations and Stimulates Insulin Secretion in Healthy Young Adults
Angélica Y. Gómez-Arauz, Nallely Bueno-Hernández, Leon F. Palomera, Raúl Alcántara-Suárez, Karen L. De León, Lucía A. Méndez-García, Miguel Carrero-Aguirre, Aaron N. Manjarrez-Reyna, Camilo P. Martínez-Reyes, Marcela Esquivel-Velázquez, Alejandra Ruiz-Bar
Journal of Immunology Research.2019; 2019: 1. CrossRef
Sugar reduction without compromising sensory perception. An impossible dream?
Scott C. Hutchings, Julia Y. Q. Low, Russell S. J. Keast
Critical Reviews in Food Science and Nutrition.2019; 59(14): 2287. CrossRef
Oral and Post‐Oral Actions of Low‐Calorie Sweeteners: A Tale of Contradictions and Controversies
John I. Glendinning
Obesity.2018;[Epub] CrossRef
Olfactory, Taste, and Photo Sensory Receptors in Non-sensory Organs: It Just Makes Sense
Nicholas M. Dalesio, Sebastian F. Barreto Ortiz, Jennifer L. Pluznick, Dan E. Berkowitz
Frontiers in Physiology.2018;[Epub] CrossRef
Emerging Concepts in Brain Glucose Metabolic Functions: From Glucose Sensing to How the Sweet Taste of Glucose Regulates Its Own Metabolism in Astrocytes and Neurons
Menizibeya O. Welcome, Nikos E. Mastorakis
NeuroMolecular Medicine.2018; 20(3): 281. CrossRef
Anti-diabetic effects of natural products an overview of therapeutic strategies
Jiyoung Park, Hyeung-Jin Jang
Molecular & Cellular Toxicology.2017; 13(1): 1. CrossRef
Natural sweetener agave inhibits gastric emptying in rats by a cholecystokinin-2- and glucagon like peptide-1 receptor-dependent mechanism
E. Bihter Gürler, Dilek Özbeyli, Hülya Buzcu, Sezin Bayraktar, İrem Carus, Beyza Dağ, Yasemin Geriş, Seda Jeral, Berrak Ç. Yeğen
Food & Function.2017; 8(2): 741. CrossRef
T1R3 homomeric sweet taste receptor regulates adipogenesis through Gαs-mediated microtubules disassembly and Rho activation in 3T3-L1 cells
Yosuke Masubuchi, Yuko Nakagawa, Johan Medina, Masahiro Nagasawa, Itaru Kojima, Mark M. Rasenick, Takeshi Inagaki, Hiroshi Shibata, Hiroaki Matsunami
PLOS ONE.2017; 12(5): e0176841. CrossRef
Hormonal responses to non-nutritive sweeteners in water and diet soda
Allison C. Sylvetsky, Rebecca J. Brown, Jenny E. Blau, Mary Walter, Kristina I. Rother
Nutrition & Metabolism.2016;[Epub] CrossRef
Gastrointestinal defense mechanisms
Hyder Said, Jonathan D. Kaunitz
Current Opinion in Gastroenterology.2016; 32(6): 461. CrossRef
Glucose-Sensing Receptor T1R3: A New Signaling Receptor Activated by Glucose in Pancreatic β-Cells
Itaru Kojima, Yuko Nakagawa, Kunihisa Hamano, Johan Medina, Longfei Li, Masahiro Nagasawa
Biological & Pharmaceutical Bulletin.2015; 38(5): 674. CrossRef
Impaired Glucose Metabolism in Mice Lacking the Tas1r3 Taste Receptor Gene
Vladimir O. Murovets, Alexander A. Bachmanov, Vasiliy A. Zolotarev, Hiroaki Matsunami
PLOS ONE.2015; 10(6): e0130997. CrossRef
Sweet Taste Receptor Signaling Network: Possible Implication for Cognitive Functioning
Menizibeya O. Welcome, Nikos E. Mastorakis, Vladimir A. Pereverzev
Neurology Research International.2015; 2015: 1. CrossRef
Expression of the glucose-sensing receptor T1R3 in pancreatic islet: changes in the expression levels in various nutritional and metabolic states
Anya Medina, Yuko Nakagawa, Jinhui Ma, Longfei Li, Kunihisa Hamano, Toshio Akimoto, Yuzo Ninomiya, Itaru Kojima
Endocrine Journal.2014; 61(8): 797. CrossRef
Normal Roles for Dietary Fructose in Carbohydrate Metabolism
Maren Laughlin
Nutrients.2014; 6(8): 3117. CrossRef
Glucose promotes its own metabolism by acting on the cell-surface glucose-sensing receptor T1R3
Yuko Nakagawa, Yoshiaki Ohtsu, Masahiro Nagasawa, Hiroshi Shibata, Itaru Kojima
Endocrine Journal.2014; 61(2): 119. CrossRef
Diverse signaling systems activated by the sweet taste receptor in human GLP-1-secreting cells
Yoshiaki Ohtsu, Yuko Nakagawa, Masahiro Nagasawa, Shigeki Takeda, Hirokazu Arakawa, Itaru Kojima
Molecular and Cellular Endocrinology.2014; 394(1-2): 70. CrossRef
Sweet Taste-Sensing Receptors Expressed in Pancreatic β-Cells: Sweet Molecules Act as Biased Agonists
Itaru Kojima, Yuko Nakagawa, Yoshiaki Ohtsu, Anya Medina, Masahiro Nagasawa
Endocrinology and Metabolism.2014; 29(1): 12. CrossRef
The Role of Sweet Taste in Satiation and Satiety
Yu Low, Kathleen Lacy, Russell Keast
Nutrients.2014; 6(9): 3431. CrossRef
Insulin release: the receptor hypothesis
Willy J. Malaisse
Diabetologia.2014; 57(7): 1287. CrossRef
The involvement of the T1R3 receptor protein in the control of glucose metabolism in mice at different levels of glycemia
V. O. Murovets, A. A. Bachmanov, S. V. Travnikov, A. A. Churikova, V. A. Zolotarev
Journal of Evolutionary Biochemistry and Physiology.2014; 50(4): 334. CrossRef
GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Franz M. Matschinsky
Trends in Pharmacological Sciences.2013; 34(2): 90. CrossRef
A Novel Regulatory Function of Sweet Taste-Sensing Receptor in Adipogenic Differentiation of 3T3-L1 Cells
Yosuke Masubuchi, Yuko Nakagawa, Jinhui Ma, Tsutomu Sasaki, Tadahiro Kitamura, Yoritsuna Yamamoto, Hitoshi Kurose, Itaru Kojima, Hiroshi Shibata, Xing-Ming Shi
PLoS ONE.2013; 8(1): e54500. CrossRef
Goût des aliments et comportement alimentaire
M. Fantino
Médecine des Maladies Métaboliques.2012; 6(5): 409. CrossRef
The role of T1r3 and Trpm5 in carbohydrate-induced obesity in mice
John I. Glendinning, Jennifer Gillman, Haley Zamer, Robert F. Margolskee, Anthony Sclafani
Physiology & Behavior.2012; 107(1): 50. CrossRef
Repair of diverse diabetic defects of β‐cells in man and mouse by pharmacological glucokinase activation
Nicolai M. Doliba, Deborah Fenner, Bogumil Zelent, Joseph Bass, Ramakanth Sarabu, Franz M. Matschinsky
Diabetes, Obesity and Metabolism.2012; 14(s3): 109. CrossRef

Understanding the Cardiovascular Effects of Incretin: Ji Sung Yoon, Hyoung Woo Lee; Diabetes Metab J. 2011;35(5):437-443. Published online October 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.5.437

6,453 View
52 Download
18 Crossref

Abstract PDF PubReader ePub

Cardiovascular disease (CVD), a leading cause of death in patients with diabetes mellitus, has several pathogenic mechanisms that are well established. However, the traditional hypoglycemic agents do not have proven positive effects on macrovascular disease. Novel therapeutic agents target the incretin pathway including the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists and the dipeptidyl peptidase-4 inhibitors. The glucose-regulatory actions of these agents function by increasing insulin secretion and suppressing glucagon. They also act to increase weight loss not only by inhibiting gastric emptying, but also by reducing appetite. Although GLP-1 and GLP-1R agonists have demonstrated beneficial effects on myocardium and vascular endothelium including coronary and peripheral mouse vessels, they also have anti-inflammatory and anti-atherogenic actions. These agents also have positive effects on the lipid profile and blood pressure. Although these cardioprotective actions seem to be beyond the effects of glucose control and weight loss, they are mediated through GLP-1R- or GLP-1R-independent actions of cleaved GLP-1 (9-36). Larger randomized controlled trials are necessary to elucidate the clinical promise of these beneficial CVD effects.

Citations

Citations to this article as recorded by

The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients
Mohammad Tanashat, Yazan A. Al-Ajlouni, Mohamed Abuelazm, Obieda Altobaishat, Almothana Manasrah, Mustafa Turkmani, Ubaid Khan, Mohamed Abouzid
American Journal of Cardiovascular Drugs.2025; 25(4): 491. CrossRef
Cardioprotective Effects of Glucagon-like Peptide-1 (9-36) Against Oxidative Injury in H9c2 Cardiomyoblasts: Potential Role of the PI3K/Akt/NOS Pathway
Narawat Nuamnaichati, Warisara Parichatikanond, Supachoke Mangmool
Journal of Cardiovascular Pharmacology.2022; 79(1): e50. CrossRef
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Aysegul Durak, Yusuf Olgar, Erkan Tuncay
Molecular and Cellular Biochemistry.2022; 477(11): 2609. CrossRef
Interrelations of components of metabolic syndrome with the level of the hormones involved in regulation of adipose tissue metabolism
A. Y. Babenko, G. A. Matveev, T. I. Alekseenko, I. V. Derevitskii, M. A. Kokina, E. V. Shlyakhto
"Arterial’naya Gipertenziya" ("Arterial Hypertension").2020; 25(6): 639. CrossRef
Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats
Soo Lim, Gha Young Lee, Ho Seon Park, Dong-Hwa Lee, Oh Tae Jung, Kim Kyoung Min, Young-Bum Kim, Hee-Sook Jun, Jang Hak Chul, Kyong Soo Park
Cardiovascular Research.2017; 113(2): 183. CrossRef
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Cristina Mega, Edite Teixeira-de-Lemos, Rosa Fernandes, Flávio Reis
Journal of Diabetes Research.2017; 2017: 1. CrossRef
Letter: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
Hannah Seok
Diabetes & Metabolism Journal.2015; 39(2): 171. CrossRef
Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin
Masao Moroi, Tetsuya Kubota
Journal of Cardiovascular Pharmacology.2015; 66(2): 159. CrossRef
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Na-Hyung Kim, Taeyang Yu, Dae Ho Lee
BioMed Research International.2014; 2014: 1. CrossRef
Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 554. CrossRef
The endothelium in diabetes: Its role in insulin access and diabetic complications
Cathryn M. Kolka, Richard N. Bergman
Reviews in Endocrine and Metabolic Disorders.2013; 14(1): 13. CrossRef
Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Lauren M Cornall, Michael L Mathai, Deanne H Hryciw, Andrew J McAinch
Expert Opinion on Investigational Drugs.2013; 22(4): 487. CrossRef
Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome
Manfredi Tesauro, Francesca Schinzari, Angelo Adamo, Valentina Rovella, Francesca Martini, Nadia Mores, Angela Barini, Dario Pitocco, Giovanni Ghirlanda, Davide Lauro, Umberto Campia, Carmine Cardillo
Diabetes Care.2013; 36(3): 683. CrossRef
Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
Soo Lim, Sung Hee Choi, Hayley Shin, Bong Jun Cho, Ho Seon Park, Byung Yong Ahn, Seon Mee Kang, Ji Won Yoon, Hak Chul Jang, Young-Bum Kim, Kyong Soo Park, Alice Y. W. Chang
PLoS ONE.2012; 7(4): e35007. CrossRef
Glucagon-like peptide 1 and cardiac cell survival
Susana Ravassa, Amaia Zudaire, Javier Díez
Endocrinología y Nutrición (English Edition).2012; 59(9): 561. CrossRef
GLP-1 and cardioprotection: from bench to bedside
S. Ravassa, A. Zudaire, J. Diez
Cardiovascular Research.2012; 94(2): 316. CrossRef
Saxagliptin improves glucose tolerance but not survival in a murine model of dilated cardiomyopathy
Arpita Kalla Vyas, Lauren B. Aerni-Flessner, Maria A. Payne, Attila Kovacs, Patrick Y. Jay, Paul W. Hruz
Cardiovascular Endocrinology.2012; 1(4): 74. CrossRef
Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca
Susana Ravassa, Amaia Zudaire, Javier Díez
Endocrinología y Nutrición.2012; 59(9): 561. CrossRef

Original Article

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus: Sung Hoon Yu, Bongjun Cho, Yejin Lee, Eunhye Kim, Sung Hee Choi, Soo Lim, Ka Hee Yi, Young Joo Park, Kyong Soo Park, Hak Chul Jang; Diabetes Metab J. 2011;35(1):58-64. Published online February 28, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.1.58

6,555 View
41 Download
7 Crossref

Abstract PDF PubReader ePub

Background

We examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) on insulin secretion in women with previous gestational diabetes (pGDM).

Methods

A 75-g oral glucose tolerance test (OGTT) was conducted on 34 women with pGDM. In addition, 11 women with normal glucose tolerance, matched for age, height and weight, were also tested. The insulin, GIP, GLP-1, and glucagon concentrations were measured, and their anthropometric and biochemical markers were also measured.

Results

Among 34 women with pGDM, 18 had normal glucose tolerance, 13 had impaired glucose tolerance (IGT) and 1 had diabetes. No significant differences were found in GLP-1 concentration between the pGDM and control group. However, a significantly high level of glucagon was present in the pGDM group at 30 minutes into the OGTT. The GIP concentration was elevated at 30 minutes and 60 minutes in the pGDM group. With the exception of the 30-minute timepoint, women with IGT had significantly high blood glucose from 0 to 120 minutes. However, there was no significant difference in insulin or GLP-1 concentration. The GIP level was significantly high from 0 to 90 minutes in patients diagnosed with IGT.

Conclusion

GLP-1 secretion does not differ between pGDM patients and normal women. GIP was elevated, but that does not seem to induce in increase in insulin secretion. Therefore, we conclude that other factors such as heredity and environment play important roles in the development of type 2 diabetes.

Citations

Citations to this article as recorded by

Association of GLP-1 secretion with parameters of glycemic control in women after gestational diabetes mellitus
Eleni Pappa, Kristina Busygina, Saori Harada, Hana Hermann, Cornelia Then, Andreas Lechner, Uta Ferrari, Jochen Seissler
BMJ Open Diabetes Research & Care.2024; 12(1): e003706. CrossRef
Inadequate Glucagon Suppression During OGTT in Prediabetes: A Systematic Review and Meta-analysis
Lina Chang, Ying Liu, Yian Gu, Siyu Yan, Li Ding, Ming Liu, Qing He
The Journal of Clinical Endocrinology & Metabolism.2024; 109(10): 2673. CrossRef
Increased Pro-Inflammatory T Cells, Senescent T Cells, and Immune-Check Point Molecules in the Placentas of Patients With Gestational Diabetes Mellitus
Yea Eun Kang, Hyon-Seung Yi, Min-Kyung Yeo, Jung Tae Kim, Danbit Park, Yewon Jung, Ok Soon Kim, Seong Eun Lee, Ji Min Kim, Kyong Hye Joung, Ju Hee Lee, Bon Jeong Ku, Mina Lee, Hyun Jin Kim
Journal of Korean Medical Science.2022;[Epub] CrossRef
Simulation of Oral Glucose Tolerance Tests and the Corresponding Isoglycemic Intravenous Glucose Infusion Studies for Calculation of the Incretin Effect
Myeungseon Kim, Tae Jung Oh, Jung Chan Lee, Karam Choi, Min Young Kim, Hee Chan Kim, Young Min Cho, Sungwan Kim
Journal of Korean Medical Science.2014; 29(3): 378. CrossRef
Metabolic, hormonal characteristics and genetic variants of TCF7L2 associated with development of gestational diabetes mellitus in Mexican women
Ruth Reyes‐López, Elva Pérez‐Luque, Juan Manuel Malacara
Diabetes/Metabolism Research and Reviews.2014; 30(8): 701. CrossRef
Reduced postprandial GLP‐1 responses in women with gestational diabetes mellitus
L. Bonde, T. Vilsbøll, T. Nielsen, J. I. Bagger, J. A. Svare, J. J. Holst, S. Larsen, F. K. Knop
Diabetes, Obesity and Metabolism.2013; 15(8): 713. CrossRef
Women with normal glucose tolerance and a history of gestational diabetes show significant impairment of β-cell function at normal insulin sensitivity
P. Molęda, K. Homa, K. Safranow, Z. Celewicz, A. Fronczyk, L. Majkowska
Diabetes & Metabolism.2013; 39(2): 155. CrossRef

Reviews

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus: Sun Woo Kim; Korean Diabetes J. 2010;34(6):331-337. Published online December 31, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.6.331

7,754 View
66 Download
11 Crossref

Abstract PDF PubReader ePub

Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c < 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal of 6.0% or less, a high dosage of sulfonylureas and insulin would be required; the trade-off would be the common adverse effects of hypoglycemia and weight gain. In contrast, hypoglycemia is uncommon with insulin sensitizers and GLP-1 analogs, allowing the physician to titrate these drugs to maximum dosage to reduce HbA1c levels below 6.0% and they have been shown to preserve β-cell function. Lastly, weight gain is common with sulfonylurea and insulin therapy, whereas GLP-1 analogs induce weight loss and offset the weight gain associated with TZDs. A treatment paradigm shift is recommended in which combination therapy is initiated with diet/exercise, metformin (which has antiatherogenic effects and improves hepatic insulin sensitivity), a TZD (which improves insulin sensitivity and preserves β-cell function with proven durability), and a GLP-1 analog (which improves β, α-cell function and promotes weight loss) or a dipeptidyl peptidase IV inhibitor in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Potential Benefits of Thiazolidinediones in Combination With Glucagon-Like Peptide-1 Receptor Agonists
Hermes Florez, Ricardo Correa, Willy Marcos Valencia
JAMA Network Open.2025; 8(3): e252587. CrossRef
An in-depth review of PPARγ modulators as anti-diabetes therapeutics
Aryan Jangra, Basuvan Babu, Selvaraj Divakar, Byran Gowramma, Saveri Rajan, Sonam Jangra, Vishnu Malakar
Drug Metabolism Reviews.2025; 57(4): 311. CrossRef
Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
Muthanna K. Zaki, Mohammed N. Abed, Fawaz A. Alassaf
Journal of Bone Metabolism.2024; 31(3): 169. CrossRef
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Xiaodong Zhu, Michael J. Fowler, Quinn S. Wells, John M. Stafford, Maureen Gannon
BMC Endocrine Disorders.2024;[Epub] CrossRef
Design, synthesis and evaluation of l-quebrachitol derivatives against α-glycosidase
Maoying Zhang, Xinjie Liang, Pengcheng Cai, Qixun Feng, Yongsong Chen, Xiaoxi Yu, Kuo Zhang, Xuefei Bao, Guoliang Chen
New Journal of Chemistry.2023; 47(28): 13387. CrossRef
Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus
Ke Su, Chunmei Lv, Zongwen Ji, Yishu Wang, Haifeng Wang, Ying Bai, Yaping Liu
American Journal of Therapeutics.2018; 25(6): e609. CrossRef
A Case Report of Diabetes Mellitus with Herniated Intervertebral Lumbar Discs Improved by Korean Medicine Treatment
Dong-geun Han, A-ryun Choi, You-jin Jung, Ah-hyun Kang, Hye-jin Seo, Jae-yeon Sung, Hyung-chul Lee, Gook-hyun Eom, Woo-sub Song
The Journal of Internal Korean Medicine.2017; 38(5): 828. CrossRef
A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang, Daoxiong Chen, Kaining Chen
Experimental and Therapeutic Medicine.2017; 14(4): 3279. CrossRef
Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang
Journal of Diabetes and its Complications.2016; 30(4): 686. CrossRef
Bioreducible polymers for therapeutic gene delivery
Young Sook Lee, Sung Wan Kim
Journal of Controlled Release.2014; 190: 424. CrossRef
Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors
Yi-Ming Mu, Anoop Misra, John M.F. Adam, Siew Pheng Chan, Francis C.C. Chow, Elaine Cheeay Cunanan, Chaicharn Deerochanawong, Hak Chul Jang, Nguyen Thy Khue, Wayne H.-H. Sheu, Kevin E.K. Tan
Diabetes Research and Clinical Practice.2012; 95(2): 179. CrossRef

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus: Mi-Hyun Kim, Moon-Kyu Lee; Korean Diabetes J. 2010;34(1):2-9. Published online February 28, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.1.2

7,903 View
57 Download
12 Crossref

Abstract PDF PubReader ePub

Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide. The complications associated with T2DM result in increased mortality and financial cost for those affected. T2DM has long been known to be associated with insulin resistance in peripheral tissues and a relative degree of insulin deficiency. However, the concept that insulin secretion and insulin sensitivity are not linked through a hyperbolic relationship in T2DM has continuously been demonstrated in many clinical trials. Thus, in order to prevent and treat T2DM, it is necessary to identify the substance(s) that will improve the function and survival of the pancreatic β-cells in both normal and pathologic conditions, so that production and secretion of insulin can be enhanced. Incretin hormones, such as glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), have been shown to lower the postprandial and fasting glucose and the glycated hemoglobin levels, suppress the elevated glucagon level, and stimulate glucose-dependent insulin synthesis and secretion. In this report, we will review the biological actions and mechanisms associated with the actions of incretin hormones, GLP-1 and GIP, on β-cell health and compare the differences between GLP-1 and GIP.

Citations

Citations to this article as recorded by

Hormonal Alterations in Individuals with Obesity After Metabolic Bariatric Surgery: A Narrative Review
Ioanna A. Anastasiou, Dimitris Kounatidis, Eleni Rebelos, Natalia G. Vallianou, Anastasios Tentolouris, Nikolaos Tentolouris, Maria Dalamaga, Irene Karampela
Medicina.2025; 61(10): 1724. CrossRef
Local Insulin for Local Needs? Insights into Retinal Insulin Signaling and RPE Metabolism
Matilde Balbi, Alessandra Puddu, Andrea Amaroli, Davide Maggi, Isabella Panfoli, Silvia Ravera
Biomolecules.2025; 15(11): 1570. CrossRef
A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
Xianglei Gao, Yujing Di, Yuan Lv, Yingcai Luan, Yang Xiong, Yuli Xu, Yusheng Li, Linfeng Guo, Xiaoping Li, Li Deng, Yulei Zhuang, Jie Hou
Clinical and Translational Science.2024;[Epub] CrossRef
A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects
Ruirui Zhou, Linfeng Guo, Xianglei Gao, Yijun Wang, Wenjing Xu, Yang Zou, Wenjia Li, Yulei Zhuang, Gangyi Liu, Yanmei Liu
Clinical and Translational Science.2022; 15(10): 2458. CrossRef
Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases
Mustafa Karabicici, Yagmur Azbazdar, Evin Iscan, Gunes Ozhan
Membranes.2021; 11(11): 844. CrossRef
Effects of newly introduced antidiabetic drugs on autophagy
Milad Ashrafizadeh, Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(4): 2445. CrossRef
Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses
Kanwal Rehman, Mehwish Bagh Ali, Muhammad Sajid Hamid Akash
Biomedicine & Pharmacotherapy.2019; 112: 108670. CrossRef
Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus
Fiorenzo Santoleri, Paola Sorice, Ruggero Lasala, Alberto Costantini
Pharmacology & Pharmacy.2014; 05(04): 332. CrossRef
Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling
Mi-Hyun Kim, Jae-Hwan Jee, Sunyoung Park, Myung-Shik Lee, Kwang-Won Kim, Moon-Kyu Lee
Journal of Endocrinology.2014; 220(2): 117. CrossRef
Predicting the DPP-IV Inhibitory ActivitypIC50Based on Their Physicochemical Properties
Tianhong Gu, Xiaoyan Yang, Minjie Li, Milin Wu, Qiang Su, Wencong Lu, Yuhui Zhang
BioMed Research International.2013; 2013: 1. CrossRef
Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis
Ju-Young Kim, Dong-Mee Lim, Hyung-Seo Park, Chan-Il Moon, Kyung-Jin Choi, Seong-Kyu Lee, Haing-Woon Baik, Keun-Young Park, Byung-Joon Kim
Journal of Pharmacological Sciences.2012; 118(1): 65. CrossRef
Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim
Diabetes & Metabolism Journal.2011; 35(3): 290. CrossRef

Stimulation of Glucagon Like Peptide-1 Secretion in Enteroendocrine L cells.: Byung Joon Kim; Korean Diabetes J. 2009;33(6):458-463. Published online December 1, 2009; DOI: https://doi.org/10.4093/kdj.2009.33.6.458

3,367 View
32 Download
2 Crossref

Abstract PDF

GLP-1 (glucagon like peptide-1) is new anti-diabetic drug with a number of beneficial effects. It stimulates glucose dependant insulin secretion and restoration of beta cell mass through enhancement of islet mass. However, it is easily inactivated after being secreted from enteroendocrine L cells. Recent trial to increased GLP-1 is to directly stimulate L cells through its receptor located in the surface of L cell. Taste receptor in the apical surface of L cell is activated by various tastants contained in the food. Tongue perceives taste sense through the heterotrimeric G-protein (alpha-gustducin) and its downstream signaling cascades. Same taste receptors are also expressed in enteroendocrine cells. In duodenal L cell, alpha-gustducin was detected by immunofluorescence stainig at the luminal projections of enteroendocrine cells. And several other taste signaling elements were also found in L cells. Ingestion of sweet or bitter compounds revealed stimulation of GLP-1 secretion and the regulation of plasma insulin and glucose. In this review, I will briefly introduce the possibilities to stimulate GLP-1 secretion though the membrane receptor in enteroendocrine cell. And it will be the good candidate to develop the treatment modality for obesity, diabetes and abnormal gut motility.

Citations

Citations to this article as recorded by

Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line
Seok-Woo Hong, Jinmi Lee, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
Molecular and Cellular Endocrinology.2012; 362(1-2): 242. CrossRef
Exendin-4 Protects Oxidative Stress-Induced β-Cell Apoptosis through Reduced JNK and GSK3β Activity
Ju-Young Kim, Dong-Mee Lim, Chan Il Moon, Kyung-Jin Jo, Seong-Kyu Lee, Haing-Woon Baik, Ki-Ho Lee, Kang-Woo Lee, Keun-Young Park, Byung-Joon Kim
Journal of Korean Medical Science.2010; 25(11): 1626. CrossRef

Original Articles

Genetic Polymorphism of Glucagon-Like Peptide 1 Receptor in Korean Type 2 Diabetes Mellitus.: Kyung Wook Lee, Meihua Jiang, Shanji Piao, Eun A Kim, Seong Bin Hong, Moon Suk Nam, Yong Seong Kim, Kyong Soo Park, Hyun Chul Lee; Korean Diabetes J. 2005;29(1):30-38. Published online January 1, 2005

1,968 View
53 Download

Abstract PDF: BACKGROUND
Glucagon-like peptide-1 (GLP-1) is a hormone secreted by intestinal L-cells, which stimulates insulin secretion from cells. The biological action of GLP-1 is mediated by the glucagon-like peptide-1 receptor (GLP-1R), which is 463 amino acids in size, with 7 transmembrane domains. Because GLP-1 plays an important modulatory role in regulating glucose-stimulated insulin, the GLP-1R could be a candidate gene contributing to impaired -cell function and the development of this genetically heterogeneous disorder. Recently, four GLP-1R SNPs were identified in Caucasian diabetic individuals, and for the SNP at the Leu- 260Phe (A/C) position, statistically significant differences were detected in the distribution of genotypes between type 2 diabetic and nondiabetic subjects. We replicated the genetic association between the SNP at the leu260Phe (A/C) position in the GLP-1R gene and Korean type 2 diabetes mellitus. METHODS: The Leu260Phe polymorphism in the GLP-1R gene was determined using a PCR- RFLP method (the genotypes were determined according to the results of polymerase chain reaction products after digestion and the digestive enzyme was BbsI) in 419 Korean type 2 diabetic patients and 345 nondiabetic subjects. RESULTS: In contrast to the Caucasian report, there was no significant difference in the frequencies of alleles, and genotypes between Korean type 2 diabetic and nondiabetic subjects. When analyzed according to gender, BMI and age of onset, the genotype distribution of type 2 diabetic subjects was not significantly different from nondiabetic subjects. CONCLUSION: The Leu260Phe polymorphism in the GLP-1R gene was not associated with type 2 diabetes mellitus, and we were unable to replicate the genetic association between this polymorphism and Korean type 2 diabetes mellitus

Relative Hyperglucagonemia and Its Related Factors in Patients with Type 2 Diabetes.: Kang Hyun Choi, Ki Ho Song, Sang Hoon Lee, Seong Hoon Chung, Eun Jung Kim, Seung Hyun Ko, Hyuk Sang Kwon, Yu Bae Ahn, Kun Ho Yoon, Bong Yun Cha, Kwang Woo Lee, Ho Young Son, Sung Koo Kang; Korean Diabetes J. 2004;28(4):338-345. Published online August 1, 2004

1,978 View
23 Download

Abstract PDF: BACKGROUND
Excessive secretion of glucagon contributes to metabolic disturbance in type 2 diabetes. A hyperglucagonemic state is likely to be involved in increased hepatic glucose output resulting from both gluconeogenesis and glycogenolysis. The mechanism of hyperglucagonemia, though still unclear, is explained, in part, by the decreased sensitivity of cells to insulin or glucose and disturbances of the normal oscillatory secretory pattern of insulin. The aim of the study was to determine the extent of glucagon excess and its related factors in Korean patients with type 2 diabetes. METHODS: The subjects of this study were 21 controls and 102 type 2 diabetic patients. The blood glucose, glucagon and insulin concentrations were measured at 0, 30, 60, 90 and 120 min after ingestion of 75 g of glucose, and the areas under the curve (AUC) calculated. RESULTS: The AUC of plasma glucose (AUCgc) was significantly higher in the type 2 diabetic patients than in the controls (2,026.1585.8 vs. 854.8190.3 mmol/min, P<0.01), but there was no difference in the AUC of plasma glucagon (AUCgn) between the two groups. The AUCgn in the type 2 diabetic patients was positively correlated with the duration of diabetes (r=0.202, P<0.05) or HbA1c (r=0.208, P<0.05). The AUC of serum insulin (AUCin) was negatively correlated with the duration of diabetes (r=-0.291, P<001). AUCgn, AUCgc and HbA1c in long-term diabetic patients (duration of diabetes 10 years, n=32) were significantly higher compared with recently diagnosed patients (duration of diabetes <1 year, n=38) (11,362.35,981.9 vs. 9,097. 22,990.4 ng/min; 2,119.9519.0 vs. 1,832.2477.6 mmol/min; 9.52.0 vs. 8.32.1%, P<0.05). In addition, the AUCin and insulinogenic index in long-term patients were significantly lower compared with recently diagnosed patients. (Eds note: the highlighted figures are confusing, due to your various uses of commas and period marks, olease clarify?) CONCLUSIONS: Our results suggest that duration of diabetes and poor glycemic control might be closely associated with relative hyperglucagonemia in Korean type 2 diabetic paticnts.

First
Prev
Page of 1
Next
Last

Search